The	O
sequences	O
for	O
all	O
promoters	O
in	O
CYP2C19	O
gene	O
are	O
as	O
follows	O
:	O
CYP2C19	O
-	O
201	O
identified	O
in	O
chromosome	O
position	O
at	O
94762681	O
(	O
ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG	O
)	O
,	O
CYP2C19	O
-	O
202	O
chromosome	O
position	O
94842926	O
(	O
ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA	O
)	O
,	O
and	O
CYP2C19	O
-	O
203	O
chromosome	O
position	O
94775489	O
(	O
ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG	O
)	O
In	O
addition	O
,	O
we	O
identified	O
the	O
following	O
Kyoto	O
Encyclopedia	O
Of	O
Genes	O
And	O
Genomes	O
pathways	O
of	O
CYP2C19	O
which	O
include	O
arachidonic	O
acid	O
metabolism	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
chemical	O
carcinogenesis	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
drug	O
metabolism	O
(	O
cytochrome	B
P450	I
)	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
linoleic	O
acid	O
metabolism	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
metabolic	O
pathways	O
,	O
organism	O
-	O
specific	O
biosystem	O
,	O
and	O
serotonergic	O
synapse	O
.	O

(	O
3	O
)	O
Pharmacokinetic	O
interaction	O
:	O
The	O
Pharmacokinetic	O
interaction	O
is	O
related	O
to	O
the	O
effects	O
on	O
the	O
cytochrome	B
P450	I
cytochromes	O
and	O
possible	O
drug	O
interactions	O
when	O
prescribed	O
with	O
other	O
drugs	O
.	O

Cells	O
are	O
equipped	O
with	O
several	O
hemoproteins	O
and	O
for	O
some	O
of	O
them	O
a	O
role	O
in	O
cancer	O
has	O
been	O
reported	O
,	O
including	O
myoglobin	O
,	O
tryptophan	O
2	O
,	O
3	O
-	O
dioxygenase	O
and	O
indoleamine	O
-	O
2	O
,	O
3	O
-	O
dioxygenase	O
1	O
and	O
2	O
(	O
IDO1	O
/	O
2	O
)	O
,	O
mitochondrial	O
cytochromes	O
,	O
cytochrome	B
P450	I
,	O
and	O
cyclooxygenases	O
(	O
,	O
.	O

Studies	O
on	O
lung	O
cancer	O
demonstrated	O
that	O
the	O
amount	O
of	O
oxygen	O
-	O
utilizing	O
hemoproteins	O
,	O
such	O
as	O
cytoglobin	O
,	O
cytochrome	O
c	O
,	O
cytochrome	B
P450	I
family	O
1	O
subfamily	O
B	O
member	O
1	O
and	O
prostaglandin	O
-	O
endoperoxide	O
synthase	O
2	O
(	O
COX2	O
)	O
are	O
higher	O
in	O
tumor	O
cells	O
as	O
compared	O
to	O
normal	O
cells	O
and	O
that	O
,	O
at	O
least	O
for	O
cytoglobin	O
and	O
cytochrome	O
c	O
,	O
their	O
levels	O
depend	O
on	O
the	O
rate	O
of	O
heme	O
synthesis	O
and	O
cellular	O
heme	O
content	O
.	O

In	O
this	O
article	O
,	O
we	O
discuss	O
the	O
physiological	O
,	O
therapeutic	O
and	O
pathophysiological	O
relevance	O
of	O
cytochrome	B
P450	I
protein	O
degradation	O
.	O

In	O
the	O
mammalian	O
liver	O
,	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
anchored	O
P450s	O
function	O
together	O
with	O
their	O
redox	O
partners	O
cytochrome	B
P450	I
reductase	O
and	O
cytochrome	O
b_5	O
in	O
the	O
oxidative	O
metabolism	O
and	O
elimination	O
of	O
numerous	O
endobiotics	O
(	O
arachidonic	O
acid	O
,	O
retinoic	O
acid	O
,	O
steroids	O
,	O
vitamin	O
D	O
)	O
as	O
well	O
as	O
xenobiotics	O
(	O
pharmacological	O
and	O
recreational	O
drugs	O
,	O
carcinogens	O
,	O
toxins	O
and	O
other	O
foreign	O
substances	O
of	O
dietary	O
or	O
environmental	O
origin	O
)	O
,	O
.	O

CYP1A	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
health	O
in	O
the	O
body	O
.	O
Image	O
1	O
The	O
cytochrome	B
P450	I
enzyme	O
is	O
one	O
of	O
the	O
most	O
abundant	O
and	O
diverse	O
superfamilies	O
,	O
which	O
contains	O
hemoprotein	O
.	O

To	O
elucidate	O
the	O
celastrol	O
biosynthetic	O
pathway	O
and	O
reconstruct	O
it	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
we	O
mined	O
a	O
root	O
-	O
transcriptome	O
of	O
Tripterygium	O
wilfordii	O
and	O
identified	O
four	O
oxidosqualene	O
cyclases	O
and	O
49	O
cytochrome	O
P450s	O
as	O
candidates	O
to	O
be	O
involved	O
in	O
the	O
early	O
steps	O
of	O
celastrol	O
biosynthesis	O
.	O

Celastrol	O
biosynthesis	O
likely	O
adheres	O
to	O
the	O
common	O
triterpenoid	O
scheme	O
that	O
starts	O
with	O
cycloisomerization	O
of	O
2	O
,	O
3	O
-	O
oxidosqualene	O
by	O
an	O
oxidosqualene	O
cyclase	O
(	O
OSC	O
)	O
and	O
continues	O
with	O
oxidative	O
decoration	O
(	O
s	O
)	O
of	O
the	O
30	O
-	O
carbon	O
triterpenoid	O
core	O
structure	O
by	O
cytochrome	B
P450	B
enzymes	I
[	O
,	O
.	O

For	O
catalysis	O
,	O
P450s	O
require	O
cytochrome	B
P450	I
reductases	O
(	O
CPRs	O
)	O
as	O
a	O
redox	O
partner	O
.	O

Output	O
includes	O
metabolism	O
to	O
oxysterols	O
by	O
the	O
cytochrome	B
P450	I
enzymes	I
Cytochromes	O
P450	O
27a1	O
and	O
CYP46A1	O
,	O
the	O
photoreceptor	O
phagocytosis	O
,	O
and	O
efflux	O
to	O
lipoprotein	O
particles	O
,	O
which	O
circulate	O
in	O
the	O
intraretinal	O
space	O
.	O

Furthermore	O
,	O
different	O
reconstituted	O
fractions	O
of	O
extract	O
(	O
petasins	O
and	O
fatty	O
acid	O
fraction	O
)	O
were	O
examined	O
in	O
three	O
in	O
vitro	O
test	O
systems	O
using	O
hepatocytes	O
:	O
Two	O
human	O
cell	O
lines	O
,	O
with	O
lower	O
and	O
higher	O
activity	O
of	O
cytochrome	B
P450	I
enzymes	I
(	O
HepG2	O
,	O
HepaRG	O
)	O
as	O
well	O
as	O
a	O
rodent	O
cell	O
line	O
with	O
high	O
cytochrome	B
P450	I
activity	O
(	O
H4IIE	O
)	O
,	O
were	O
used	O
.	O

The	O
analysis	O
focused	O
on	O
three	O
different	O
in	O
vitro	O
test	O
systems	O
of	O
hepatocytes	O
:	O
two	O
human	O
hepatic	O
cell	O
lines	O
,	O
with	O
lower	O
and	O
higher	O
activity	O
of	O
cytochrome	B
P450	I
enzymes	I
(	O
HepG2	O
and	O
HepaRG	O
,	O
respectively	O
,	O
(	O
Andersson	O
,	O
Kanebratt	O
,	O
&	O
Kenna	O
,	O
;	O
Guillouzo	O
et	O
al	O
.	O
,	O
)	O
)	O
and	O
a	O
rat	O
cell	O
line	O
(	O
H4IIE	O
[	O
Fujimura	O
,	O
Murakami	O
,	O
Miwa	O
,	O
Aruga	O
,	O
&	O
Toriumi	O
,	O
;	O
Westerink	O
,	O
Stevenson	O
,	O
&	O
Schoonen	O
,	O
]	O
)	O
were	O
used	O
.	O

Isolated	O
cytochrome	B
P450	I
enzymes	I
and	O
phosphate	O
buffer	O
were	O
obtained	O
from	O
BD	O
Gentest	O
(	O
Switzerland	O
)	O
.	O

The	O
metabolism	O
of	O
petasin	O
,	O
isopetasin	O
,	O
and	O
neopetasin	O
was	O
investigated	O
using	O
three	O
different	O
S9	O
fractions	O
originating	O
from	O
three	O
different	O
species	O
(	O
isolated	O
from	O
rat	O
,	O
dog	O
,	O
and	O
human	O
liver	O
homogenates	O
containing	O
cytochrome	B
P450	I
isoforms	O
)	O
and	O
isolated	O
cytochromes	O
of	O
two	O
different	O
species	O
(	O
human	O
and	O
rat	O
;	O
rat	O
analogues	O
of	O
the	O
respective	O
human	O
cytochromes	O
were	O
used	O
)	O
.	O

Comparison	O
of	O
two	O
human	O
cell	O
lines	O
(	O
HepG2	O
and	O
HepaRG	O
)	O
with	O
different	O
activities	O
of	O
cytochrome	B
P450	I
enzymes	O
revealed	O
that	O
Ze	O
339	O
and	O
its	O
single	O
constituents	O
petasin	O
,	O
isopetasin	O
,	O
neopetasin	O
,	O
isopetasol	O
,	O
and	O
petasol	O
exerted	O
higher	O
toxicity	O
in	O
cells	O
having	O
a	O
higher	O
cytochrome	O
activity	O
.	O

Furthermore	O
,	O
Ze	O
399	O
and	O
petasin	O
,	O
isopetasin	O
,	O
and	O
neopetasin	O
were	O
more	O
toxic	O
in	O
rat	O
cells	O
(	O
H4IIE	O
)	O
,	O
which	O
are	O
known	O
to	O
have	O
a	O
high	O
expression	O
of	O
cytochrome	B
P450	I
(	O
Fujimura	O
et	O
al	O
.	O
,	O
;	O
Westerink	O
et	O
al	O
.	O
,	O
)	O
than	O
in	O
both	O
human	O
cell	O
lines	O
.	O

In	O
humans	O
,	O
30	O
-	O
50	O
%	O
of	O
Valproic	O
Acid	O
is	O
metabolized	O
by	O
glucuronidation	O
and	O
by	O
BETA	O
oxidation	O
in	O
the	O
mitochondria	O
,	O
and	O
about	O
10	O
-	O
20	O
%	O
is	O
metabolized	O
by	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
-	O
mediated	O
oxidation	O
.	O

Meanwhile	O
,	O
the	O
examined	O
series	O
inhibited	O
the	O
cytochrome	B
P450	I
isomers	O
,	O
ie	O
,	O
CYP2C19	O
,	O
CYP2C9	O
,	O
and	O
CYP3A4	O
-	O
except	O
for	O
Compound	O
2g	O
,	O
which	O
did	O
not	O
inhibit	O
CYP2C19	O
.	O

Hepatocytes	O
express	O
a	O
set	O
of	O
highly	O
specific	O
cytochrome	B
P450	I
biotransforming	O
enzymes	O
that	O
convert	O
many	O
drugs	O
to	O
inactive	O
or	O
hepatotoxic	O
compounds	O
.	O

We	O
observed	O
a	O
significant	O
increase	O
in	O
HIV	O
-	O
1	O
replication	O
,	O
which	O
was	O
associated	O
with	O
an	O
increase	O
in	O
the	O
expression	O
of	O
cytochrome	B
P450	I
(	O
CYPs	O
1A1	O
and	O
2A6	O
)	O
in	O
the	O
CCS	O
-	O
treated	O
U1	O
cells	O
.	O

We	O
recently	O
demonstrated	O
that	O
oxidative	O
stress	O
generated	O
via	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
-	O
mediated	O
metabolism	O
of	O
tobacco	O
constituents	O
,	O
especially	O
cigarette	O
smoke	O
condensate	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
BaP	O
)	O
,	O
triggers	O
HIV	O
-	O
1	O
replication	O
in	O
monocytes	O
and	O
macrophages	O
.	O

The	O
molecular	O
docking	O
study	O
suggested	O
that	O
compound	O
12n	O
fitted	O
the	O
active	O
sites	O
of	O
cytochrome	B
P450	I
17A1	O
(	O
6CIZ	O
)	O
well	O
.	O

Moreover	O
it	O
is	O
important	O
to	O
emphasize	O
that	O
tocilizumab	O
decreases	O
the	O
concentration	O
of	O
several	O
medications	O
as	O
a	O
cytochrome	B
P450	I
,	O
isoenzyme	O
CYP3A4	O
inducer	O
in	O
terms	O
of	O
antagonisms	O
or	O
synergy	O
but	O
this	O
is	O
not	O
yet	O
entirely	O
clear	O
(	O
;	O
.	O

Here	O
,	O
we	O
examined	O
the	O
rate	O
of	O
gene	O
flow	O
from	O
abiotic	O
stress	O
-	O
tolerant	O
transgenic	O
rice	O
that	O
over	O
-	O
express	O
AtCYP78A7	O
,	O
a	O
gene	O
encoding	O
cytochrome	B
P450	I
protein	O
,	O
to	O
six	O
weedy	O
rice	O
accessions	O
and	O
compared	O
the	O
phenotypic	O
performance	O
and	O
drought	O
tolerance	O
of	O
their	O
hybrids	O
over	O
generations	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
overexpression	O
of	O
AtCYP78A7	O
,	O
a	O
gene	O
encoding	O
cytochrome	B
P450	I
protein	O
,	O
exhibits	O
improved	O
drought	O
tolerance	O
and	O
increased	O
seed	O
size	O
in	O
transgenic	O
rice	O
^	O
.	O

They	O
were	O
derived	O
from	O
a	O
rice	O
cultivar	O
Hwayoung	O
and	O
contain	O
AtCYP78A7	O
a	O
gene	O
that	O
encodes	O
a	O
cytochrome	B
P450	I
protein	O
under	O
the	O
control	O
of	O
the	O
cauliflower	O
mosaic	O
virus	O
35S	O
promoter	O
,	O
nos	O
terminator	O
and	O
hygromycin	O
phosphotransferase	O
gene	O
for	O
hygromycin	O
selection	O
^	O
,	O
.	O

Apart	O
from	O
this	O
QC	O
also	O
reported	O
as	O
an	O
inhibitor	O
of	O
cytochrome	B
P450	B
enzyme	I
which	O
is	O
the	O
main	O
enzyme	O
of	O
Mycophenolic	O
Acid	O
metabolism	O
(	O
;	O
.	O

In	O
addition	O
,	O
the	O
blood	O
circulation	O
time	O
of	O
Mycophenolic	O
Acid	O
also	O
increased	O
by	O
QC	O
through	O
inhibition	O
of	O
Mycophenolic	O
Acid	O
metabolism	O
mediated	O
by	O
cytochrome	B
P450	B
enzyme	I
as	O
discussed	O
blow	O
in	O
pharmacokinetic	O
analysis	O
.	O

Higher	O
AUC_	O
(	O
_0_	O
-	O
__	O
)	O
and	O
T_1_	O
/	O
_2	O
might	O
be	O
due	O
sustained	O
release	O
of	O
drugs	O
from	O
liposomes	O
and	O
long	O
blood	O
circulation	O
time	O
due	O
Mycophenolic	O
Acid	O
breakdown	O
inhibition	O
through	O
cytochrome	B
P450	I
enzyme	I
by	O
QC	O
.	O

This	O
is	O
metabolized	O
by	O
ROS	O
scavenger	O
like	O
cytochrome	B
P450	I
to	O
prevent	O
cellular	O
damages	O
,	O
ultimately	O
leading	O
to	O
redox	O
homeostasis	O
.	O

Some	O
parameters	O
such	O
as	O
blood	O
-	O
brain	O
barrier	O
permeation	O
,	O
human	O
drug	O
-	O
likeness	O
,	O
interaction	O
with	O
cytochrome	B
P450	I
(	O
isoenzymes	O
that	O
play	O
an	O
important	O
role	O
in	O
drug	O
elimination	O
through	O
metabolic	O
transformation	O
)	O
and	O
bioavailability	O
score	O
were	O
predicted	O
,	O
.	O

The	O
interaction	O
of	O
SIM	O
-	O
53B	O
with	O
cytochrome	B
P450	I
isoforms	O
plays	O
an	O
important	O
role	O
in	O
SIM	O
-	O
53B	O
elimination	O
through	O
metabolic	O
biotransformation	O
.	O

SIM	O
-	O
53B	O
may	O
inhibit	O
some	O
of	O
the	O
cytochrome	B
P450	I
isoforms	O
such	O
as	O
CYP1A2	O
,	O
CYP2C9	O
and	O
CYP3A4	O
.	O

A	O
history	O
of	O
the	O
roles	O
of	O
cytochrome	B
P450	I
enzymes	O
in	O
the	O
toxicity	O
of	O
drugs	O
.	O

Once	O
absorbed	O
in	O
the	O
small	O
intestines	O
or	O
later	O
in	O
the	O
large	O
intestines	O
,	O
absorbed	O
flavonoid	O
aglycones	O
will	O
move	O
along	O
to	O
the	O
liver	O
by	O
portal	O
circulation	O
and	O
undergo	O
extensive	O
first	O
pass	O
metabolism	O
,	O
as	O
shown	O
in	O
A	O
.	O
Largely	O
in	O
the	O
liver	O
,	O
but	O
also	O
in	O
the	O
small	O
intestines	O
,	O
flavonoid	O
aglycones	O
undergo	O
oxidative	O
and	O
reductive	O
modifications	O
by	O
NADPH	O
dependent	O
cytochromes	O
P450	B
enzymes	I
.	O

For	O
isoflavones	O
,	O
the	O
gut	O
microbiome	O
and	O
phase	O
I	O
cytochrome	O
P450	B
enzymes	I
in	O
human	O
liver	O
microsome	O
were	O
responsible	O
for	O
O	O
-	O
demethylation	O
at	O
4	O
carbon	O
;	O
hence	O
formononetin	O
is	O
converted	O
to	O
daidzein	O
and	O
biochanin	O
A	O
to	O
genistein	O
Anthocyanidins	O
,	O
or	O
their	O
monoglucosides	O
of	O
anthocyanins	O
,	O
remained	O
unchanged	O
when	O
incubated	O
with	O
rat	O
liver	O
microsomes	O
in	O
the	O
presence	O
of	O
NADPH	O
,	O
which	O
suggests	O
that	O
anthocyanidins	O
are	O
not	O
affected	O
by	O
phase	O
I	O
enzymes	O
.	O

The	O
heme	O
-	O
containing	O
Cytochrome	O
P450	B
enzymes	I
activate	O
molecular	O
oxygen	O
utilizing	O
NADPH	O
as	O
an	O
electron	O
donor	O
.	O

Cytochrome	O
P450	B
enzymes	I
involved	O
in	O
steroidogenesis	O
can	O
be	O
divided	O
into	O
two	O
groups	O
based	O
on	O
their	O
intracellular	O
location	O
and	O
mode	O
of	O
electron	O
transfer	O
.	O

In	O
addition	O
to	O
the	O
steroidogenic	O
Cytochrome	B
P450	I
enzymes	I
described	O
in	O
Section	O
,	O
hepatic	O
xenobiotic	O
-	O
metabolizing	O
members	O
of	O
the	O
Cytochrome	B
P450	I
superfamily	O
are	O
able	O
to	O
modify	O
steroid	O
hormones	O
and	O
generate	O
a	O
plethora	O
of	O
minor	O
steroid	O
metabolites	O
.	O

Cytochrome	B
P450	I
enzymes	I
have	O
potential	O
uses	O
in	O
the	O
synthesis	O
and	O
discovery	O
of	O
drugs	O
,	O
as	O
well	O
as	O
drug	O
development	O
.	O

Cytochrome	B
P450	I
enzymes	I
metabolize	O
thousands	O
of	O
endogenous	O
and	O
exogenous	O
chemicals	O
.	O

Cytochrome	B
P450	I
enzymes	I
are	O
bound	O
to	O
membranes	O
within	O
a	O
cell	O
and	O
contain	O
a	O
heme	O
pigment	O
that	O
absorbs	O
light	O
at	O
a	O
wavelength	O
of	O
450	O
nm	O
when	O
exposed	O
to	O
carbon	O
monoxide	O
.	O

There	O
are	O
more	O
than	O
50	O
Cytochrome	B
P450	I
enzymes	I
,	O
but	O
the	O
CYP1A2	O
,	O
CYP2C9	B
,	O
CYP2C19	O
,	O
CYP2D6	B
,	O
CYP3A4	O
,	O
and	O
CYP3A5	O
enzymes	O
metabolize	O
90	O
percent	O
of	O
drugs	O
.	O

Cytochrome	B
P450	I
enzymes	I
play	O
a	O
role	O
in	O
the	O
synthesis	O
of	O
many	O
molecules	O
including	O
steroid	O
hormones	O
,	O
certain	O
Fatty	O
Acids	O
(	O
cholesterol	O
and	O
other	O
fatty	O
acids	O
)	O
,	O
and	O
acids	O
used	O
to	O
digest	O
Fatty	O
Acids	O
(	O
bile	O
acids	O
)	O
.	O

Genetic	O
polymorphisms	O
of	O
Cytochrome	B
P450	I
enzymes	I
mainly	O
influence	O
drug	O
metabolism	O
,	O
disposition	O
and	O
elimination	O
and	O
lead	O
to	O
alteration	O
of	O
pharmacokinetic	O
parameters	O
resulting	O
in	O
changes	O
in	O
drug	O
response	O
as	O
well	O
as	O
adverse	O
drug	O
reactions	O
.	O

The	O
Cytochrome	B
P450	I
enzymes	I
activity	O
have	O
four	O
recognizable	O
metabolic	O
categories	O
:	O
(	O
a	O
)	O
poor	O
metabolizers	O
which	O
lack	O
functional	O
enzymes	O
due	O
to	O
deficient	O
allele	O
inheritance	O
;	O
(	O
b	O
)	O
intermediate	O
metabolizers	O
,	O
that	O
are	O
heterozygous	O
with	O
one	O
deficient	O
allele	O
or	O
carrying	O
two	O
reduced	O
activity	O
alleles	O
;	O
(	O
c	O
)	O
extensive	O
metabolizers	O
that	O
have	O
normally	O
functional	O
enzymes	O
due	O
to	O
wild	O
type	O
alleles	O
inheritance	O
,	O
and	O
(	O
d	O
)	O
ultra	O
-	O
rapid	O
metabolizers	O
,	O
which	O
carry	O
more	O
than	O
two	O
copies	O
of	O
active	O
alleles	O
.	O

For	O
example	O
,	O
the	O
Cytochrome	B
P450	I
enzymes	I
can	O
play	O
a	O
major	O
role	O
in	O
metabolic	O
drug	O
oxidation	O
and	O
accounts	O
for	O
approximately	O
75	O
%	O
of	O
the	O
total	O
drug	O
metabolism	O
.	O

Furthermore	O
,	O
Cytochrome	B
P450	I
enzymes	I
are	O
classified	O
based	O
on	O
gene	O
similarity	O
(	O
cytochromes	O
within	O
families	O
have	O
more	O
than	O
40	O
%	O
homology	O
in	O
their	O
protein	O
sequence	O
)	O
.	O

For	O
the	O
decomposition	O
of	O
clinical	O
drugs	O
,	O
human	O
Cytochrome	B
P450	I
enzymes	I
belong	O
to	O
the	O
Phase	O
I	O
drug	O
metabolizing	O
enzymes	O
.	O

Estradiol	O
is	O
converted	O
into	O
the	O
less	O
potent	O
estrogens	O
to	O
be	O
inactivated	O
and	O
hydroxylated	O
into	O
catechol	O
estrogens	O
through	O
Cytochrome	B
P450	I
enzymes	I
.	O

In	O
addition	O
to	O
the	O
conjugation	O
pathway	O
and	O
17	O
-	O
ketosteroid	O
pathway	O
,	O
hydroxylation	O
and	O
oxidation	O
of	O
hepatic	O
Cytochrome	B
P450	I
enzymes	I
are	O
additional	O
pathways	O
for	O
testosterone	O
metabolism	O
.	O

Therefore	O
,	O
it	O
can	O
be	O
suggested	O
that	O
ellagic	O
acid	O
may	O
affect	O
warfarin	O
binding	O
to	O
CYP2C8	B
and	O
CYP3A4	B
by	O
changing	O
the	O
conformation	O
of	O
these	O
enzymes	O
that	O
leads	O
to	O
more	O
affinity	O
towards	O
warfarin	O
binding	O
[	O
,	O
.	O

These	O
results	O
contradict	O
those	O
of	O
a	O
previous	O
study	O
by	O
Kaneko	O
,	O
2013	O
where	O
ellagic	O
acid	O
had	O
a	O
clear	O
inhibitory	O
effect	O
on	O
CYP2C8	B
and	O
CYP3A4	B
activities	O
.	O

Although	O
guava	O
leaves	O
extract	O
showed	O
an	O
insignificant	O
effect	O
on	O
CYP2C8	B
when	O
used	O
alone	O
,	O
it	O
significantly	O
reduced	O
its	O
activity	O
when	O
combined	O
with	O
warfarin	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
a	O
previous	O
study	O
conducted	O
by	O
Kaneko	O
in	O
2013	O
,	O
it	O
was	O
reported	O
that	O
guava	O
leaves	O
extract	O
had	O
an	O
inhibitory	O
effect	O
on	O
CYP2C8	B
.	O

Therefore	O
,	O
it	O
might	O
be	O
suggested	O
that	O
CYP2C8	B
enzyme	O
can	O
be	O
influenced	O
by	O
the	O
presence	O
of	O
warfarin	O
,	O
which	O
can	O
modify	O
the	O
uncompetitive	O
binding	O
of	O
the	O
active	O
extract	O
components	O
on	O
the	O
enzyme	O
.	O

It	O
seems	O
possible	O
that	O
some	O
competition	O
could	O
have	O
happened	O
between	O
quercetin	O
and	O
warfarin	O
on	O
the	O
binding	O
site	O
of	O
CYP2C8	B
since	O
previous	O
studies	O
showed	O
that	O
quercetin	O
can	O
competitively	O
inhibit	O
the	O
effect	O
of	O
CYP2C8	B
[	O
,	O
.	O

Thus	O
,	O
explains	O
the	O
influence	O
of	O
quercetin	O
in	O
reducing	O
CYP2C8	B
activity	O
in	O
tested	O
rat	O
hepatocytes	O
.	O

Mostly	O
all	O
the	O
compounds	O
were	O
found	O
to	O
be	O
a	O
substrate	O
of	O
CYP1A2	O
,	O
except	O
F25	O
,	O
whereas	O
,	O
for	O
CYP2C8	B
,	O
only	O
compound	O
F2	O
was	O
found	O
to	O
be	O
the	O
substrate	O
.	O

Moreover	O
,	O
even	O
if	O
sorafenib	O
is	O
not	O
a	O
substrate	O
for	O
the	O
cytochrome	O
isoforms	O
CYP2B6	O
,	O
CYP2C8	B
,	O
and	O
CYP2C9	B
and	O
the	O
UDP	O
glucuronosyltransferase	O
UGT1A1	O
,	O
the	O
biological	O
agent	O
in	O
vivo	O
inhibits	O
activity	O
of	O
these	O
enzymes	O
with	O
potential	O
pharmacological	O
consequences	O
and	O
drug	O
-	O
interaction	O
events	O
.	O

Regorafenib	O
and	O
its	O
major	O
metabolites	O
are	O
also	O
reported	O
to	O
inhibit	O
a	O
number	O
of	O
cytochromes	O
(	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2B6	O
,	O
Cytochrome	B
P450	I
3a4	I
,	O
CYP2D6	B
)	O
,	O
UGT1A	O
enzymes	O
(	O
UGT1A9	O
,	O
UGT1A1	O
)	O
,	O
and	O
transporters	O
(	O
BCRP	O
)	O
and	O
induce	O
others	O
(	O
CYP1A2	O
,	O
CYP2B6	O
,	O
CYP2C19	O
,	O
CYP3A4	B
)	O
with	O
potential	O
alteration	O
in	O
the	O
exposure	O
of	O
co	O
-	O
administered	O
drugs	O
.	O

Visual	O
inspection	O
of	O
the	O
data	O
points	O
of	O
the	O
correlation	O
between	O
CYP2C9	B
activity	O
and	O
flucloxacillin	O
hydroxylation	O
shows	O
a	O
trend	O
that	O
the	O
line	O
does	O
not	O
cross	O
the	O
Xaxis	O
at	O
the	O
origin	O
but	O
at	O
280	O
pmolmin	O
^	O
1mg	O
^	O
1	O
protein	O
.	O

At	O
10	O
M	O
flucloxacillin	O
,	O
CYP2C9	B
showed	O
a	O
8	O
to	O
10fold	O
lower	O
activity	O
.	O

did	O
not	O
detect	O
5HMFLX	O
in	O
incubations	O
with	O
recombinant	O
CYP1A2	O
,	O
CYP2C9	B
and	O
CYP3A5	O
might	O
be	O
attributed	O
to	O
the	O
less	O
sensitive	O
analytical	O
method	O
used	O
(	O
HPLC	O
-	O
UV	O
detection	O
versus	O
LC	O
-	O
MS	O
)	O
and	O
/	O
or	O
the	O
use	O
of	O
yeastexpressed	O
CYPs	O
with	O
lower	O
specific	O
activity	O
than	O
the	O
Supersomes	O
used	O
in	O
the	O
present	O
study	O
.	O

Remarkably	O
,	O
sulfaphenazole	O
,	O
which	O
is	O
considered	O
to	O
be	O
a	O
highly	O
selective	O
inhibitor	O
of	O
CYP2C9	B
(	O
Khojasteh	O
et	O
al	O
.	O
,	O
)	O
,	O
showed	O
clear	O
inhibition	O
of	O
flucloxacillin	O
hydroxylation	O
by	O
pooled	O
HLM	O
,	O
CYP3A4	B
and	O
CYP3A7	O
,	O
whereas	O
the	O
6BETAhydroxylation	O
of	O
testosterone	O
was	O
not	O
affected	O
.	O

A	O
similar	O
situation	O
has	O
been	O
described	O
recently	O
in	O
a	O
study	O
where	O
sulfaphenazole	O
significantly	O
inhibited	O
bioactivation	O
of	O
hydroxylapatinib	O
by	O
HLM	O
,	O
although	O
recombinant	O
CYP2C9	B
showed	O
only	O
very	O
low	O
activity	O
(	O
Towles	O
et	O
al	O
.	O
,	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
present	O
study	O
confirm	O
the	O
involvement	O
of	O
CYP3A4	B
in	O
the	O
hydroxylation	O
of	O
flucloxacillin	O
,	O
whereas	O
CYP3A7	O
and	O
CYP2C9	B
may	O
also	O
contribute	O
significantly	O
in	O
individuals	O
expressing	O
high	O
hepatic	O
levels	O
.	O

The	O
large	O
variability	O
of	O
both	O
hepatic	O
CYP3A	B
and	O
CYP2C9	B
levels	O
may	O
contribute	O
to	O
the	O
variability	O
of	O
plasma	O
levels	O
of	O
5HMFLX	O
,	O
which	O
is	O
suspected	O
to	O
play	O
a	O
role	O
in	O
flucloxacillin	O
induced	O
DILI	O
by	O
causing	O
cytotoxicity	O
to	O
biliary	O
epithelial	O
cells	O
.	O

The	O
strong	O
inhibition	O
of	O
CYP3Acatalysed	O
hydroxylation	O
of	O
flucloxacillin	O
by	O
the	O
commonly	O
used	O
CYP2C9	B
inhibitor	O
sulfaphenazole	O
suggest	O
that	O
unanticipated	O
drug	O
-	O
drug	O
interactions	O
can	O
occur	O
with	O
coadministered	O
drugs	O
.	O

For	O
example	O
,	O
St	O
Johns	O
wort	O
induces	O
microsomal	O
cytochrome	O
P450	O
enzyme	O
-	O
mediated	O
metabolism	O
of	O
warfarin	O
,	O
particularly	O
CYP2C9	B
and	O
increases	O
warfarin	O
clearance	O
.	O

P450	O
-	O
Glo	O
CYP2C9	B
with	O
Luciferin	O
-	O
H	O
,	O
P450	O
-	O
Glo	O
2C8	O
with	O
Luciferin	O
-	O
ME	O
and	O
P450	O
-	O
Glo	O
3A4	O
with	O
Luciferin	O
-	O
IPA	O
Assay	O
kits	O
were	O
purchased	O
from	O
Promega	O
(	O
Madison	O
,	O
USA	O
)	O
.	O

All	O
utilized	O
control	O
inhibitors	O
namely	O
;	O
sulfamethoxazole	O
,	O
trimethoprim	O
and	O
ketoconazole	O
significantly	O
reduced	O
corresponding	O
CYPs	O
,	O
CYP2C9	B
,	O
2C8	O
and	O
3A4	O
activities	O
,	O
respectively	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Combination	O
of	O
ellagic	O
acid	O
with	O
warfarin	O
significantly	O
inhibited	O
activities	O
of	O
CYP2C8	O
,	O
2C9	O
and	O
3A4	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
however	O
treatment	O
of	O
cells	O
with	O
ellagic	O
acid	O
alone	O
presented	O
significant	O
inhibition	O
on	O
CYP2C9	B
activity	O
despite	O
other	O
CYPs	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Although	O
guava	O
leaves	O
extract	O
showed	O
an	O
insignificant	O
effect	O
on	O
CYP2C8	O
when	O
used	O
alone	O
,	O
it	O
significantly	O
reduced	O
its	O
activity	O
when	O
combined	O
with	O
warfarin	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
however	O
,	O
inhibited	O
the	O
activities	O
of	O
CYP2C9	B
and	O
3A4	O
when	O
used	O
alone	O
and	O
concomitantly	O
with	O
warfarin	O
(	O
p	O
-	O
values	O
are	O
marked	O
in	O
Figs	O
.	O

Noteworthy	O
,	O
the	O
evaluation	O
of	O
CYP450	O
enzymes	O
,	O
namely	O
,	O
CYP2C9	B
,	O
2C8	O
,	O
3A4	O
was	O
based	O
on	O
cell	O
-	O
based	O
investigations	O
and	O
sufficient	O
inhibition	O
of	O
corresponding	O
well	O
-	O
known	O
Cytochrome	B
P450	B
Enzymes	I
control	O
inhibitors	O
including	O
,	O
sulfamethoxazole	O
,	O
trimethoprim	O
and	O
ketoconazole	O
confirms	O
that	O
in	O
vitro	O
investigation	O
of	O
mentioned	O
Cytochrome	B
P450	B
Enzymes	I
isoforms	O
on	O
rat	O
hepatocyte	O
is	O
possible	O
,	O
as	O
raised	O
in	O
the	O
literature	O
[	O
,	O
.	O

In	O
regard	O
to	O
results	O
presented	O
for	O
ellagic	O
acid	O
,	O
and	O
since	O
it	O
is	O
known	O
to	O
exert	O
inhibition	O
on	O
CYP2C9	B
,	O
its	O
effect	O
may	O
be	O
due	O
to	O
a	O
decrease	O
in	O
hepatic	O
first	O
-	O
pass	O
metabolism	O
of	O
warfarin	O
due	O
to	O
its	O
ability	O
to	O
inhibit	O
such	O
Cytochrome	O
P450	O
Enzymes	O
isoform	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
guava	O
leaves	O
extract	O
and	O
quercetin	O
to	O
inhibit	O
some	O
of	O
hepatic	O
Cytochrome	O
P450	O
Enzymes	O
isoforms	O
associated	O
with	O
warfarin	O
metabolism	O
such	O
as	O
CYP2C9	B
,	O
2C8	O
and	O
3A4	O
may	O
be	O
responsible	O
for	O
increasing	O
warfarin	O
plasma	O
concentration	O
[	O
,	O
.	O

In	O
vitro	O
warfarin	O
-	O
herb	O
interactions	O
and	O
their	O
effects	O
on	O
hepatic	O
Cytochrome	O
P450	O
Enzymes	O
isoforms	O
showed	O
that	O
CYP2C9	B
,	O
2C8	O
and	O
3A4	O
activities	O
in	O
primary	O
isolated	O
and	O
cultured	O
rat	O
hepatocytes	O
were	O
not	O
affected	O
by	O
warfarin	O
.	O

Significant	O
reduction	O
exerted	O
by	O
the	O
use	O
of	O
ellagic	O
acid	O
whether	O
used	O
alone	O
or	O
concomitantly	O
with	O
warfarin	O
is	O
in	O
line	O
with	O
those	O
reported	O
in	O
previous	O
studies	O
which	O
showed	O
that	O
ellagic	O
acid	O
had	O
inhibitory	O
effect	O
on	O
many	O
CYPs	O
isoforms	O
including	O
CYP2C9	B
.	O

In	O
reviewing	O
the	O
literature	O
,	O
no	O
data	O
was	O
found	O
on	O
warfarin	O
combinations	O
with	O
pomegranate	O
peel	O
extract	O
and	O
ellagic	O
acid	O
effect	O
on	O
CYP2C9	B
,	O
2C8	O
and	O
3A4	O
activities	O
.	O

The	O
observed	O
reduction	O
in	O
CYP2C9	B
activity	O
upon	O
treatment	O
with	O
by	O
guava	O
leaves	O
extract	O
,	O
quercetin	O
and	O
their	O
combinations	O
with	O
warfarin	O
could	O
be	O
attributed	O
to	O
the	O
competitive	O
inhibitory	O
effect	O
of	O
quercetin	O
on	O
CYP2C9	B
.	O

These	O
results	O
were	O
consistent	O
with	O
previous	O
studies	O
that	O
demonstrated	O
the	O
inhibitory	O
effects	O
of	O
guava	O
leaves	O
extract	O
and	O
quercetin	O
on	O
CYP2C9	B
activity	O
[	O
,	O
.	O

The	O
possible	O
mechanism	O
for	O
that	O
is	O
their	O
inhibitory	O
effect	O
on	O
CYP2C9	B
,	O
2C8	O
and	O
3A4	O
isoforms	O
which	O
are	O
responsible	O
for	O
warfarin	O
metabolism	O
.	O

The	O
previously	O
mentioned	O
interactions	O
might	O
be	O
attributed	O
to	O
the	O
inhibitory	O
effects	O
of	O
guava	O
leaves	O
,	O
quercetin	O
and	O
ellagic	O
acid	O
on	O
CYP2C9	B
,	O
2C8	O
and	O
3A4	O
that	O
are	O
responsible	O
for	O
the	O
metabolism	O
of	O
warfarin	O
.	O

Additionally	O
,	O
the	O
compounds	O
F2	O
,	O
F3	O
,	O
F11	O
,	O
F20	O
,	O
and	O
F21	O
were	O
found	O
to	O
be	O
the	O
substrate	O
of	O
CYP2C9	B
.	O

Likewise	O
for	O
predicting	O
the	O
site	O
of	O
enzyme	O
CYP2C9	B
,	O
the	O
K_m	O
value	O
was	O
3	O
.	O
43	O
,	O
5	O
.	O
38	O
,	O
3	O
.	O
81	O
,	O
3	O
.	O
59	O
and	O
37	O
.	O
40	O
M	O
,	O
whereas	O
the	O
V_max	O
constant	O
was	O
0	O
.	O
38	O
,	O
0	O
.	O
35	O
,	O
0	O
.	O
24	O
,	O
0	O
.	O
49	O
and	O
4	O
.	O
95	O
nM	O
/	O
min	O
/	O
nM	O
and	O
the	O
C_Lint	O
was	O
8	O
.	O
14	O
,	O
4	O
.	O
8	O
,	O
4	O
.	O
61	O
,	O
9	O
.	O
97	O
and	O
9	O
.	O
67	O
L	O
/	O
min	O
/	O
mg	O
for	O
compounds	O
F2	O
,	O
F3	O
,	O
F11	O
,	O
F20	O
and	O
F21	O
,	O
respectively	O
.	O

However	O
,	O
results	O
of	O
inhibition	O
studies	O
showed	O
that	O
all	O
the	O
compound	O
might	O
inhibit	O
CYP1A2	O
,	O
CYP2C9	B
,	O
and	O
CYP2D6	O
,	O
except	O
compound	O
F2	O
which	O
did	O
not	O
inhibit	O
the	O
CYP2D6	O
.	O

This	O
drug	O
undergoes	O
hepatic	O
metabolism	O
by	O
Cytochrome	O
P450	O
3a4	O
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
CYP2C9	B
.	O

The	O
CYP2C19	O
gene	O
is	O
part	O
of	O
the	O
CYP2C	O
cluster	O
comprising	O
four	O
genes	O
(	O
CYP2C8	O
,	O
CYP2C9	B
,	O
CYP2C18	O
and	O
CYP2C19	O
)	O
.	O

In	O
additions	O
,	O
others	O
have	O
also	O
reported	O
strong	O
association	O
between	O
CYP2C9	B
allelic	O
variants	O
and	O
phenytoin	O
dose	O
requirement	O
.	O

Several	O
studies	O
have	O
been	O
focused	O
on	O
drug	O
-	O
drug	O
interactions	O
and	O
genetic	O
polymorphisms	O
including	O
CYP2D6	B
,	O
CYP2C9	B
and	O
CYP2C19	B
activities	O
.	O

In	O
contrast	O
,	O
variants	O
of	O
CYP2C9	B
are	O
more	O
prevalent	O
among	O
whites	O
(	O
35	O
%	O
)	O
compared	O
with	O
African	O
-	O
American	O
and	O
Asian	O
populations	O
(	O
<	O
10	O
%	O
)	O
.	O

CYP1A	O
-	O
catalyzed	O
reactions	O
include	O
hydroxylation	O
and	O
oxidation	O
of	O
aromatic	O
compounds	O
,	O
in	O
which	O
CYP1A1	B
is	O
mainly	O
involved	O
in	O
the	O
metabolism	O
of	O
aromatic	O
hydrocarbon	O
,	O
while	O
CYP1A2	O
prefers	O
aromatic	O
amines	O
and	O
heterocyclic	O
compounds	O
.	O

Compared	O
with	O
CYP1A2	O
,	O
CYP1A1	B
is	O
the	O
main	O
isoform	O
mediating	O
the	O
biotransformation	O
of	O
pregnenolone	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
CYP1A1	B
is	O
the	O
dominating	O
enzyme	O
and	O
catalyzes	O
the	O
BETA	O
-	O
hydroxylation	O
of	O
pregnenolone	O
at	O
the	O
C	O
-	O
7	O
site	O
,	O
with	O
the	O
K_m	O
of	O
3	O
.	O
2	O
-	O
4	O
.	O
1	O
mol	O
/	O
L	O
and	O
CL_int	O
of	O
117	O
-	O
135	O
pmol	O
/	O
min	O
/	O
nmol	O
.	O

Moreover	O
,	O
the	O
CYP1A1	B
,	O
which	O
involves	O
7	O
-	O
hydroxylated	O
steroids	O
,	O
may	O
contribute	O
to	O
the	O
activation	O
of	O
immune	O
defense	O
.	O

Furthermore	O
,	O
CYP1A1	B
also	O
hydroxylates	O
pregnenolone	O
to	O
form	O
16ALPHA	O
-	O
and	O
17ALPHA	O
-	O
hydroxylated	O
pregnenolone	O
.	O

For	O
example	O
,	O
CYP1A1	B
shows	O
high	O
hydroxylase	O
activity	O
of	O
progesterone	O
,	O
which	O
results	O
in	O
the	O
formation	O
of	O
6BETA	O
-	O
hydroxyl	O
and	O
16ALPHA	O
-	O
hydroxyl	O
progesterone	O
,	O
with	O
the	O
V_max	O
at	O
16	O
.	O
4	O
and	O
7	O
.	O
7	O
pmol	O
/	O
min	O
/	O
pmol	O
P450	O
,	O
respectively	O
.	O

Both	O
CYP1A1	B
and	O
CYP1A2	B
are	O
involved	O
in	O
the	O
biotransformation	O
of	O
estrone	O
,	O
but	O
they	O
mediate	O
different	O
reaction	O
types	O
.	O

In	O
contrast	O
,	O
CYP1A1	B
oxidizes	O
estrone	O
to	O
quinol	O
at	O
the	O
C	O
-	O
10	O
position	O
.	O

CYP1A1	B
is	O
the	O
main	O
isoform	O
mediating	O
the	O
hydroxylation	O
of	O
estradiol	O
at	O
different	O
sites	O
(	O
A	O
)	O
.	O

CYP1A1	B
mediates	O
the	O
hydroxylation	O
of	O
estradiol	O
at	O
a	O
relatively	O
low	O
K_m	O
of	O
2	O
.	O
9	O
and	O
2	O
.	O
7	O
mol	O
/	O
L	O
,	O
respectively	O
.	O

The	O
V_max	O
of	O
CYP1A1	B
at	O
C	O
-	O
2	O
and	O
C	O
-	O
4	O
are	O
14	O
.	O
7	O
and	O
0	O
.	O
4	O
nmol	O
/	O
min	O
/	O
nmol	O
P450	O
,	O
respectively	O
,	O
which	O
indicates	O
the	O
main	O
production	O
of	O
2	O
-	O
hydroxylation	O
estradiol	O
compared	O
with	O
4	O
-	O
hydroxylation	O
estradiol	O
^	O
,	O
.	O

Moreover	O
,	O
CYP1A1	B
also	O
hydroxylates	O
estradiol	O
at	O
C	O
-	O
6	O
and	O
C	O
-	O
15	O
,	O
and	O
forms	O
ALPHA	O
-	O
hydroxylated	O
estradiol	O
at	O
corresponding	O
sites	O
.	O

In	O
addition	O
to	O
participating	O
in	O
the	O
hydroxylation	O
of	O
estradiol	O
,	O
CYP1A1	B
is	O
also	O
involved	O
in	O
the	O
quinol	O
formation	O
,	O
with	O
the	O
product	O
of	O
10BETA	O
,	O
17BETA	O
-	O
dihydroxy	O
-	O
1	O
,	O
4	O
-	O
estradiene	O
-	O
3	O
-	O
one	O
.	O

Compared	O
with	O
CYP1A1	B
,	O
CYP1A2	B
contributes	O
to	O
the	O
hydroxylation	O
of	O
estradiol	O
at	O
C	O
-	O
2	O
and	O
C	O
-	O
4	O
with	O
a	O
lower	O
V_max	O
^	O
,	O
^	O
,	O
(	O
A	O
)	O
.	O

CYP1A1	B
and	O
CYP1A2	B
metabolize	O
estradiol	O
3	O
-	O
methyl	O
ether	O
to	O
estradiol	O
through	O
3	O
-	O
demethylation	O
reaction	O
with	O
the	O
V_max	O
of	O
0	O
.	O
07	O
and	O
0	O
.	O
02	O
pmol	O
/	O
min	O
/	O
pmol	O
P450	O
,	O
respectively	O
(	O
B	O
)	O
.	O

CYP1A1	B
hydroxylates	O
testosterone	O
to	O
produce	O
6BETA	O
-	O
hydroxyl	O
testosterone	O
,	O
with	O
the	O
K_m	O
and	O
V_max	O
at	O
10	O
.	O
1	O
mol	O
/	O
L	O
and	O
14	O
.	O
8	O
pmol	O
/	O
min	O
/	O
pmol	O
P450	O
,	O
respectively	O
.	O

CYP1A1	B
and	O
CYP1A2	B
both	O
catalyze	O
melatonin	O
to	O
form	O
6	O
-	O
hydroxymelatonin	O
,	O
and	O
CYP1A2	B
is	O
the	O
primary	O
isoform	O
,	O
which	O
promotes	O
this	O
biotransformation	O
^	O
,	O
(	O
A	O
)	O
.	O

Compared	O
with	O
other	O
Cytochrome	B
P450	I
isoforms	O
,	O
CYP1A1	B
and	O
CYP1A2	B
exhibited	O
retinol	O
dehydrogenase	O
activity	O
with	O
a	O
relative	O
low	O
K_m	O
(	O
8	O
mol	O
/	O
L	O
for	O
CYP1A1	B
and	O
9	O
mol	O
/	O
L	O
for	O
CYP1A2	B
)	O
and	O
high	O
V_max	O
(	O
507	O
pmol	O
/	O
min	O
/	O
nmol	O
Cytochrome	B
P450	I
for	O
CYP1A1	B
and	O
491	O
pmol	O
/	O
min	O
/	O
nmol	O
Cytochrome	B
P450	I
for	O
CYP1A2	B
)	O
(	O
B	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
CYP1A1	B
and	O
CYP1A2	B
also	O
showed	O
high	O
activity	O
of	O
retinal	O
dehydrogenase	O
,	O
forming	O
the	O
functional	O
metabolite	O
t	O
-	O
RA	O
(	O
B	O
)	O
.	O

These	O
studies	O
indicate	O
that	O
CYP1A1	B
and	O
CYP1A2	B
are	O
two	O
major	O
enzymes	O
for	O
human	O
t	O
-	O
ROH	O
to	O
form	O
t	O
-	O
RA	O
,	O
compared	O
with	O
other	O
Cytochrome	B
P450	I
isoforms	O
.	O

In	O
particular	O
,	O
CYP1A1	B
or	O
CYP1A2	B
mutations	O
are	O
reported	O
to	O
be	O
associated	O
with	O
many	O
human	O
diseases	O
,	O
suggesting	O
that	O
CYP1A	O
may	O
affect	O
these	O
diseases	O
by	O
regulating	O
the	O
formation	O
or	O
metabolism	O
of	O
some	O
endogenous	O
mediators	O
.	O

At	O
the	O
Pharmacogene	O
Variation	O
Consortium	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
pharmvar	O
.	O
org	O
/	O
)	O
,	O
there	O
are	O
27	O
and	O
48	O
Single	O
Nucleotide	O
Polymorphisms	O
for	O
human	O
CYP1A1	B
and	O
CYP1A2	B
,	O
respectively	O
,	O
of	O
which	O
14	O
and	O
40	O
variants	O
have	O
been	O
identified	O
.	O

In	O
this	O
section	O
,	O
we	O
will	O
focus	O
on	O
the	O
relationship	O
between	O
single	O
nucleotide	O
changes	O
in	O
CYP1A1	B
/	O
2	O
and	O
human	O
diseases	O
.	O

Eleven	O
Single	O
Nucleotide	O
Polymorphisms	O
of	O
CYP1A1	B
in	O
human	O
diseases	O
such	O
as	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
male	O
infertility	O
,	O
and	O
various	O
cancers	O
were	O
collected	O
.	O

CYP1A1	B
*	O
2A	O
(	O
SNP	O
ID	O
:	O
rs4646903	O
)	O
,	O
also	O
known	O
as	O
Mspl	O
,	O
has	O
T	O
-	O
C	O
mutation	O
at	O
3801	O
.	O

CYP1A1	B
*	O
2A	O
is	O
reported	O
to	O
be	O
positively	O
correlated	O
with	O
the	O
risk	O
or	O
incidence	O
of	O
a	O
series	O
of	O
cancers	O
,	O
including	O
esophageal	O
,	O
oral	O
,	O
laryngeal	O
,	O
prostate	O
,	O
cervical	O
,	O
bladder	O
,	O
and	O
lung	O
cancers	O
.	O

In	O
contrast	O
,	O
CYP1A2	B
is	O
more	O
likely	O
to	O
mediate	O
hydroxylation	O
at	O
the	O
C	O
-	O
6	O
site	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
6BETA	O
-	O
hydroxyl	O
progesterone	O
.	O

CYP1A2	B
is	O
thought	O
to	O
be	O
involved	O
in	O
estrone	O
metabolism	O
by	O
direct	O
hydrolysis	O
of	O
C	O
-	O
2	O
,	O
C	O
-	O
4	O
,	O
and	O
C	O
-	O
16	O
sites	O
^	O
,	O
.	O

CYP1A2	B
also	O
participates	O
in	O
the	O
hydroxylation	O
of	O
estradiol	O
at	O
C	O
-	O
16	O
,	O
while	O
the	O
C	O
-	O
2	O
hydroxylation	O
estradiol	O
is	O
a	O
dominant	O
hydroxylated	O
metabolite	O
catalyzed	O
by	O
CYP1A2	B
^	O
,	O
(	O
A	O
)	O
.	O

CYP1A2	B
also	O
hydroxylates	O
estradiol	O
3	O
-	O
methyl	O
ether	O
at	O
C	O
-	O
2	O
to	O
increase	O
its	O
hydrophilicity	O
,	O
which	O
may	O
contribute	O
to	O
its	O
excretion	O
from	O
the	O
body	O
.	O

In	O
addition	O
,	O
CYP1A2	B
catalyzes	O
the	O
O	O
-	O
demethylation	O
of	O
melatonin	O
to	O
produce	O
N	O
-	O
acetylserotonin	O
(	O
A	O
)	O
.	O

In	O
recent	O
ten	O
years	O
,	O
a	O
new	O
metabolite	O
of	O
melatonin	O
has	O
been	O
reported	O
,	O
named	O
melatonin	O
metabolite	O
VII	O
,	O
which	O
is	O
also	O
a	O
metabolite	O
mediated	O
by	O
CYP1A2	B
.	O

In	O
particular	O
,	O
CYP1A2	B
converts	O
linoleic	O
acid	O
into	O
hydroxyoctadecdienoic	O
acids	O
and	O
cis	O
-	O
epoxyoctadecenoics	O
(	O
C	O
)	O
with	O
comparable	O
catalytic	O
activity	O
.	O

CYP1A2	B
possesses	O
an	O
unusual	O
catalytic	O
activity	O
similar	O
to	O
phospholipase	O
D	O
-	O
type	O
hydrolysis	O
enzymes	O
.	O

Based	O
on	O
the	O
metabolic	O
activity	O
,	O
CYP1A2	B
converts	O
phosphatidylcholine	O
to	O
choline	O
and	O
phosphatidic	O
acid	O
^	O
,	O
^	O
,	O
(	O
A	O
)	O
.	O

This	O
may	O
imply	O
the	O
important	O
physiological	O
role	O
of	O
CYP1A2	B
,	O
because	O
as	O
a	O
signal	O
transduction	O
messenger	O
,	O
phosphatidic	O
acid	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
cell	O
activity	O
.	O

Previous	O
studies	O
have	O
also	O
found	O
that	O
human	O
CYP1A2	B
catalyzes	O
the	O
oxidation	O
of	O
uroporphyrinogen	O
^	O
,	O
(	O
B	O
)	O
.	O

For	O
CYP1A2	B
,	O
nine	O
Single	O
Nucleotide	O
Polymorphisms	O
are	O
found	O
to	O
be	O
associated	O
with	O
human	O
diseases	O
,	O
including	O
hypertension	O
,	O
age	O
-	O
related	O
macular	O
degeneration	O
,	O
and	O
some	O
cancers	O
.	O

CYP1A2	B
*	O
1F	O
(	O
SNP	O
ID	O
:	O
rs762551	O
)	O
has	O
a	O
C	O
to	O
A	O
mutation	O
at	O
-	O
163	O
,	O
which	O
may	O
be	O
related	O
to	O
breast	O
cancer	O
,	O
ovarian	O
cancer	O
,	O
mammographic	O
density	O
,	O
and	O
risk	O
of	O
infant	O
birth	O
size	O
,	O
because	O
it	O
is	O
involved	O
in	O
the	O
biological	O
transformation	O
of	O
sex	O
hormones	O
^	O
,	O
^	O
,	O
^	O
,	O
.	O

As	O
mentioned	O
earlier	O
,	O
CYP1A1	O
and	O
CYP1A2	B
are	O
involved	O
in	O
the	O
biotransformation	O
of	O
multiple	O
estrogens	O
,	O
and	O
thus	O
are	O
important	O
for	O
maintaining	O
the	O
balance	O
of	O
estrogens	O
.	O

However	O
,	O
the	O
metabolic	O
activity	O
of	O
CYP1A2	B
SNP	O
(	O
rs2069514	O
)	O
was	O
lower	O
than	O
that	O
of	O
wild	O
type	O
.	O

There	O
was	O
no	O
significant	O
correlation	O
between	O
CYP1A2	B
SNP	O
and	O
mental	O
disorders	O
.	O

Similarly	O
,	O
another	O
CYP1A2	B
SNP	O
(	O
rs762551	O
)	O
showed	O
no	O
significant	O
dependence	O
on	O
mental	O
disorders	O
with	O
the	O
increase	O
of	O
inducibility	O
.	O

However	O
,	O
for	O
super	O
-	O
refractory	O
schizophrenia	O
,	O
the	O
frequency	O
of	O
CYP1A2	B
SNP	O
(	O
rs762551	O
)	O
in	O
super	O
-	O
refractory	O
group	O
(	O
87	O
%	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
refractory	O
group	O
(	O
53	O
.	O
7	O
%	O
)	O
.	O

Therefore	O
,	O
the	O
role	O
of	O
CYP1A2	B
SNP	O
in	O
mental	O
disorders	O
should	O
be	O
studied	O
in	O
more	O
detail	O
.	O

Although	O
neonatal	O
survival	O
is	O
associated	O
with	O
CYP1A2	B
in	O
Cyp1a2	O
knockout	O
mice	O
,	O
the	O
relationship	O
between	O
retinol	O
and	O
reproductive	O
diseases	O
remains	O
unclear	O
.	O

However	O
,	O
CYP1A1	O
SNP	O
(	O
rs1048943	O
)	O
and	O
CYP1A2	B
Single	O
Nucleotide	O
Polymorphisms	O
(	O
rs762551	O
,	O
rs1133323	O
,	O
and	O
rs1378942	O
)	O
are	O
positively	O
correlated	O
with	O
hypertension	O
susceptibility	O
^	O
,	O
.	O

CYP1A2	B
is	O
mainly	O
responsible	O
for	O
the	O
transformation	O
of	O
uroporphyrinogen	O
to	O
uroporphyrin	O
.	O

Nonetheless	O
,	O
the	O
association	O
between	O
CYP1A2	B
Single	O
Nucleotide	O
Polymorphisms	O
and	O
porphyria	O
cutanea	O
tarda	O
remains	O
uncertain	O
.	O

In	O
this	O
part	O
,	O
the	O
Single	O
Nucleotide	O
Polymorphisms	O
of	O
CYP1A	O
(	O
11	O
for	O
CYP1A1	O
and	O
9	O
for	O
CYP1A2	B
)	O
studied	O
most	O
in	O
recent	O
10	O
years	O
are	O
reviewed	O
for	O
the	O
first	O
time	O
,	O
and	O
the	O
relationship	O
between	O
CYP1A	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
human	O
diseases	O
is	O
summarized	O
.	O

For	O
human	O
cells	O
:	O
phenacetin	O
(	O
CYP1A2	B
)	O
,	O
efavirenz	O
(	O
CYP2B6	O
)	O
,	O
amodiaquine	O
(	O
CYP2C8	O
)	O
,	O
diclofenac	O
(	O
CYP2C9	O
)	O
,	O
dextromethorphan	O
(	O
CYP2D6	B
)	O
,	O
testosterone	O
(	O
CYP3A4	O
)	O
,	O
and	O
for	O
rat	O
cells	O
phenacetin	O
(	O
CYP1A2	B
)	O
,	O
testosterone	O
(	O
CYP2A1	O
,	O
CYP3A1	O
,	O
CYP3A2	O
)	O
,	O
diclofenac	O
(	O
CYP2C6	O
)	O
testosterone	O
(	O
CYP2C11	O
)	O
,	O
and	O
Pnitrophenol	O
(	O
CYP2E1	O
)	O
were	O
used	O
.	O

We	O
identified	O
the	O
position	O
of	O
each	O
amino	O
acid	O
for	O
each	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
the	O
upstream	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
downstream	O
Single	O
Nucleotide	O
Polymorphisms	O
including	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
rs28399504	O
(	O
CYP2C19	B
*	O
4	O
)	O
located	O
on	O
amino	O
acid	O
number	O
1	O
(	O
valine	O
)	O
,	O
rs17878459	O
(	O
CYP2C19	B
*	O
17	O
)	O
,	O
located	O
on	O
amino	O
acid	O
92	O
,	O
(	O
aspartic	O
,	O
D	O
)	O
,	O
rs4986893	O
CYP2C19	B
*	O
3	O
located	O
on	O
amino	O
acid	O
number	O
212	O
(	O
NA	O
)	O
,	O
rs4244285	O
(	O
CYP2C19	B
*	O
2	O
)	O
located	O
on	O
amino	O
acid	O
227	O
(	O
proline	O
)	O
,	O
and	O
rs56337013	O
(	O
CYP2C19	B
*	O
5	O
)	O
located	O
on	O
amino	O
acid	O
number	O
433	O
(	O
tryptophan	O
,	O
W	O
)	O
.	O

In	O
general	O
terms	O
,	O
people	O
carrying	O
two	O
loss	O
-	O
of	O
-	O
function	O
CYP2C19	B
alleles	O
(	O
eg	O
,	O
CYP2C19	B
*	O
2	O
,	O
CYP2C19	B
*	O
3	O
or	O
CYP2C19	B
*	O
4	O
)	O
are	O
considered	O
to	O
be	O
poor	O
metabolizers	O
with	O
deficient	O
enzyme	O
activity	O
.	O

Individuals	O
with	O
single	O
loss	O
-	O
of	O
-	O
function	O
allele	O
and	O
a	O
wild	O
-	O
type	O
allele	O
(	O
CYP2C19	B
*	O
1	O
)	O
are	O
intermediate	O
metabolizers	O
,	O
whereas	O
two	O
wild	O
-	O
type	O
are	O
extensive	O
metabolizers	O
.	O

People	O
that	O
are	O
homozygous	O
or	O
heterozygous	O
for	O
CYP2C19	B
*	O
17	O
alleles	O
are	O
typically	O
considered	O
to	O
be	O
ultrarapid	O
metabolizers	O
,	O
supposing	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
are	O
not	O
present	O
.	O

It	O
has	O
been	O
suggested	O
that	O
inherited	O
genetic	O
variation	O
in	O
CYP2C19	B
and	O
its	O
variable	O
hepatic	O
expression	O
can	O
contribute	O
to	O
inter	O
-	O
individual	O
phenotypic	O
variability	O
in	O
CYP2C19	B
-	O
substrate	O
metabolism	O
.	O

CYP2C19	B
proteins	O
can	O
catalyze	O
many	O
reactions	O
involved	O
in	O
drug	O
metabolism	O
and	O
synthesis	O
of	O
cholesterol	O
,	O
steroids	O
and	O
other	O
lipids	O
,	O
and	O
this	O
protein	O
localizes	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
is	O
known	O
to	O
metabolize	O
many	O
drugs	O
.	O

The	O
genotype	O
has	O
been	O
suggested	O
CYP2C19	B
to	O
affect	O
the	O
metabolism	O
of	O
several	O
.	O

It	O
has	O
been	O
reported	O
that	O
CYP2C19	B
*	O
2	O
and	O
*	O
3	O
mutant	O
alleles	O
caused	O
decreased	O
hydroxylation	O
of	O
phenytoin	O
in	O
vivo	O
,	O
whereas	O
the	O
mutant	O
alleles	O
of	O
CYP2C19	B
played	O
only	O
a	O
minor	O
role	O
in	O
the	O
metabolism	O
of	O
phenytoin	O
in	O
subjects	O
.	O

The	O
genetic	O
polymorphisms	O
of	O
CYP2C19	B
have	O
been	O
associated	O
with	O
variable	O
responses	O
of	O
drugs	O
with	O
clinical	O
relevance	O
,	O
by	O
affecting	O
drug	O
metabolic	O
clearance	O
that	O
subsequently	O
contribute	O
to	O
variabilities	O
in	O
pharmacodynamics	O
that	O
include	O
both	O
efficacy	O
and	O
safety	O
.	O

In	O
particular	O
,	O
CYP2C19	B
enzyme	O
is	O
involved	O
in	O
the	O
hepatic	O
metabolism	O
of	O
drugs	O
such	O
as	O
chemotherapeutic	O
agents	O
(	O
cyclophosphamide	O
)	O
,	O
anti	O
-	O
epileptics	O
(	O
S	O
-	O
mephenytoin	O
,	O
diazepam	O
,	O
phenobarbitone	O
)	O
,	O
antiplatelets	O
(	O
clopidogrel	O
)	O
,	O
proton	O
pump	O
inhibitors	O
(	O
omeprazole	O
,	O
pantoprazole	O
,	O
lansoprazole	O
,	O
rabeprazole	O
)	O
,	O
antivirals	O
(	O
nelfinavir	O
)	O
,	O
and	O
antidepressants	O
(	O
amitriptyline	O
,	O
clomipramine	O
)	O
.	O

To	O
better	O
understand	O
the	O
genetics	O
and	O
drug	O
metabolizing	O
enzymes	O
of	O
CYP2C19	B
it	O
is	O
important	O
to	O
study	O
the	O
variability	O
in	O
drug	O
response	O
and	O
adverse	O
drug	O
reactions	O
.	O

Subjects	O
with	O
epilepsy	O
can	O
be	O
classified	O
based	O
on	O
the	O
ability	O
to	O
metabolize	O
CYP2C19	B
substrates	O
.	O

For	O
example	O
,	O
Extensive	O
Metabolizers	O
individuals	O
are	O
homozygous	O
for	O
the	O
CYP2C19	B
*	O
1	O
allele	O
,	O
which	O
is	O
associated	O
with	O
functional	O
CYP2C19	B
-	O
mediated	O
metabolism	O
.	O

The	O
IM	O
genotype	O
consists	O
of	O
one	O
wild	O
-	O
type	O
allele	O
and	O
one	O
variant	O
allele	O
that	O
encodes	O
reduced	O
or	O
absent	O
enzyme	O
function	O
(	O
eg	O
,	O
*	O
1	O
/	O
*	O
2	O
,	O
*	O
1	O
/	O
*	O
3	O
)	O
,	O
resulting	O
in	O
decreased	O
CYP2C19	B
activity	O
,	O
while	O
,	O
PM	O
individuals	O
have	O
two	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
(	O
eg	O
,	O
*	O
2	O
/	O
*	O
2	O
,	O
*	O
2	O
/	O
*	O
3	O
,	O
*	O
3	O
/	O
*	O
3	O
)	O
,	O
resulting	O
in	O
markedly	O
reduced	O
or	O
absent	O
CYP2C19	B
activity	O
.	O

For	O
CYP2C19	B
(	O
rs12248560	O
)	O
,	O
SNP	O
is	O
located	O
on	O
the	O
CYP2C19	B
*	O
17	O
allele	O
and	O
is	O
a	O
C	O
>	O
T	O
transition	O
in	O
the	O
promoter	O
that	O
creates	O
a	O
consensus	O
binding	O
site	O
for	O
the	O
GATA	O
transcription	O
factor	O
family	O
,	O
resulting	O
in	O
increased	O
CYP2C19	B
expression	O
and	O
activity	O
.	O

It	O
has	O
been	O
indicated	O
that	O
the	O
CYP2C19	B
*	O
17	O
allele	O
frequencies	O
are	O
approximately	O
21	O
%	O
in	O
Caucasians	O
,	O
16	O
%	O
in	O
African	O
-	O
Americans	O
,	O
and	O
3	O
%	O
in	O
Asians	O
.	O

There	O
was	O
conflict	O
about	O
whether	O
CYP2C19	B
*	O
1	O
/	O
*	O
17	O
is	O
considered	O
an	O
Ultrarapid	O
Metabolizers	O
or	O
Extensive	O
Metabolizers	O
in	O
literature	O
.	O

Two	O
studies	O
reported	O
about	O
this	O
CYP2C19	B
*	O
1	O
/	O
*	O
17	O
metabolism	O
,	O
while	O
,	O
another	O
considered	O
those	O
with	O
the	O
CYP2C19	B
*	O
1	O
/	O
*	O
17	O
heterozygotes	O
as	O
Ultrarapid	O
Metabolizers	O
,	O
while	O
,	O
other	O
considered	O
them	O
as	O
EMs	O
within	O
the	O
same	O
group	O
as	O
the	O
wild	O
-	O
type	O
CYP2C19	B
*	O
1	O
homozygotes	O
.	O

Finally	O
,	O
a	O
CYP2D6	B
*	O
17	O
polymorphism	O
with	O
reduced	O
activity	O
was	O
not	O
investigated	O
in	O
our	O
study	O
as	O
it	O
was	O
not	O
included	O
in	O
the	O
array	O
used	O
for	O
the	O
PI	O
.	O

Carriers	O
of	O
CYP2C19	O
*	O
2	O
(	O
rs4244285	O
;	O
Pro227Pro	O
)	O
or	O
CYP2D6	B
*	O
10	O
(	O
rs1065852	O
,	O
Pro34Ser	O
)	O
had	O
sorafenib	O
plasma	O
levels	O
and	O
associated	O
liver	O
/	O
renal	O
toxicity	O
that	O
were	O
intermediate	O
between	O
those	O
of	O
rats	O
carrying	O
CYP3A5	B
*	O
3	O
or	O
CYP3A4	B
*	O
1	O
genetic	O
variants	O
.	O

Specific	O
UPD	O
/	O
ALD	O
probes	O
reveal	O
that	O
CYP2D6	B
and	O
CYP2A5	O
also	O
similarly	O
turn	O
over	O
via	O
both	O
pathways	O
,	O
.	O

Anti	O
-	O
P450	O
autoantibodies	O
(	O
anti	O
-	O
liver	O
kidney	O
microsomal	O
Type	O
I	O
)	O
targeting	O
CYP2D6	B
are	O
also	O
detected	O
in	O
chronic	O
autoimmune	O
hepatitis	O
and	O
hepatitis	O
C	O
viral	O
infections	O
,	O
anti	O
-	O
CYP11A1	O
in	O
type	O
II	O
autoimmune	O
hepatic	O
polyendocrine	O
syndrome	O
,	O
and	O
anti	O
-	O
CYP17	O
and	O
anti	O
-	O
CYP21	O
in	O
Addison	O
'	O
s	O
disease	O
,	O
.	O

To	O
investigate	O
whether	O
metabolic	O
activation	O
by	O
human	O
phase	O
I	O
enzymes	O
-	O
at	O
least	O
in	O
part	O
-	O
contributes	O
to	O
the	O
cytotoxic	O
effect	O
,	O
Ze	O
339	O
(	O
concentrations	O
up	O
to	O
100	O
g	O
/	O
ml	O
)	O
was	O
coincubated	O
in	O
HepaRG	O
cells	O
for	O
4	O
hr	O
with	O
different	O
single	O
cytochromes	O
inhibitors	O
:	O
ketoconazole	O
(	O
CYP3A4	O
)	O
,	O
sulfaphenazole	O
(	O
CYP2C9	O
)	O
,	O
montelukast	O
(	O
CYP2C8	O
)	O
,	O
omeprazole	O
(	O
CYP2C19	O
)	O
,	O
ALPHAnaphthoflavone	O
(	O
CYP1A2	O
)	O
,	O
quinidine	O
(	O
CYP2D6	B
)	O
,	O
xanthotoxin	O
(	O
CYP2A6	O
)	O
,	O
chlormethiazole	O
(	O
CYP2E1	O
)	O
,	O
and	O
ticlopidine	O
(	O
CYP2B6	O
)	O
-	O
(	O
each	O
at	O
a	O
concentration	O
of	O
10	O
M	O
)	O
.	O

The	O
incubation	O
with	O
single	O
human	O
cytochromes	O
revealed	O
that	O
petasin	O
was	O
mainly	O
metabolized	O
by	O
CYP2D6	B
(	O
80	O
.	O
2	O
%	O
)	O
and	O
to	O
an	O
intermediate	O
extent	O
by	O
CYP3A4	O
(	O
34	O
%	O
)	O
,	O
CYP2B6	O
(	O
50	O
%	O
)	O
,	O
CYP2C8	O
(	O
54	O
%	O
)	O
,	O
and	O
CYP2C9	O
(	O
51	O
%	O
)	O
.	O

However	O
,	O
for	O
isopetasin	O
and	O
neopetasin	O
,	O
the	O
cytochromes	O
mainly	O
involved	O
in	O
their	O
metabolism	O
were	O
CYP3A4	O
(	O
87	O
%	O
and	O
86	O
%	O
)	O
,	O
CYP2D6	B
(	O
61	O
%	O
and	O
83	O
%	O
)	O
,	O
and	O
CYP2C8	O
(	O
44	O
%	O
and	O
71	O
%	O
)	O
.	O

Most	O
pronounced	O
was	O
the	O
difference	O
for	O
the	O
CYP2D	O
family	O
:	O
Extend	O
of	O
petasin	O
/	O
neopetasin	O
/	O
isopetasin	O
metabolism	O
was	O
82	O
%	O
/	O
61	O
%	O
/	O
83	O
%	O
for	O
CYP2D6	B
(	O
human	O
)	O
versus	O
37	O
%	O
/	O
36	O
%	O
/	O
7	O
%	O
for	O
CYP2D2	O
(	O
rats	O
)	O
.	O

In	O
HepaRG	O
cells	O
,	O
the	O
effect	O
of	O
cytochrome	O
inhibition	O
on	O
the	O
toxic	O
effects	O
of	O
Ze	O
339	O
was	O
investigated	O
;	O
addition	O
of	O
quinidine	O
(	O
CYP2D6	B
inhibitor	O
)	O
and	O
montelukast	O
(	O
CYP2C8	O
inhibitor	O
)	O
attenuated	O
(	O
p	O
<	O
.	O
001	O
and	O
p	O
=	O
.	O
041	O
,	O
respectively	O
)	O
;	O
most	O
of	O
the	O
cytotoxic	O
effect	O
of	O
Ze	O
339	O
demonstrated	O
for	O
the	O
highest	O
concentration	O
studied	O
(	O
100	O
g	O
/	O
ml	O
)	O
.	O

The	O
biggest	O
contribution	O
was	O
shown	O
for	O
CYP2D6	B
.	O

Inhibition	O
of	O
different	O
cytochromes	O
in	O
HepaRG	O
showed	O
an	O
attenuation	O
of	O
the	O
toxic	O
effects	O
,	O
which	O
was	O
pronounced	O
for	O
CYP2D6	B
and	O
to	O
a	O
minor	O
extend	O
CYP2C8	O
.	O

However	O
,	O
HepaRG	O
cells	O
are	O
generated	O
from	O
a	O
donor	O
carrying	O
a	O
polymorphism	O
for	O
CYP2D6	B
(	O
Guillouzo	O
et	O
al	O
.	O
,	O
)	O
,	O
which	O
leads	O
to	O
a	O
lower	O
expression	O
of	O
this	O
enzyme	O
in	O
HepaRG	O
cells	O
compared	O
with	O
,	O
for	O
example	O
,	O
primary	O
hepatocytes	O
(	O
Kanebratt	O
&	O
Andersson	O
,	O
;	O
Zanelli	O
,	O
Caradonna	O
,	O
Hallifax	O
,	O
Turlizzi	O
,	O
&	O
Houston	O
,	O
)	O
,	O
and	O
therefore	O
,	O
CYP2D6	B
activity	O
might	O
be	O
underestimated	O
.	O

On	O
the	O
other	O
hand	O
,	O
because	O
CYP2D6	B
inhibition	O
by	O
quinidine	O
resulted	O
in	O
attenuated	O
toxicity	O
of	O
Ze	O
339	O
in	O
HepaRG	O
cells	O
,	O
this	O
still	O
emphasizes	O
the	O
involvement	O
of	O
this	O
cytochrome	O
enzyme	O
in	O
the	O
development	O
of	O
the	O
hepatotoxicity	O
.	O

Studies	O
had	O
showed	O
that	O
the	O
metabolism	O
of	O
Valproic	O
Acid	O
and	O
DM	O
can	O
be	O
metabolically	O
and	O
pharmacokinetically	O
affected	O
by	O
the	O
same	O
enzymes	O
:	O
CYP2C9	O
and	O
CYP3A4	O
;	O
that	O
multiple	O
human	O
cytochromes	O
contribute	O
to	O
the	O
bio	O
-	O
transformation	O
of	O
DM	O
,	O
including	O
the	O
enzymes	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	B
,	O
and	O
CYP3A	O
;	O
and	O
that	O
Valproic	O
Acid	O
inhibits	O
CYP2C9	O
,	O
CYP3A4	O
or	O
induces	O
CYP3A4	O
gene	O
expression	O
in	O
vitro	O
which	O
support	O
the	O
possible	O
drug	O
interaction	O
of	O
these	O
two	O
drugs	O
.	O

On	O
the	O
other	O
hand	O
,	O
all	O
the	O
screened	O
molecules	O
emerged	O
as	O
non	O
-	O
inhibitors	O
of	O
the	O
cytochromes	O
CYP1A2	O
and	O
CYP2D6	B
.	O

Genotype	O
for	O
the	O
CYP2D6	B
enzyme	O
,	O
the	O
primary	O
metabolic	O
pathway	O
for	O
metoprolol	O
,	O
was	O
evaluated	O
for	O
each	O
subject	O
.	O

Urinary	O
metoprolol	O
metabolite	O
ratios	O
are	O
indicative	O
of	O
patient	O
CYP2D6	B
genotypes	O
.	O

In	O
summary	O
,	O
urinary	O
metabolites	O
predict	O
CYP2D6	B
genotype	O
in	O
hypertensive	O
patients	O
taking	O
metoprolol	O
.	O

However	O
,	O
metoprolol	O
is	O
primarily	O
metabolized	O
through	O
a	O
saturable	O
metabolic	O
pathway	O
,	O
hepatic	O
cytochrome	O
2D6	O
(	O
CYP2D6	B
)	O
,	O
that	O
is	O
responsible	O
for	O
the	O
metabolism	O
of	O
approximately	O
25	O
%	O
of	O
all	O
xenobiotics	O
in	O
addition	O
to	O
many	O
endogenous	O
hormones	O
.	O

Metoprolol	O
is	O
primarily	O
metabolized	O
to	O
ALPHA	O
-	O
hydroxymetoprolol	O
and	O
O	O
-	O
demethylmetoprolol	O
by	O
CYP2D6	B
(	O
Fig	O
.	O

Additionally	O
,	O
co	O
-	O
administration	O
of	O
other	O
CYP2D6	B
metabolized	O
drugs	O
did	O
not	O
impact	O
the	O
abundance	O
of	O
metoprolol	O
metabolites	O
.	O

Metoprolol	O
metabolite	O
abundance	O
was	O
compared	O
in	O
all	O
patient	O
samples	O
and	O
analyzed	O
by	O
CYP2D6	B
metabolizer	O
phenotype	O
,	O
namely	O
Intermediate	O
Metabolizer	O
,	O
Normal	O
Metabolizer	O
,	O
and	O
Ultra	O
-	O
Rapid	O
Metabolizer	O
and	O
CYP2D6	B
activity	O
scores	O
.	O

Unmetabolized	O
metoprolol	O
and	O
metoprolol	O
glucuronide	O
concentrations	O
decreased	O
with	O
increasing	O
CYP2D6	B
activity	O
.	O

Conversely	O
,	O
urinary	O
hydroxymetoprolol	O
abundance	O
increased	O
with	O
increasing	O
CYP2D6	B
metabolic	O
capacity	O
.	O

Comparing	O
classification	O
by	O
CYP2D6	B
phenotype	O
and	O
activity	O
score	O
found	O
that	O
urinary	O
metoprolol	O
metabolite	O
profiles	O
of	O
patients	O
with	O
an	O
activity	O
score	O
of	O
2	O
.	O
0	O
more	O
closely	O
correlate	O
to	O
Ultra	O
-	O
Rapid	O
Metabolizer	O
patients	O
than	O
other	O
Normal	O
Metabolizer	O
activity	O
score	O
groups	O
,	O
namely	O
1	O
.	O
0	O
and	O
1	O
.	O
5	O
.	O

Metoprolol	O
to	O
demethylmetoprolol	O
ratios	O
(	O
M	O
to	O
DM	O
)	O
and	O
metoprolol	O
to	O
hydroxymetoprolol	O
ratios	O
(	O
M	O
to	O
HM	O
)	O
closely	O
correlated	O
to	O
increasing	O
CYP2D6	B
activity	O
.	O

An	O
inverse	O
relationship	O
was	O
observed	O
when	O
samples	O
were	O
normalized	O
to	O
metoprolol	O
acid	O
and	O
ratios	O
decreased	O
with	O
reduced	O
CYP2D6	B
capacity	O
as	O
reflected	O
by	O
patient	O
phenotype	O
and	O
activity	O
scores	O
.	O

The	O
fact	O
that	O
metoprolol	O
metabolites	O
can	O
quickly	O
be	O
used	O
to	O
provide	O
insight	O
into	O
CYP2D6	B
genotype	O
independent	O
of	O
dose	O
or	O
time	O
after	O
the	O
dosage	O
is	O
interesting	O
.	O

The	O
numbers	O
of	O
the	O
more	O
uncommon	O
CYP2D6	B
genotypes	O
,	O
Poor	O
Metabolizer	O
and	O
Ultra	O
-	O
Rapid	O
Metabolizer	O
,	O
are	O
low	O
in	O
this	O
cohort	O
,	O
which	O
limits	O
our	O
ability	O
to	O
identify	O
endogenous	O
metabolites	O
associated	O
with	O
CYP2D6	B
genotype	O
.	O

However	O
,	O
we	O
were	O
powered	O
to	O
detect	O
metabolites	O
with	O
more	O
than	O
95	O
%	O
power	O
when	O
advised	O
by	O
drug	O
ingestion	O
and	O
CYP2D6	B
genotype	O
.	O

Metoprolol	O
metabolites	O
segregated	O
very	O
well	O
with	O
CYP2D6	B
phenotype	O
,	O
suggesting	O
that	O
drug	O
metabolism	O
can	O
be	O
predicted	O
based	O
upon	O
knowledge	O
of	O
CYP2D6	B
genotype	O
and	O
the	O
presence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O

The	O
individual	O
roles	O
of	O
CHIP	O
and	O
gp78	O
in	O
CYP3A	O
and	O
CYP2E1	B
ubiquitination	O
and	O
Endoplasmic	O
Reticulum	O
-	O
Associated	O
Degradation	O
were	O
verified	O
upon	O
lentiviral	O
shRNA	O
interference	O
analyses	O
targeted	O
individually	O
against	O
each	O
of	O
these	O
E3s	O
in	O
cultured	O
rat	O
hepatocytes	O
,	O
.	O

CYP2E1	B
degradation	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
biphasic	O
,	O
exhibiting	O
a	O
rapid	O
phase	O
(	O
t_1	O
/	O
2	O
,	O
7	O
h	O
)	O
and	O
a	O
slow	O
phase	O
(	O
t_1	O
/	O
2	O
,	O
37	O
h	O
)	O
presumed	O
to	O
reflect	O
its	O
Endoplasmic	O
Reticulum	O
-	O
Associated	O
Degradation	O
via	O
Ubiquitin	O
-	O
Dependent	O
Proteasomal	O
Degradation	O
and	O
Autophagic	O
-	O
Lysosomal	O
Degradation	O
,	O
respectively	O
,	O
.	O

Functional	O
inactivation	O
of	O
its	O
catalytic	O
partner	O
Cytochrome	B
P450	I
Reductase	O
abolishes	O
all	O
redox	O
-	O
flux	O
,	O
thus	O
minimizing	O
oxidative	O
damage	O
and	O
stabilizing	O
CYP2E1	B
by	O
prolonging	O
its	O
t_1	O
/	O
2	O
,	O
.	O

Notably	O
,	O
this	O
dual	O
CYP2E1	B
proteolytic	O
mode	O
is	O
conserved	O
upon	O
its	O
heterologous	O
expression	O
in	O
yeast	O
,	O
even	O
though	O
P450	O
redox	O
flux	O
and	O
consequent	O
ROS	O
-	O
generating	O
potential	O
are	O
greatly	O
minimized	O
by	O
the	O
poor	O
yeast	O
Cytochrome	B
P450	I
Reductase	O
content	O
.	O

Hepatic	O
CYP2E1	B
stabilization	O
upon	O
liver	O
-	O
specific	O
genetic	O
ablation	O
of	O
gp78	O
E3	O
-	O
ligase	O
in	O
mice	O
enhances	O
acetaminophen	O
-	O
metabolism	O
to	O
its	O
reactive	O
N	O
-	O
acetyl	O
-	O
p	O
-	O
quinoneimine	O
,	O
thereby	O
predisposing	O
the	O
hepatocytes	O
to	O
drug	O
-	O
induced	O
hepatotoxicity	O
at	O
relatively	O
innocuous	O
concentrations	O
.	O

On	O
the	O
other	O
hand	O
,	O
hepatic	O
CYP2E1	B
stabilization	O
through	O
disruption	O
of	O
its	O
Endoplasmic	O
Reticulum	O
-	O
Associated	O
Degradation	O
via	O
genetic	O
CHIP	O
-	O
ablation	O
contributes	O
to	O
pathogenic	O
NASH	O
(	O
non	O
-	O
alcoholic	O
steatohepatitis	O
)	O
syndrome	O
(	O
see	O
below	O
)	O
.	O

In	O
patients	O
with	O
severe	O
INH	O
-	O
induced	O
liver	O
injury	O
,	O
not	O
only	O
serum	O
autoantibodies	O
to	O
CYP2E1	B
,	O
CYP3A4	O
and	O
CYP2C9	O
(	O
the	O
three	O
major	O
P450s	O
that	O
metabolize	O
and	O
/	O
or	O
interact	O
with	O
INH	O
)	O
,	O
but	O
also	O
serum	O
antibodies	O
to	O
INH	O
-	O
adducted	O
CYP2E1	B
and	O
other	O
INH	O
-	O
adducted	O
non	O
-	O
P450	O
proteins	O
are	O
detected	O
.	O

Similar	O
serum	O
antibodies	O
to	O
drug	O
-	O
modified	O
and	O
/	O
or	O
unmodified	O
P450s	O
and	O
other	O
native	O
cellular	O
proteins	O
have	O
also	O
been	O
detected	O
in	O
idiosyncratic	O
liver	O
injury	O
upon	O
halothane	O
-	O
exposure	O
(	O
anti	O
-	O
trifluoroacetyl	O
-	O
CYP2E1	B
)	O
,	O
aromatic	O
anti	O
-	O
convulsant	O
(	O
anti	O
-	O
CYP3A	O
)	O
,	O
dihydralazine	O
(	O
anti	O
-	O
CYP1A2	O
)	O
,	O
tienilic	O
acid	O
(	O
anti	O
-	O
tienilic	O
acid	O
-	O
CYP2C9	O
)	O
and	O
/	O
or	O
chronic	O
alcohol	O
intake	O
(	O
anti	O
-	O
acetaldehyde	O
-	O
CYP2E1	B
and	O
anti	O
-	O
hydroxyethyl	O
-	O
CYP2E1	B
)	O
,	O
.	O

In	O
parallel	O
,	O
starting	O
at	O
2	O
-	O
months	O
of	O
age	O
,	O
Chip	O
-	O
KO	O
hepatocytes	O
exhibited	O
oxidative	O
stress	O
-	O
induced	O
activation	O
of	O
the	O
pathogenic	O
ASK1	O
-	O
MKK4	O
-	O
JNK1	O
-	O
c	O
-	O
Jun	O
-	O
ATF2	O
and	O
ASK1	O
-	O
MKK4	O
-	O
JNK1	O
-	O
c	O
-	O
Jun	O
-	O
AP	O
-	O
1	O
signaling	O
pathways	O
,	O
which	O
were	O
not	O
only	O
found	O
to	O
be	O
CYP2E1	B
-	O
dependent	O
,	O
but	O
also	O
to	O
remain	O
persistently	O
activated	O
throughout	O
the	O
observation	O
period	O
,	O
ie	O
,	O
first	O
12	O
months	O
of	O
age	O
.	O

It	O
revealed	O
a	O
two	O
-	O
fold	O
activation	O
of	O
the	O
energy	O
sensor	O
,	O
AMP	O
-	O
protein	O
kinase	O
(	O
AMPKALPHA1	O
)	O
in	O
these	O
2	O
-	O
month	O
-	O
old	O
Chip	O
-	O
KO	O
livers	O
relative	O
to	O
corresponding	O
age	O
-	O
matched	O
controls	O
that	O
was	O
also	O
CYP2E1	B
-	O
dependent	O
.	O

The	O
magnitude	O
of	O
CYP2E1	B
and	O
CYP3A	O
functional	O
stabilization	O
is	O
comparable	O
in	O
Gp78	O
-	O
KO	O
and	O
Chip	O
-	O
KO	O
mouse	O
livers	O
,	O
.	O

However	O
,	O
in	O
marked	O
contrast	O
to	O
cultured	O
Chip	O
-	O
KO	O
hepatocytes	O
,	O
Gp78	O
-	O
KO	O
hepatocytes	O
upon	O
culture	O
retained	O
much	O
higher	O
basal	O
CYP2E1	B
levels	O
(	O
comparable	O
to	O
the	O
INH	O
-	O
induced	O
levels	O
in	O
cultured	O
Chip	O
-	O
KO	O
hepatocytes	O
)	O
,	O
which	O
were	O
further	O
increased	O
upon	O
INH	O
-	O
induction	O
(	O
C	O
)	O
.	O

Additionally	O
,	O
in	O
the	O
course	O
of	O
defining	O
the	O
liver	O
specific	O
Gp78	O
-	O
KO	O
mouse	O
phenotype	O
,	O
preliminary	O
SILAC	O
-	O
like	O
proteomic	O
analyses	O
of	O
unlabeled	O
Gp78	O
-	O
KO	O
and	O
stable	O
isotope	O
-	O
labeled	O
Wild	O
-	O
Type	O
age	O
/	O
strain	O
-	O
matched	O
livers	O
revealed	O
that	O
in	O
addition	O
to	O
the	O
stabilization	O
of	O
several	O
hepatic	O
P450s	O
(	O
including	O
CYP2E1	B
and	O
CYPs	O
3A	O
)	O
,	O
several	O
cytoplasmic	O
enzymes	O
in	O
the	O
fructose	O
metabolic	O
pathway	O
were	O
increased	O
in	O
Gp78	O
-	O
KO	O
-	O
liver	O
[	O
ie	O
,	O
ketohexokinase	O
(	O
500	O
%	O
)	O
;	O
3	O
-	O
phosphoglycerokinase	O
(	O
200	O
%	O
-	O
300	O
%	O
)	O
;	O
phosphoglyceromutase	O
(	O
177	O
%	O
-	O
250	O
%	O
)	O
;	O
.	O

These	O
relative	O
differences	O
in	O
FA	O
-	O
and	O
TG	O
-	O
accumulation	O
were	O
maintained	O
even	O
upon	O
further	O
INH	O
-	O
mediated	O
induction	O
of	O
CYP2E1	B
content	O
(	O
B	O
)	O
.	O

Furthermore	O
,	O
only	O
minor	O
relative	O
increases	O
in	O
Malondialdehyde	O
levels	O
were	O
observed	O
,	O
indicative	O
of	O
a	O
mild	O
oxidative	O
stress	O
response	O
,	O
despite	O
the	O
relatively	O
elevated	O
basal	O
CYP2E1	B
content	O
in	O
Gp78	O
-	O
KO	O
hepatocytes	O
,	O
and	O
its	O
further	O
elevation	O
upon	O
INH	O
-	O
induction	O
(	O
B	O
)	O
.	O

Several	O
converging	O
factors	O
,	O
we	O
believe	O
,	O
synergistically	O
contribute	O
to	O
the	O
observed	O
striking	O
differences	O
in	O
CYP2E1	B
-	O
elicited	O
lipogenic	O
potential	O
in	O
Chip	O
-	O
KO	O
versus	O
Gp78	O
-	O
KO	O
hepatocytes	O
:	O
(	O
i	O
)	O
The	O
differential	O
effects	O
of	O
each	O
E3	O
-	O
KO	O
on	O
hepatic	O
Insig	O
and	O
SREBP	O
-	O
1c	O
protein	O
levels	O
:	O
upon	O
INH	O
-	O
induction	O
of	O
CYP2E1	B
,	O
hepatic	O
Insig	O
1	O
and	O
Insig	O
2	O
proteins	O
decline	O
in	O
Chip	O
-	O
KO	O
hepatocytes	O
due	O
to	O
the	O
progressive	O
hepatic	O
insulin	O
resistance	O
,	O
whereas	O
these	O
proteins	O
being	O
bona	O
fide	O
gp78	O
-	O
substrates	O
are	O
markedly	O
stabilized	O
in	O
Gp78	O
-	O
KO	O
hepatocytes	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
Chip	O
-	O
KO	O
mice	O
,	O
despite	O
CYP2E1	B
functional	O
stabilization	O
,	O
the	O
Gp78	O
-	O
KO	O
mice	O
exhibit	O
enhanced	O
energy	O
expenditure	O
relative	O
to	O
Wild	O
-	O
Type	O
controls	O
,	O
remain	O
leaner	O
and	O
do	O
not	O
develop	O
NASH	O
,	O
even	O
upon	O
aging	O
and	O
/	O
or	O
a	O
high	O
fat	O
-	O
high	O
sucrose	O
obesity	O
-	O
inducing	O
diet	O
.	O

Intriguingly	O
,	O
in	O
spite	O
of	O
the	O
comparable	O
CYP2E1	B
content	O
upon	O
INH	O
induction	O
,	O
hepatic	O
MDA	O
-	O
levels	O
were	O
only	O
minimally	O
increased	O
in	O
Gp78	O
-	O
KO	O
hepatocytes	O
(	O
B	O
)	O
,	O
in	O
contrast	O
to	O
the	O
marked	O
Malondialdehyde	O
elevation	O
observed	O
in	O
Chip	O
-	O
KO	O
hepatocytes	O
.	O

This	O
finding	O
strongly	O
suggests	O
that	O
hepatic	O
CYP2E1	B
-	O
dependent	O
ROS	O
-	O
elicited	O
lipid	O
peroxidation	O
with	O
consequent	O
JNK1	O
activation	O
and	O
insulin	O
resistance	O
occur	O
only	O
when	O
hepatic	O
lipid	O
is	O
markedly	O
elevated	O
and	O
available	O
for	O
peroxidation	O
.	O

demonstrated	O
that	O
in	O
the	O
713	O
human	O
livers	O
analysed	O
,	O
CYP3A4	B
levels	O
varied	O
markedly	O
,	O
ranging	O
from	O
0	O
to	O
601	O
pmolmg	O
^	O
1	O
protein	O
(	O
Achour	O
et	O
al	O
.	O
,	O
.	O

As	O
mentioned	O
,	O
next	O
to	O
CYP3A4	B
,	O
another	O
CYP	O
,	O
CYP3A7	O
,	O
showed	O
high	O
activity	O
in	O
flucloxacillin	O
hydroxylation	O
.	O

CYP3A7	O
was	O
originally	O
considered	O
to	O
be	O
a	O
CYP	O
only	O
expressed	O
in	O
fetal	O
tissues	O
(	O
Schuetz	O
et	O
al	O
.	O
,	O
.	O

However	O
,	O
more	O
recent	O
studies	O
have	O
indicated	O
that	O
in	O
approximately	O
10	O
%	O
of	O
adult	O
livers	O
,	O
CYP3A7	O
is	O
expressed	O
to	O
a	O
significant	O
extent	O
,	O
up	O
to	O
90	O
pmolmg	O
^	O
1	O
protein	O
,	O
which	O
equals	O
the	O
mean	O
level	O
of	O
CYP3A4	B
(	O
Sim	O
et	O
al	O
.	O
,	O
;	O
Ohtsuki	O
et	O
al	O
.	O
,	O
.	O

This	O
markedly	O
increased	O
CYP3A7	O
expression	O
appears	O
to	O
be	O
strongly	O
associated	O
with	O
the	O
CYP3A7	O
*	O
1C	O
allele	O
which	O
has	O
arisen	O
through	O
the	O
conversion	O
of	O
60	O
bp	O
of	O
the	O
promotor	O
of	O
CYP3A4	B
into	O
the	O
corresponding	O
region	O
of	O
CYP3A7	O
(	O
Burk	O
et	O
al	O
.	O
,	O
.	O

To	O
what	O
extent	O
the	O
variability	O
in	O
CYP3A7	O
expression	O
contributes	O
to	O
the	O
variability	O
of	O
flucloxacillin	O
hydroxylation	O
remains	O
to	O
be	O
established	O
and	O
is	O
complicated	O
by	O
the	O
present	O
lack	O
of	O
specific	O
inhibitors	O
for	O
the	O
CYP3A	B
isoforms	O
.	O

Involvement	O
of	O
CYP3A	B
isoforms	O
in	O
drug	O
metabolism	O
is	O
well	O
known	O
to	O
result	O
in	O
very	O
diverse	O
types	O
of	O
enzyme	O
kinetics	O
and	O
poorly	O
predictable	O
drug	O
-	O
drug	O
interactions	O
.	O

Dependent	O
on	O
the	O
substrate	O
used	O
,	O
for	O
all	O
CYP3A	B
isoforms	O
,	O
enzyme	O
kinetics	O
can	O
appear	O
as	O
normal	O
Michaelis	O
-	O
Menten	O
kinetics	O
or	O
atypical	O
kinetics	O
such	O
as	O
autoactivation	O
and	O
substrate	O
inhibition	O
(	O
Williams	O
et	O
al	O
.	O
,	O
;	O
Atkins	O
,	O
.	O

Because	O
of	O
the	O
multiple	O
binding	O
sites	O
in	O
CYP3A	B
enzymes	O
,	O
also	O
the	O
type	O
of	O
drug	O
-	O
drug	O
interactions	O
appears	O
complex	O
and	O
strongly	O
substrate	O
dependent	O
(	O
Stresser	O
et	O
al	O
.	O
,	O
;	O
Ekins	O
et	O
al	O
.	O
,	O
.	O

Therefore	O
,	O
to	O
predict	O
the	O
ability	O
to	O
cause	O
CYP3A4	B
inhibition	O
,	O
the	O
use	O
of	O
multiple	O
CYP3A4	B
substrates	O
has	O
been	O
recommended	O
(	O
Stresser	O
et	O
al	O
.	O
,	O
.	O

The	O
inhibition	O
experiments	O
in	O
the	O
present	O
study	O
seem	O
to	O
confirm	O
the	O
complicated	O
inhibition	O
pattern	O
of	O
CYP3A	B
reactions	O
.	O

The	O
established	O
CYP3A4	B
inhibitors	O
ketoconazole	O
,	O
troleandomycin	O
and	O
miconazole	O
showed	O
relatively	O
low	O
degree	O
of	O
inhibition	O
at	O
the	O
concentrations	O
used	O
.	O

These	O
results	O
suggest	O
that	O
flucloxacillin	O
has	O
a	O
unique	O
binding	O
mode	O
to	O
the	O
active	O
site	O
to	O
CYP3A4	B
,	O
explaining	O
the	O
relatively	O
weak	O
inhibition	O
by	O
1	O
M	O
ketaconazole	O
and	O
the	O
unexpectedly	O
strong	O
inhibition	O
by	O
sulfaphenazole	O
.	O

Therefore	O
,	O
the	O
CYP3A	B
family	O
in	O
rare	O
occurrences	O
can	O
be	O
inhibited	O
by	O
sulfaphenazole	O
in	O
a	O
substratedependent	O
manner	O
.	O

Recently	O
,	O
it	O
has	O
been	O
confirmed	O
that	O
ellagic	O
acid	O
can	O
significantly	O
inhibit	O
CYP3A	B
and	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
-	O
mediated	O
efflux	O
in	O
the	O
intestine	O
,	O
thus	O
,	O
increase	O
warfarin	O
plasma	O
concentration	O
and	O
its	O
pharmacological	O
effect	O
.	O

It	O
has	O
been	O
suggested	O
that	O
guava	O
leaves	O
extract	O
constituents	O
,	O
such	O
as	O
gallic	O
acid	O
and	O
ursolic	O
acid	O
,	O
have	O
the	O
ability	O
to	O
diminish	O
the	O
activity	O
of	O
CYP3A4	B
in	O
human	O
liver	O
microsomes	O
[	O
,	O
.	O

That	O
comes	O
in	O
line	O
with	O
the	O
results	O
obtained	O
from	O
testing	O
guava	O
leaves	O
extract	O
both	O
alone	O
and	O
in	O
combination	O
with	O
warfarin	O
in	O
significantly	O
affecting	O
CYP3A4	B
activity	O
in	O
primary	O
isolated	O
rat	O
hepatocytes	O
.	O

Further	O
reduction	O
in	O
CYP3A4	B
activity	O
was	O
observed	O
upon	O
administerating	O
quercetin	O
concomitantly	O
with	O
warfarin	O
,	O
suggesting	O
that	O
CYP3A4	B
may	O
undergo	O
an	O
allosteric	O
change	O
during	O
its	O
binding	O
with	O
warfarin	O
that	O
possibly	O
enhances	O
quercetin	O
binding	O
which	O
leads	O
to	O
increase	O
its	O
inhibitory	O
effect	O
.	O

Hepatocyte	O
spheroids	O
formed	O
in	O
this	O
device	O
were	O
subjected	O
to	O
different	O
flow	O
rates	O
,	O
of	O
which	O
a	O
flow	O
rate	O
of	O
50	O
L	O
/	O
min	O
provided	O
the	O
optimal	O
microenvironment	O
for	O
spheroid	O
formation	O
,	O
maintained	O
significantly	O
higher	O
rates	O
of	O
albumin	O
and	O
urea	O
synthesis	O
,	O
yielded	O
higher	O
CYP3A1	O
(	O
cytochrome	O
P450	O
3A1	O
)	O
and	O
CYP2C11	O
(	O
cytochrome	O
P450	O
2C11	O
)	O
enzyme	O
activities	O
for	O
metabolism	O
,	O
and	O
demonstrated	O
higher	O
expression	O
levels	O
of	O
liver	O
-	O
specific	O
genes	O
.	O

BFC	O
and	O
7	O
-	O
Methoxy	O
-	O
4	O
-	O
Trifluoromethylcoumarin	O
were	O
used	O
as	O
fluorescent	O
substrates	O
to	O
measure	O
the	O
activities	O
of	O
CYP3A1	O
and	O
CYP2C11	O
enzymes	O
under	O
different	O
culture	O
systems	O
.	O

Changes	O
in	O
gene	O
expression	O
of	O
CYP3A1	O
and	O
CYP2C11	O
enzymes	O
were	O
investigated	O
by	O
quantitative	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
as	O
described	O
previously	O
.	O

The	O
sequences	O
of	O
primers	O
for	O
CYP3A1	O
,	O
CYP2C11	O
,	O
and	O
BETA	O
-	O
actin	O
are	O
shown	O
in	O
.	O

To	O
investigate	O
the	O
specific	O
action	O
of	O
different	O
drugs	O
on	O
hepatic	O
-	O
metabolism	O
enzymes	O
,	O
testosterone	O
and	O
tolbutamide	O
were	O
chosen	O
to	O
study	O
the	O
hepatic	O
clearance	O
rates	O
by	O
CYP3A1	O
and	O
CYP2C11	O
,	O
respectively	O
.	O

In	O
the	O
rat	O
liver	O
,	O
CYP3A1	O
is	O
the	O
main	O
CYP3A	B
,	O
and	O
CYP2C11	O
is	O
its	O
predominant	O
isoform	O
,	O
with	O
both	O
comprising	O
up	O
to	O
50	O
%	O
of	O
the	O
total	O
CYP	O
content	O
.	O

The	O
maintenance	O
of	O
the	O
activity	O
of	O
the	O
drug	O
-	O
metabolizing	O
enzymes	O
CYP3A1	O
and	O
CYP2C11	O
were	O
examined	O
in	O
hepatocytes	O
at	O
flow	O
rates	O
of	O
0	O
and	O
50	O
L	O
/	O
min	O
and	O
in	O
PELA	O
mats	O
.	O

At	O
0	O
L	O
/	O
min	O
,	O
hepatocytes	O
showed	O
higher	O
expression	O
levels	O
of	O
CYP3A1	O
(	O
5	O
.	O
3	O
-	O
fold	O
higher	O
)	O
and	O
CYP2C11	O
(	O
4	O
.	O
7	O
-	O
fold	O
higher	O
)	O
than	O
those	O
of	O
hepatocytes	O
cultured	O
in	O
PELA	O
.	O

However	O
,	O
there	O
were	O
significant	O
reductions	O
,	O
by	O
around	O
10	O
.	O
2	O
%	O
and	O
8	O
.	O
4	O
%	O
,	O
respectively	O
,	O
in	O
the	O
mRNA	O
levels	O
of	O
CYP3A1	O
and	O
CYP2C11	O
enzymes	O
at	O
0	O
L	O
/	O
min	O
for	O
15	O
days	O
,	O
compared	O
with	O
those	O
after	O
7	O
days	O
.	O

Given	O
that	O
7	O
-	O
Benzyloxy	O
-	O
4	O
-	O
Trifluoromethylcoumarin	O
and	O
7	O
-	O
Methoxy	O
-	O
4	O
-	O
Trifluoromethylcoumarin	O
are	O
the	O
specific	O
substrates	O
for	O
CYP3A1	O
and	O
CYP2C11	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
throughout	O
the	O
culture	O
period	O
.	O

CYP3A1	O
and	O
CYP2C11	O
enzymatic	O
activities	O
in	O
PELA	O
fibrous	O
mats	O
were	O
much	O
lower	O
and	O
fluctuating	O
than	O
hepatocytes	O
on	O
the	O
chip	O
at	O
a	O
flow	O
rate	O
of	O
0	O
L	O
/	O
min	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

lac	O
-	O
PLA	O
enhanced	O
hepatocyte	O
function	O
,	O
and	O
there	O
was	O
a	O
continuous	O
increase	O
in	O
the	O
activities	O
of	O
CYP3A1	O
and	O
CYP2C11	O
enzymes	O
in	O
hepatocytes	O
at	O
0	O
L	O
/	O
min	O
during	O
the	O
15	O
-	O
day	O
incubation	O
.	O

Hepatocytes	O
at	O
a	O
flow	O
rate	O
of	O
50	O
L	O
/	O
min	O
were	O
therefore	O
comparatively	O
more	O
stable	O
and	O
maintained	O
the	O
highest	O
enzyme	O
activities	O
among	O
the	O
groups	O
,	O
reaching	O
6	O
.	O
7	O
and	O
3	O
.	O
8	O
pmol	O
/	O
min	O
/	O
10	O
^	O
6	O
cells	O
for	O
CYP3A1	O
and	O
CYP2C11	O
,	O
respectively	O
.	O

The	O
level	O
of	O
activity	O
of	O
CYP3A1	O
and	O
CYP2C11	O
enzymes	O
showed	O
a	O
similar	O
trend	O
until	O
15	O
days	O
.	O

After	O
culture	O
for	O
15	O
days	O
,	O
the	O
CYP3A1	O
and	O
CYP2C11	O
activities	O
of	O
the	O
hepatocytes	O
at	O
a	O
flow	O
of	O
50	O
L	O
/	O
min	O
were	O
more	O
than	O
3	O
.	O
9	O
-	O
and	O
3	O
.	O
4	O
-	O
fold	O
higher	O
,	O
respectively	O
,	O
than	O
those	O
of	O
hepatocytes	O
cultured	O
on	O
PELA	O
.	O

Tolbutamide	O
and	O
testosterone	O
were	O
used	O
as	O
the	O
substrates	O
of	O
hepatocyte	O
CYP3A1	O
and	O
CYP2C11	O
enzymes	O
,	O
respectively	O
,	O
for	O
the	O
drug	O
metabolism	O
study	O
.	O

The	O
results	O
of	O
testosterone	O
metabolism	O
by	O
CYP2C11	O
indicated	O
a	O
profile	O
similar	O
to	O
that	O
of	O
CYP3A1	O
(	O
b	O
)	O
.	O

Moreover	O
,	O
only	O
compound	O
F13	O
was	O
found	O
to	O
be	O
the	O
substrate	O
of	O
CYP2C19	O
and	O
compound	O
F25	O
was	O
found	O
to	O
be	O
the	O
substrate	O
of	O
CYP3A4	B
.	O

On	O
the	O
other	O
hand	O
for	O
predicting	O
the	O
site	O
of	O
enzyme	O
CYP3A4	B
mediated	O
metabolism	O
the	O
K_m	O
value	O
was	O
46	O
.	O
37	O
M	O
and	O
the	O
Human	O
Liver	O
Microsomes	O
Km	O
value	O
was	O
1055	O
.	O
87	O
M	O
,	O
whereas	O
the	O
V_max	O
constant	O
was	O
6	O
.	O
36	O
nM	O
/	O
min	O
/	O
nM	O
and	O
Human	O
Liver	O
Microsomes	O
V_max	O
constant	O
was	O
1	O
.	O
25	O
nM	O
/	O
min	O
/	O
nM	O
,	O
and	O
the	O
C_Lint	O
was	O
15	O
.	O
23	O
L	O
/	O
min	O
/	O
mg	O
,	O
and	O
the	O
Human	O
Liver	O
Microsomes	O
C_Lint	O
was	O
1	O
.	O
19	O
for	O
compound	O
F25	O
.	O

Moreover	O
,	O
the	O
compounds	O
when	O
studies	O
for	O
CYP3A4	B
,	O
it	O
was	O
observed	O
that	O
compound	O
F2	O
,	O
F8	O
and	O
F13	O
may	O
inhibit	O
the	O
CYP3A4	B
.	O

Results	O
showed	O
that	O
all	O
compounds	O
might	O
inhibit	O
the	O
CYP3A4	B
mediated	O
midazolam	O
and	O
testosterone	O
metabolism	O
.	O

While	O
cytochromes	O
P450	O
(	O
CYP	O
)	O
2D6	O
and	O
CYP3A4	B
have	O
been	O
implicated	O
in	O
the	O
metabolism	O
of	O
Paliperidone	O
in	O
in	O
vitro	O
studies	O
,	O
these	O
isoenzymes	O
play	O
a	O
limited	O
role	O
in	O
the	O
metabolism	O
of	O
Paliperidone	O
in	O
vivo	O
.	O

CYPs	O
are	O
responsible	O
for	O
the	O
biotransformation	O
of	O
widely	O
used	O
antipsychotics	O
such	O
as	O
clozapine	O
(	O
CYP1A2	O
and	O
CYP2C19	O
)	O
,	O
olanzapine	O
(	O
CYP1A2	O
)	O
,	O
risperidone	O
and	O
haloperidol	O
(	O
CYP2D6	O
)	O
,	O
quetiapine	O
and	O
ziprasidone	O
(	O
CYP3A5	O
)	O
amongst	O
others	O
^	O
,	O
.	O

A	O
commercial	O
pharmacogenetic	O
test	O
(	O
Brainchip	O
,	O
Brainco	O
,	O
Bilbao	O
,	O
Spain	O
)	O
was	O
used	O
to	O
characterise	O
common	O
and	O
functional	O
polymorphisms	O
in	O
CYP1A2	O
,	O
CYP2D6	O
,	O
CYP2C19	O
and	O
CYP3A5	B
enzymes	O
,	O
the	O
main	O
metabolic	O
pathways	O
of	O
currently	O
available	O
antipsychotics	O
.	O

Doses	O
were	O
adjusted	O
according	O
to	O
main	O
metabolic	O
pathways	O
:	O
^	O
,	O
clozapine	O
doses	O
were	O
adjusted	O
according	O
to	O
the	O
genotypic	O
variants	O
observed	O
in	O
CYP1A2	O
and	O
CYP2C19	O
;	O
olanzapine	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP1A2	O
polymorphisms	O
;	O
risperidone	O
,	O
aripiprazole	O
,	O
haloperidol	O
,	O
pimozide	O
and	O
trifluoperazine	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP2D6	O
polymorphisms	O
;	O
finally	O
,	O
quetiapine	O
and	O
ziprasidone	O
doses	O
were	O
adjusted	O
according	O
to	O
CYP3A5	B
genetic	O
variants	O
.	O

In	O
preclinical	O
aflatoxin	O
-	O
induced	O
Hepatocellular	O
Carcinoma	O
rat	O
models	O
,	O
CYP3A4	B
*	O
1B	O
(	O
rs2740574	O
;	O
located	O
in	O
the	O
5	O
untranslated	O
region	O
[	O
5UTR	O
]	O
)	O
and	O
CYP3A5	B
*	O
3	O
(	O
rs776746	O
;	O
located	O
in	O
the	O
intron	O
3	O
)	O
variants	O
were	O
associated	O
with	O
the	O
lowest	O
and	O
highest	O
sorafenib	O
plasma	O
concentrations	O
,	O
respectively	O
.	O

This	O
difference	O
in	O
drug	O
disposition	O
was	O
consistent	O
with	O
a	O
different	O
toxicity	O
risk	O
;	O
CYP3A5	B
*	O
3	O
-	O
carrier	O
rats	O
had	O
the	O
most	O
severe	O
liver	O
(	O
measured	O
as	O
a	O
change	O
in	O
alanine	O
aminotransferase	O
[	O
ALT	O
]	O
and	O
Aspartate	O
Aminotransferase	O
blood	O
concentration	O
[	O
IU	O
/	O
L	O
]	O
over	O
time	O
)	O
and	O
renal	O
(	O
measured	O
as	O
a	O
change	O
in	O
blood	O
urea	O
nitrogen	O
[	O
nmol	O
/	O
L	O
]	O
and	O
creatinin	O
[	O
umol	O
/	O
L	O
]	O
blood	O
concentration	O
[	O
IU	O
/	O
L	O
]	O
over	O
time	O
)	O
injury	O
,	O
whereas	O
CYP3A4	B
*	O
1	O
-	O
carrier	O
rats	O
had	O
the	O
mildest	O
toxicity	O
outcome	O
.	O

In	O
these	O
patients	O
,	O
the	O
CYP3A5	B
*	O
3	O
polymorphism	O
was	O
associated	O
with	O
rapid	O
worsening	O
of	O
hepatic	O
damage	O
,	O
but	O
CYP3A4	B
*	O
1	O
carriers	O
showed	O
only	O
a	O
small	O
effect	O
.	O

The	O
findings	O
therefore	O
suggested	O
that	O
the	O
CYP3A5	B
*	O
3	O
variant	O
that	O
determines	O
decreased	O
CYP3A5	B
enzymatic	O
activity	O
could	O
influence	O
hepatic	O
and	O
renal	O
exposure	O
to	O
sorafenib	O
,	O
with	O
severe	O
associated	O
damage	O
.	O

However	O
,	O
a	O
very	O
recent	O
study	O
by	O
Ozeki	O
et	O
al	O
on	O
Japanese	O
patients	O
with	O
thyroid	O
cancer	O
,	O
demonstrated	O
for	O
the	O
first	O
time	O
an	O
impact	O
of	O
CYP3A4	B
/	O
5	O
and	O
Atp	O
-	O
Binding	O
Cassette	O
transporter	O
genetic	O
variants	O
on	O
lenvatinib	O
pharmacokinetics	O
.	O

Particularly	O
,	O
the	O
CYP3A4	B
*	O
1G	O
(	O
rs2242480	O
,	O
intronic	O
variation	O
)	O
and	O
ABCC2	O
rs717620	O
polymorphisms	O
were	O
suggested	O
to	O
have	O
an	O
effect	O
on	O
the	O
steady	O
-	O
state	O
mean	O
plasma	O
[	O
ie	O
,	O
mean	O
dose	O
-	O
adjusted	O
C_0	O
,	O
(	O
ng	O
/	O
mL	O
/	O
mg	O
)	O
]	O
trough	O
concentrations	O
of	O
lenvatinib	O
.	O

The	O
mean	O
dose	O
-	O
adjusted	O
C_0	O
values	O
of	O
lenvatinib	O
in	O
patients	O
with	O
the	O
CYP3A4	B
*	O
1	O
/	O
*	O
1	O
genotype	O
and	O
ABCC2	O
rs717620	O
-	O
T	O
allele	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
patients	O
with	O
the	O
CYP3A4	B
*	O
1G	O
allele	O
and	O
ABCC2	O
rs717620	O
-	O
CC	O
genotype	O
,	O
respectively	O
(	O
effect	O
size	O
:	O
0	O
.	O
863	O
,	O
P	O
=	O
0	O
.	O
018	O
and	O
effect	O
size	O
:	O
0	O
.	O
605	O
,	O
P	O
=	O
0	O
.	O
036	O
,	O
respectively	O
)	O
.	O

Moreover	O
,	O
the	O
dose	O
-	O
adjusted	O
C_0	O
of	O
lenvatinib	O
in	O
patients	O
with	O
both	O
the	O
CYP3A4	B
*	O
1	O
/	O
*	O
1	O
genotype	O
and	O
ABCC2	O
rs717620	O
-	O
T	O
allele	O
(	O
median	O
6	O
.	O
70	O
ng	O
/	O
mL	O
/	O
mg	O
)	O
was	O
about	O
1	O
.	O
5	O
-	O
fold	O
higher	O
than	O
that	O
in	O
patients	O
with	O
both	O
the	O
CYP3A4	B
*	O
1G	O
/	O
*	O
1G	O
and	O
ABCC2	O
rs717620	O
-	O
CC	O
genotypes	O
(	O
median	O
4	O
.	O
42	O
ng	O
/	O
mL	O
/	O
mg	O
;	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

Following	O
oral	O
administration	O
,	O
palbociclib	O
and	O
ribociclib	O
undergo	O
extensive	O
hepatic	O
metabolism	O
mainly	O
by	O
CYP3A	B
;	O
palbociclib	O
also	O
is	O
metabolized	O
through	O
the	O
sulfotransferase	O
enzyme	O
SULT2A1	O
.	O

In	O
term	O
of	O
pharmacokinetics	O
,	O
tivantinib	O
is	O
metabolized	O
by	O
CYP2C19	O
,	O
CYP3A4	B
/	O
5	O
,	O
Udp	O
Glucuronosyltransferase	O
1a9	O
,	O
and	O
alcohol	O
dehydrogenase	O
isoform	O
4	O
.	O

CYP2C19	O
shows	O
catalytic	O
activity	O
for	O
the	O
formation	O
of	O
the	O
hydroxylated	O
metabolite	O
(	O
M5	O
)	O
,	O
whereas	O
CYP3A4	B
/	O
5	O
catalyzes	O
formation	O
of	O
M5	O
and	O
its	O
stereoisomer	O
(	O
M4	O
)	O
.	O

Moreover	O
,	O
CYP3A4	B
/	O
5	O
represents	O
the	O
major	O
cytochrome	O
isoform	O
involved	O
in	O
the	O
elimination	O
of	O
M4	O
,	O
M5	O
,	O
and	O
the	O
keto	O
-	O
metabolite	O
(	O
M8	O
)	O
,	O
and	O
together	O
with	O
Udp	O
Glucuronosyltransferase	O
1a9	O
,	O
involved	O
in	O
the	O
glucuronidation	O
of	O
M4	O
and	O
M5	O
.	O

About	O
20	O
%	O
of	O
apixaban	O
undergoes	O
P450	O
Cytochromes	O
metabolism	O
(	O
mainly	O
via	O
the	O
same	O
CYP3A4	B
)	O
,	O
while	O
30	O
%	O
of	O
the	O
drug	O
is	O
eliminated	O
via	O
urinary	O
excretion	O
.	O

stated	O
that	O
the	O
continued	O
ingestion	O
of	O
(	O
88	O
)	O
isolated	O
from	O
K	O
.	O
parviflora	O
decreases	O
liver	O
CYP3A	B
expression	O
,	O
which	O
in	O
turn	O
increased	O
levels	O
of	O
compounds	O
metabolized	O
by	O
CYP3As	O
such	O
as	O
midazolam	O
.	O

In	O
addition	O
,	O
differential	O
expression	O
profiles	O
of	O
functionally	O
different	O
isoforms	O
of	O
the	O
CYP3A	B
subfamily	O
during	O
prenatal	O
and	O
early	O
postnatal	O
life	O
complicate	O
the	O
assessment	O
of	O
hepatic	O
steroid	O
metabolism	O
.	O

CYP3A4	B
is	O
the	O
most	O
abundant	O
Cytochrome	B
P450	I
expressed	O
in	O
the	O
adult	O
liver	O
and	O
makes	O
the	O
major	O
contribution	O
to	O
steroid	O
metabolism	O
.	O

CYP3A5	O
catalyzes	O
a	O
comparable	O
range	O
of	O
reactions	O
as	O
CYP3A4	O
but	O
its	O
role	O
in	O
drug	O
and	O
steroid	O
metabolism	O
is	O
limited	O
due	O
to	O
its	O
generally	O
low	O
activity	O
and	O
expression	O
in	O
a	O
relatively	O
small	O
percentage	O
of	O
individuals	O
[	O
,	O
.	O

CYP3A7	O
is	O
the	O
major	O
CYP3A	B
isoform	O
in	O
prenatal	O
and	O
early	O
postnatal	O
life	O
and	O
differs	O
from	O
CYP3A4	O
in	O
terms	O
of	O
expression	O
and	O
function	O
.	O

CYP3A4	O
-	O
catalyzed	O
6BETA	O
-	O
hydroxylation	O
is	O
the	O
most	O
common	O
hydroxylation	O
for	O
^	O
4	O
steroids	O
,	O
eg	O
cortisol	O
(	O
(	O
e	O
)	O
)	O
,	O
while	O
6ALPHA	O
-	O
hydroxylated	O
pregnanolones	O
are	O
quantitatively	O
important	O
urine	O
steroid	O
metabolites	O
during	O
pregnancy	O
.	O

The	O
differential	O
substrate	O
specificity	O
,	O
regioselectivity	O
and	O
catalytic	O
activity	O
of	O
CYP3A4	O
and	O
CYP3A7	O
and	O
the	O
dynamic	O
expression	O
pattern	O
of	O
the	O
two	O
isoforms	O
throughout	O
fetal	O
development	O
and	O
the	O
first	O
year	O
of	O
life	O
lead	O
to	O
substantial	O
changes	O
in	O
the	O
hepatic	O
steroid	O
metabolome	O
during	O
this	O
period	O
of	O
life	O
.	O

CYP3A7	O
is	O
highly	O
expressed	O
in	O
fetal	O
liver	O
and	O
up	O
to	O
6	O
months	O
postnatal	O
but	O
expression	O
levels	O
gradually	O
decrease	O
over	O
this	O
time	O
.	O

CYP3A4	O
levels	O
are	O
low	O
in	O
the	O
fetus	O
and	O
newborn	O
compared	O
to	O
the	O
adult	O
.	O

Thus	O
,	O
there	O
is	O
a	O
switch	O
from	O
CYP3A7	O
to	O
CYP3A4	O
during	O
the	O
first	O
months	O
after	O
birth	O
.	O

Additionally	O
,	O
the	O
total	O
liver	O
CYP3A	B
content	O
is	O
significantly	O
higher	O
prenatally	O
followed	O
by	O
a	O
reduction	O
after	O
birth	O
reaching	O
plateau	O
at	O
6	O
months	O
.	O

In	O
fact	O
,	O
CYP2C19	O
and	O
CYP3A4	O
can	O
21	O
-	O
hydroxylate	O
progesterone	O
and	O
pregnenolone	O
,	O
possibly	O
partially	O
compensating	O
mineralocorticoid	O
deficiency	O
in	O
CAH	O
due	O
to	O
21	O
-	O
hydroxylase	O
deficiency	O
;	O
however	O
,	O
the	O
two	O
enzymes	O
are	O
not	O
capable	O
of	O
catalyzing	O
the	O
21	O
-	O
hydroxylation	O
of	O
17OHP	O
to	O
11	O
-	O
deoxycortisol	O
.	O

Cortisol	O
can	O
also	O
be	O
6BETA	O
-	O
hydroxylated	O
by	O
CYP3A4	O
expressed	O
in	O
the	O
liver	O
,	O
resulting	O
in	O
6BETA	O
-	O
hydroxycortisol	O
(	O
6BETA	O
-	O
OHF	O
)	O
.	O

Circulating	O
Dehydroepiandrosterone	O
is	O
readily	O
16ALPHA	O
-	O
hydroxylated	O
by	O
CYP3A4	O
/	O
7	O
within	O
the	O
liver	O
.	O

CYP3A4	O
is	O
the	O
major	O
enzyme	O
responsible	O
for	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
estrone	O
in	O
adults	O
,	O
though	O
CYP1A1	O
,	O
CYP2C19	O
and	O
CYP3A5	O
can	O
also	O
catalyze	O
the	O
reaction	O
.	O

Conversely	O
,	O
CYP1A2	O
is	O
the	O
dominant	O
enzyme	O
catalyzing	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
17BETA	O
-	O
estradiol	O
,	O
with	O
CYP3A4	O
,	O
CYP1A1	O
and	O
CYP1B1	O
also	O
demonstrating	O
this	O
activity	O
.	O

These	O
reactions	O
are	O
catalyzed	O
by	O
a	O
variety	O
of	O
CYPs	O
,	O
including	O
CYP3A4	O
and	O
CYP1A2	O
in	O
the	O
liver	O
,	O
or	O
CYP1A1	O
and	O
CYP3A4	O
in	O
peripheral	O
tissues	O
.	O

Accordingly	O
,	O
the	O
dominant	O
human	O
liver	O
/	O
intestinal	O
CYP3A4	O
and	O
human	O
liver	O
CYP2E1	O
are	O
found	O
to	O
be	O
prototypic	O
ERAD	O
-	O
C	O
substrates	O
.	O

CYP3A4	O
,	O
accounting	O
for	O
30	O
%	O
of	O
the	O
hepatic	O
P450	O
content	O
,	O
is	O
engaged	O
in	O
the	O
metabolism	O
of	O
>	O
50	O
%	O
of	O
clinically	O
relevant	O
drugs	O
and	O
other	O
xenobiotics	O
,	O
whereas	O
CYP2E1	O
biotransforms	O
clinically	O
relevant	O
drugs	O
(	O
acetaminophen	O
,	O
halothane	O
)	O
,	O
EtOH	O
,	O
and	O
other	O
xenobiotics	O
,	O
carcinogens	O
(	O
nitrosamines	O
)	O
,	O
endogenous	O
acetone	O
and	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
)	O
to	O
toxic	O
/	O
reactive	O
intermediates	O
,	O
.	O

Substrates	O
such	O
as	O
troleandomycin	O
,	O
ketoconazole	O
,	O
and	O
clotrimazole	O
that	O
bind	O
tightly	O
to	O
CYP3A	B
prosthetic	O
heme	O
and	O
/	O
or	O
active	O
site	O
stabilize	O
the	O
P450	O
protein	O
,	O
reduce	O
its	O
oxidative	O
turnover	O
and	O
extend	O
its	O
t_1	O
/	O
2	O
,	O
.	O

Furthermore	O
,	O
reduced	O
futile	O
oxidative	O
cycling	O
upon	O
conditional	O
deletion	O
of	O
the	O
liver	O
Cytochrome	B
P450	I
Reductase	O
gene	O
elevates	O
the	O
constitutive	O
hepatic	O
CYP3A	B
content	O
in	O
mice	O
,	O
plausibly	O
via	O
protein	O
stabilization	O
.	O

Systematic	O
dissection	O
of	O
the	O
hepatic	O
CYP3A	B
and	O
CYP2E1	O
ERAD	O
-	O
C	O
process	O
employing	O
various	O
in	O
vivo	O
and	O
in	O
vitro	O
reconstituted	O
eukaryotic	O
systems	O
has	O
revealed	O
that	O
it	O
involves	O
initial	O
post	O
-	O
translational	O
phosphorylation	O
by	O
cytosolic	O
protein	O
kinases	O
A	O
and	O
C	O
of	O
P450	O
Ser	O
/	O
Thr	O
residues	O
,	O
.	O

In	O
vitro	O
functional	O
reconstitution	O
studies	O
,	O
of	O
E1	O
/	O
E2	O
/	O
E3	O
-	O
mediated	O
CYP3A4	O
and	O
CYP2E1	O
ubiquitination	O
have	O
identified	O
UbcH5a	O
/	O
Hsc70	O
/	O
Hsp40	O
/	O
CHIP	O
and	O
UBC7	O
/	O
AMFR	O
/	O
gp78	O
complexes	O
as	O
two	O
relevant	O
E2	O
/	O
E3	O
systems	O
in	O
CYP3A4	O
and	O
CYP2E1	O
ubiquitination	O
:	O
(	O
i	O
)	O
CHIP	O
(	O
carboxy	O
-	O
terminus	O
of	O
Hsc70	O
-	O
interacting	O
protein	O
)	O
,	O
a	O
cytoplasmic	O
Hsc70	O
-	O
cochaperone	O
,	O
functions	O
with	O
its	O
cognate	O
UbcH5a	O
E2	O
and	O
Hsc70	O
/	O
Hsp40	O
co	O
-	O
chaperones	O
in	O
substrate	O
ubiquitination	O
,	O
.	O

We	O
turned	O
our	O
attention	O
to	O
other	O
carbon	O
nanostructures	O
,	O
such	O
as	O
diamond	O
nanoparticles	O
(	O
DN	O
)	O
,	O
graphene	O
oxide	O
(	O
GO	O
)	O
and	O
graphite	O
nanoparticles	O
(	O
GN	O
)	O
,	O
which	O
were	O
previously	O
shown	O
to	O
be	O
nontoxic	O
or	O
low	O
toxic	O
;	O
however	O
,	O
no	O
data	O
are	O
available	O
on	O
their	O
potential	O
interactions	O
with	O
CYP	O
isoenzymes	O
.	O
,	O
,	O
We	O
hypothesized	O
that	O
a	O
physicochemical	O
interaction	O
occurs	O
between	O
employed	O
carbon	O
nanostructures	O
and	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
enzymes	O
.	O

Additionally	O
,	O
the	O
control	O
Baculosomes	O
without	O
CYP450	O
expression	O
were	O
mixed	O
in	O
the	O
same	O
manner	O
as	O
the	O
Baculosomes	O
with	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
expression	O
.	O

Known	O
inhibitors	O
of	O
CYP450	O
enzymes	O
were	O
used	O
as	O
positive	O
controls	O
:	O
miconazole	O
for	O
CYP1A2	O
,	O
quinidine	O
for	O
CYP2D6	O
and	O
ketoconazole	O
for	O
CYP3A4	B
.	O

In	O
the	O
first	O
step	O
,	O
Vivid	O
Substrates	O
(	O
EOMCC	O
for	O
CYP1A2	O
and	O
CYP2D6	O
,	O
BOMCC	O
for	O
CYP3A4	B
)	O
were	O
reconstituted	O
in	O
anhydrous	O
acetonitrile	O
,	O
and	O
then	O
40	O
L	O
of	O
tested	O
compounds	O
(	O
DN	O
,	O
GO	O
,	O
GN	O
or	O
inhibitors	O
)	O
or	O
working	O
buffer	O
(	O
control	O
)	O
was	O
added	O
to	O
each	O
well	O
on	O
96	O
-	O
well	O
black	O
-	O
bottom	O
plate	O
(	O
Corning	O
,	O
New	O
York	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Then	O
,	O
50	O
L	O
of	O
Master	O
Pre	O
-	O
Mix	O
consisting	O
of	O
Baculosomes	O
(	O
containing	O
either	O
CYP1A2	O
,	O
CYP2D6	O
or	O
CYP3A4	B
isoenzyme	O
and	O
NADPH	O
reductase	O
)	O
in	O
working	O
buffer	O
and	O
the	O
regeneration	O
system	O
(	O
consisting	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
and	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
)	O
were	O
added	O
to	O
each	O
well	O
.	O

In	O
the	O
experiment	O
,	O
the	O
expression	O
levels	O
of	O
genes	O
for	O
the	O
previously	O
studied	O
cytochromes	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
,	O
for	O
two	O
other	O
cytochromes	O
vastly	O
expressed	O
in	O
the	O
liver	O
:	O
CYP2B6	O
and	O
CYP2E1	O
,	O
as	O
well	O
as	O
the	O
receptors	O
responsible	O
for	O
cytochrome	O
gene	O
expression	O
regulation	O
:	O
pregnane	O
X	O
receptor	O
(	O
PXR	O
)	O
,	O
constitutive	O
androstane	O
receptor	O
(	O
CAR	O
)	O
and	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
were	O
measured	O
.	O

DN	O
almost	O
did	O
not	O
affect	O
the	O
diameter	O
or	O
zeta	O
potential	O
of	O
the	O
microsomes	O
expressing	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
isoenzymes	O
,	O
whereas	O
GO	O
and	O
GN	O
visibly	O
increased	O
the	O
diameter	O
of	O
the	O
microsomes	O
,	O
especially	O
for	O
the	O
Baculosomes	O
expressing	O
CYP1A2	O
and	O
CYP3A4	B
isoenzymes	O
(	O
>	O
1	O
,	O
000	O
nm	O
in	O
comparison	O
to	O
~	O
300	O
nm	O
in	O
0	O
mg	O
/	O
L	O
samples	O
)	O
.	O

GN	O
also	O
shifted	O
zeta	O
potential	O
of	O
the	O
microsomes	O
from	O
highly	O
negative	O
(	O
37	O
,	O
31	O
and	O
42	O
mV	O
for	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
,	O
respectively	O
)	O
toward	O
more	O
positive	O
values	O
(	O
2	O
,	O
16	O
and	O
30	O
mV	O
for	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
,	O
respectively	O
)	O
and	O
GO	O
shifted	O
the	O
values	O
toward	O
more	O
negative	O
values	O
(	O
43	O
,	O
44	O
and	O
48	O
mV	O
for	O
1A2	O
,	O
2D6	O
and	O
3A4	O
,	O
respectively	O
)	O
,	O
which	O
indicates	O
the	O
impact	O
of	O
GO	O
and	O
GN	O
on	O
the	O
stability	O
of	O
microsome	O
hydrocolloids	O
and	O
the	O
occurrence	O
of	O
physicochemical	O
interactions	O
between	O
the	O
nanostructures	O
and	O
microsomes	O
expressing	O
the	O
CYP	O
enzymes	O
.	O

However	O
,	O
additional	O
measurements	O
performed	O
with	O
the	O
control	O
Baculosomes	O
,	O
which	O
did	O
not	O
express	O
any	O
recombinant	O
CYP	O
isoenzyme	O
,	O
revealed	O
that	O
the	O
binding	O
might	O
not	O
be	O
specific	O
for	O
the	O
CYP1A2	O
,	O
CYP2D6	O
or	O
CYP3A4	B
proteins	O
,	O
since	O
a	O
similar	O
decrease	O
in	O
the	O
protein	O
level	O
was	O
observed	O
.	O

In	O
the	O
enzymatic	O
test	O
based	O
on	O
Baculosomes	O
,	O
all	O
three	O
types	O
of	O
nanostructures	O
inhibited	O
reactions	O
by	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
isoenzymes	O
.	O

Inhibition	O
rate	O
was	O
compared	O
to	O
inhibition	O
in	O
positive	O
control	O
samples	O
with	O
the	O
known	O
specific	O
inhibitors	O
miconazole	O
,	O
quinidine	O
and	O
ketoconazole	O
for	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
,	O
respectively	O
.	O

The	O
inhibition	O
rate	O
of	O
CYP3A4	B
was	O
comparable	O
for	O
DN	O
,	O
GO	O
and	O
GN	O
at	O
all	O
concentrations	O
(	O
50	O
%	O
-	O
60	O
%	O
inhibition	O
)	O
;	O
however	O
,	O
at	O
the	O
highest	O
concentration	O
,	O
we	O
observed	O
an	O
effect	O
similar	O
to	O
the	O
one	O
in	O
CYP1A2	O
.	O

The	O
level	O
of	O
CYP3A4	B
was	O
decreased	O
in	O
all	O
nanostructure	O
groups	O
in	O
both	O
cell	O
lines	O
(	O
<	O
40	O
%	O
of	O
the	O
control	O
,	O
reaching	O
only	O
1	O
%	O
in	O
the	O
GO	O
group	O
in	O
HepaRG	O
cells	O
)	O
,	O
except	O
the	O
GN	O
group	O
in	O
HepaRG	O
cells	O
,	O
where	O
no	O
changes	O
occurred	O
.	O

In	O
this	O
study	O
,	O
we	O
presented	O
interactions	O
among	O
three	O
nanostructures	O
of	O
different	O
carbon	O
allotropes	O
,	O
namely	O
,	O
DN	O
,	O
GO	O
and	O
GN	O
,	O
and	O
isoenzymes	O
of	O
CYP450	O
,	O
namely	O
,	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
,	O
in	O
the	O
model	O
of	O
Baculosomes	O
.	O

The	O
most	O
important	O
evidence	O
for	O
the	O
direct	O
interaction	O
between	O
CYP	O
-	O
expressing	O
microsomes	O
and	O
DN	O
,	O
GO	O
and	O
GN	O
is	O
inhibition	O
of	O
the	O
catalytic	O
activity	O
of	O
CYP1A2	O
,	O
CYP2D6	O
and	O
CYP3A4	B
measured	O
separately	O
for	O
all	O
three	O
isoforms	O
and	O
revealing	O
subtle	O
differences	O
among	O
the	O
isoenzymes	O
.	O

Product	O
formation	O
on	O
CYP1A2	O
was	O
highly	O
inhibited	O
by	O
DN	O
and	O
GN	O
,	O
while	O
on	O
CYP2D6	O
and	O
CYP3A4	B
,	O
all	O
nanostructures	O
inhibited	O
the	O
reaction	O
at	O
similar	O
levels	O
.	O

Interestingly	O
,	O
inhibition	O
of	O
CYP1A2	O
and	O
CYP3A4	B
was	O
lower	O
in	O
the	O
presence	O
of	O
the	O
highest	O
concentration	O
of	O
DN	O
and	O
GN	O
(	O
100	O
mg	O
/	O
L	O
)	O
,	O
which	O
could	O
be	O
related	O
to	O
the	O
formation	O
of	O
nanoparticle	O
agglomerates	O
in	O
higher	O
concentrations	O
and	O
then	O
reduction	O
of	O
their	O
surface	O
area	O
available	O
to	O
interact	O
.	O

General	O
downregulation	O
of	O
the	O
genes	O
was	O
especially	O
visible	O
in	O
HepaRG	O
cells	O
,	O
which	O
probably	O
results	O
from	O
a	O
weaker	O
expression	O
of	O
genes	O
encoding	O
enzymes	O
of	O
Phases	O
I	O
and	O
II	O
of	O
the	O
xenobiotic	O
metabolism	O
in	O
the	O
HepG2	O
cell	O
line	O
,	O
making	O
HepaRG	O
a	O
more	O
suitable	O
model	O
for	O
drug	O
metabolism	O
studies	O
.	O
-	O
The	O
strongest	O
downregulation	O
of	O
CYP	O
genes	O
was	O
induced	O
by	O
GO	O
,	O
which	O
influenced	O
not	O
only	O
CYP1A2	O
and	O
CYP3A4	B
genes	O
,	O
but	O
also	O
CYP2B6	O
,	O
CYP2E1	O
and	O
AhR	O
,	O
CAR	O
and	O
PXR	O
,	O
which	O
are	O
responsive	O
elements	O
regulating	O
the	O
expression	O
of	O
CYP	O
genes	O
.	O

It	O
was	O
previously	O
reported	O
that	O
SWCNT	O
inhibited	O
the	O
most	O
important	O
of	O
the	O
isoenzymes	O
,	O
CYP3A4	B
,	O
mostly	O
due	O
to	O
the	O
occurrence	O
of	O
-	O
stacking	O
interactions	O
between	O
the	O
nanotube	O
walls	O
and	O
aromatic	O
residues	O
of	O
the	O
enzyme	O
.	O

Recombinant	O
CYPs	O
showing	O
the	O
highest	O
specific	O
activity	O
were	O
CYP3A4	B
,	O
CYP3A7	O
and	O
to	O
lower	O
extent	O
CYP2C9	O
and	O
CTP2C8	O
.	O

Michaelis	O
-	O
Menten	O
enzyme	O
kinetics	O
were	O
determined	O
for	O
pooled	O
human	O
liver	O
microsomes	O
,	O
recombinant	O
CYP3A4	B
,	O
CYP3A7	O
and	O
CYP2C9	O
.	O

Surprisingly	O
,	O
sulfaphenazole	O
appeared	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
5hydroxylation	O
of	O
flucloxacillin	O
by	O
both	O
recombinant	O
CYP3A4	B
and	O
CYP3A7	O
.	O

The	O
combined	O
results	O
show	O
that	O
the	O
5hydroxylation	O
of	O
flucloxacillin	O
is	O
primarily	O
catalysed	O
by	O
CYP3A4	B
,	O
CYP3A7	O
and	O
CYP2C9	O
.	O

There	O
are	O
large	O
interindividual	O
differences	O
in	O
plasma	O
concentrations	O
of	O
flucloxacillin	O
and	O
5hydroxymethyl	O
flucloxacillin	O
.	O
5Hydroxymethyl	O
flucloxacillin	O
is	O
much	O
more	O
toxic	O
to	O
biliary	O
epithelial	O
cells	O
than	O
flucloxacillin	O
.	O
A	O
previous	O
study	O
on	O
four	O
human	O
CYPs	O
showed	O
that	O
CYP3A4	B
exerted	O
the	O
highest	O
activity	O
of	O
flucloxacillin	O
hydroxylation	O
.	O

Quantification	O
of	O
specific	O
activities	O
and	O
enzyme	O
kinetics	O
of	O
flucloxacillin	O
hydroxylation	O
by	O
HLM	O
and	O
14	O
recombinant	O
human	O
CYPs	O
.	O
Next	O
to	O
CYP3A4	B
,	O
CYP3A7	O
and	O
CYP2C9	O
may	O
contribute	O
significantly	O
to	O
flucloxacillin	O
hydroxylation	O
.	O
Sulfaphenazole	O
,	O
considered	O
as	O
a	O
selective	O
CYP2C9	O
inhibitor	O
,	O
strongly	O
inhibits	O
CYP3Amediated	O
flucloxacillin	O
hydroxylation	O
.	O

Interindividual	O
variability	O
and	O
drugdrug	O
interactions	O
at	O
the	O
level	O
of	O
CYP3A4	B
,	O
CYP3A7	O
and	O
CYP2C9	O
may	O
be	O
important	O
factors	O
determining	O
the	O
risk	O
of	O
flucloxacillininduced	O
liver	O
injury	O
.	O

Nonrenal	O
clearance	O
of	O
flucloxacillin	O
occurs	O
predominantly	O
by	O
cytochrome	O
P450mediated	O
hydroxylation	O
of	O
flucloxacillin	O
to	O
5HMFLX	O
and	O
partly	O
by	O
hydrolysis	O
to	O
the	O
corresponding	O
penicilloic	O
acid	O
,	O
showed	O
that	O
CYP3A4	B
was	O
able	O
to	O
catalyse	O
the	O
5hydroxylation	O
of	O
flucloxacillin	O
.	O

Another	O
study	O
showed	O
that	O
flucloxacillin	O
induces	O
CYP3A4	B
in	O
cell	O
lines	O
exposed	O
to	O
200	O
-	O
400	O
M	O
flucloxacillin	O
(	O
Huwyler	O
et	O
al	O
.	O
,	O
.	O

Furthermore	O
,	O
a	O
major	O
involvement	O
of	O
CYP3A4	B
in	O
drug	O
metabolism	O
complicates	O
prediction	O
of	O
pharmacokinetics	O
based	O
on	O
enzyme	O
kinetics	O
because	O
of	O
the	O
occurrence	O
of	O
atypical	O
enzyme	O
kinetics	O
,	O
such	O
as	O
substrate	O
activation	O
(	O
Houston	O
and	O
Kenworthy	O
,	O
;	O
Ekins	O
et	O
al	O
.	O
,	O
;	O
Atkins	O
,	O
;	O
Houston	O
and	O
Galetin	O
,	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
CYP3A4	B
by	O
drugs	O
appears	O
to	O
be	O
substratedependent	O
,	O
further	O
complicating	O
prediction	O
of	O
drug	O
-	O
drug	O
interactions	O
(	O
Stresser	O
et	O
al	O
.	O
,	O
.	O

456264	O
)	O
,	O
CYP3A4	B
(	O
Lot	O
No	O
.	O

Because	O
these	O
incubations	O
were	O
only	O
performed	O
to	O
identify	O
the	O
most	O
active	O
enzymes	O
,	O
duplicate	O
experiments	O
were	O
deemed	O
sufficient	O
since	O
reproducibility	O
of	O
incubations	O
with	O
recombinant	O
enzymes	O
from	O
the	O
same	O
source	O
was	O
always	O
within	O
5	O
%	O
,	O
For	O
the	O
most	O
active	O
Gentest	O
Supersomes	O
and	O
pooled	O
HLM	O
,	O
the	O
enzyme	O
kinetics	O
of	O
the	O
formation	O
of	O
5HMFLX	O
were	O
determined	O
by	O
incubating	O
with	O
11	O
concentrations	O
of	O
flucloxacillin	O
,	O
ranging	O
from	O
0	O
to	O
500	O
M	O
.	O
Each	O
flucloxacillin	O
concentration	O
was	O
incubated	O
in	O
duplicate	O
for	O
10	O
min	O
with	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
pooled	O
HLM	O
,	O
100	O
nM	O
CYP3A4	B
,	O
CYP3A7	O
and	O
CYP2C9	O
Supersomes	O
in	O
100	O
mM	O
potassium	O
phosphate	O
buffer	O
,	O
pH	O
7	O
.	O
4	O
supplemented	O
with	O
5	O
mM	O
MgCl_2	O
and	O
2	O
mM	O
EDTA	O
.	O

Flucloxacillin	O
was	O
incubated	O
at	O
substrate	O
concentrations	O
of	O
10	O
and	O
100	O
M	O
with	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
HLM	O
,	O
as	O
described	O
above	O
,	O
and	O
in	O
the	O
absence	O
or	O
presence	O
of	O
the	O
following	O
inhibitors	O
:	O
10	O
M	O
ALPHAnaphtoflavone	O
(	O
CYP1A2	O
)	O
,	O
3	O
M	O
ticlopidine	O
(	O
CYP2B6	O
)	O
,	O
15	O
M	O
quercetin	O
(	O
CYP2C8	O
)	O
,	O
10	O
M	O
sulfaphenazole	O
(	O
CYP2C9	O
)	O
,	O
10	O
M	O
fluvoxamine	O
(	O
CYP2C9	O
/	O
CYP1A2	O
)	O
,	O
1	O
M	O
(	O
+	O
)	O
N3benzylnirvanol	O
(	O
CYP2C19	O
)	O
,	O
2	O
M	O
quinidine	O
(	O
CYP2D6	O
)	O
,	O
20	O
M	O
diethylthiocarbamate	O
(	O
CYP2E1	O
)	O
,	O
3	O
M	O
troleandomycin	O
(	O
CYP3A4	B
)	O
;	O
2	O
M	O
miconazole	O
(	O
CYP3A4	B
/	O
CYP2C9	O
)	O
and	O
0	O
.	O
1	O
M	O
(	O
CYP3A4	B
)	O
and	O
1	O
M	O
(	O
CYP3A	O
)	O
ketoconazole	O
respectively	O
.	O

Because	O
the	O
CYP2C9specific	O
inhibitor	O
sulfaphenazole	O
appeared	O
to	O
almost	O
completely	O
block	O
formation	O
of	O
5HMFLX	O
by	O
pooled	O
HLM	O
,	O
it	O
was	O
also	O
added	O
at	O
different	O
concentrations	O
to	O
incubations	O
of	O
CYP3A4	B
and	O
CYP3A7	O
Supersomes	O
with	O
flucloxacillin	O
(	O
10	O
M	O
)	O
and	O
testosterone	O
(	O
50	O
M	O
)	O
.	O

To	O
determine	O
the	O
variability	O
of	O
5hydroxylation	O
of	O
flucloxacillin	O
,	O
the	O
substrate	O
was	O
incubated	O
(	O
10	O
and	O
100	O
M	O
)	O
with	O
a	O
panel	O
of	O
individual	O
HLM	O
fractions	O
from	O
16	O
donors	O
(	O
0	O
.	O
5	O
mgmL	O
^	O
1	O
)	O
which	O
were	O
phenotyped	O
with	O
respect	O
to	O
activities	O
of	O
CYP1A2	O
(	O
phenacetin	O
Odeethylation	O
)	O
,	O
CYP2A6	O
(	O
coumarin	O
7hydroxylation	O
)	O
,	O
CYP2B6	O
(	O
bupropion	O
hydroxylation	O
)	O
,	O
CYP2C8	O
(	O
amodiaquine	O
Ndeethylation	O
)	O
,	O
CYP2C9	O
(	O
diclofenac	O
4hydroxylation	O
)	O
,	O
CYP2C19	O
(	O
mephenytoin	O
4hydroxylation	O
)	O
,	O
CYP2D6	O
(	O
bufuralol	O
1hydroxylation	O
)	O
,	O
CYP2E1	O
(	O
chlorzoxazone	O
6hydroxylation	O
)	O
and	O
CYP3A4	B
(	O
midazolam	O
1hydroxylation	O
and	O
testosterone	O
6BETAhydroxylation	O
)	O
using	O
the	O
concentrations	O
described	O
previously	O
(	O
den	O
BraverSewradj	O
et	O
al	O
.	O
,	O
.	O

At	O
a	O
flucloxacillin	O
concentration	O
of	O
10	O
M	O
,	O
recombinant	O
CYP3A4	B
,	O
CYP3A7	O
and	O
to	O
a	O
lesser	O
extent	O
CYP2C9	O
showed	O
the	O
highest	O
activity	O
,	O
in	O
terms	O
of	O
the	O
formation	O
of	O
5HMFLX	O
.	O

At	O
100	O
M	O
flucloxacillin	O
,	O
CYP3A7	O
was	O
the	O
most	O
active	O
CYP	O
followed	O
by	O
CYP3A4	B
.	O

As	O
CYP3A4	B
,	O
CYP3A7	O
and	O
CYP2C9	O
Supersomes	O
showed	O
highest	O
activity	O
at	O
both	O
concentrations	O
,	O
the	O
enzyme	O
kinetics	O
of	O
5HMFLX	O
formation	O
was	O
also	O
determined	O
for	O
these	O
recombinant	O
CYPs	O
.	O

Using	O
the	O
Michaelis	O
-	O
Menten	O
model	O
,	O
the	O
following	O
enzyme	O
kinetic	O
parameters	O
were	O
determined	O
:	O
CYP3A4	B
,	O
K	O
_M	O
124	O
15	O
M	O
,	O
V_max	O
197	O
9	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
;	O
CYP3A7	O
:	O
K	O
_M	O
65	O
8	O
M	O
,	O
V_max	O
193	O
7	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
;	O
and	O
CYP2C9	O
:	O
K	O
_M	O
of	O
508	O
82	O
M	O
,	O
V_max	O
67	O
7	O
pmolmin	O
^	O
1nmol	O
^	O
1	O
P450	O
.	O

The	O
other	O
CYP3A4	B
inhibitors	O
showed	O
only	O
20	O
to	O
40	O
%	O
inhibition	O
at	O
10	O
M	O
flucloxacillin	O
concentration	O
.	O

Although	O
recombinant	O
CYP2C9	O
showed	O
much	O
lower	O
activity	O
when	O
compared	O
to	O
CYP3A4	B
,	O
an	O
almost	O
90	O
%	O
inhibition	O
of	O
5HMFLX	O
formation	O
was	O
observed	O
in	O
the	O
presence	O
of	O
sulfaphenazole	O
,	O
which	O
is	O
considered	O
to	O
be	O
a	O
selective	O
CYP2C9	O
inhibitor	O
.	O

To	O
study	O
whether	O
sulfaphenazole	O
has	O
the	O
ability	O
to	O
inhibit	O
CYP3Amediated	O
hydroxylation	O
of	O
flucloxacillin	O
,	O
the	O
inhibitor	O
was	O
added	O
at	O
different	O
concentrations	O
to	O
incubations	O
of	O
CYP3A4	B
and	O
CYP3A7	O
,	O
with	O
flucloxacillin	O
and	O
testosterone	O
as	O
substrates	O
.	O

As	O
shown	O
in	O
Figure	O
A	O
,	O
B	O
,	O
sulfaphenazole	O
appeared	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
flucloxacillin	O
hydroxylation	O
by	O
recombinant	O
CYP3A4	B
and	O
CYP3A7	O
with	O
an	O
IC_50	O
of	O
4	O
.	O
1	O
0	O
.	O
4	O
M	O
and	O
6	O
.	O
1	O
0	O
.	O
5	O
M	O
respectively	O
.	O

At	O
these	O
sulfaphenazole	O
concentrations	O
,	O
no	O
inhibition	O
of	O
CYP3A4catalysed	O
6BETAhydroxylation	O
of	O
testosterone	O
was	O
observed	O
.	O

By	O
using	O
recombinant	O
CYPs	O
,	O
at	O
both	O
substrate	O
concentrations	O
used	O
,	O
CYP3A4	B
and	O
CYP3A7	O
appeared	O
to	O
be	O
the	O
most	O
active	O
enzymes	O
.	O

that	O
CYP3A4	B
is	O
likely	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
formation	O
of	O
5HMFLX	O
,	O
as	O
it	O
is	O
,	O
on	O
average	O
,	O
the	O
most	O
abundant	O
CYP	O
in	O
human	O
liver	O
(	O
mean	O
93	O
pmolmg	O
^	O
1	O
protein	O
)	O
(	O
Achour	O
et	O
al	O
.	O
,	O
.	O

No	O
lauric	O
acid	O
hydroxylation	O
(	O
CYP4A1	O
-	O
selective	O
)	O
was	O
observed	O
.	O

According	O
to	O
the	O
GTEx	O
portal	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
gtexportal	O
.	O
org	O
)	O
(	O
Access	O
on	O
:	O
10	O
February	O
2021	O
)	O
,	O
the	O
expression	O
quantitative	O
trait	O
loci	O
analysis	O
showed	O
that	O
rs17102977	O
was	O
significantly	O
associated	O
with	O
CYP4A22	O
gene	O
expression	O
in	O
the	O
brain	O
,	O
but	O
not	O
in	O
the	O
breast	O
tissue	O
.	O

P450	O
Oxidoreductase	O
contains	O
a	O
flavin	O
adenine	O
dinucleotide	O
and	O
a	O
flavin	O
mononucleotide	O
allowing	O
the	O
enzyme	O
to	O
oxidize	O
NADPH	O
and	O
reduce	O
the	O
Cytochrome	B
P450	I
enzyme	O
in	O
a	O
stepwise	O
manner	O
.	O

The	O
availability	O
of	O
NADPH	O
is	O
a	O
vital	O
aspect	O
of	O
CYP	O
-	O
catalyzed	O
reactions	O
,	O
with	O
redox	O
partner	O
ratios	O
differentially	O
influencing	O
Cytochrome	B
P450	I
activities	O
[	O
,	O
.	O

A	O
high	O
inter	O
-	O
and	O
intra	O
-	O
individual	O
variability	O
of	O
hepatic	O
Cytochrome	B
P450	I
activity	O
results	O
from	O
the	O
strong	O
potential	O
for	O
induction	O
by	O
pharmacological	O
and	O
natural	O
compounds	O
,	O
the	O
high	O
frequency	O
and	O
number	O
of	O
polymorphisms	O
,	O
and	O
promoter	O
and	O
copy	O
number	O
variants	O
.	O

Human	O
Cytochrome	B
P450	I
are	O
primarily	O
membrane	O
-	O
associated	O
proteins	O
located	O
either	O
in	O
the	O
inner	O
membrane	O
of	O
mitochondria	O
or	O
in	O
the	O
endoplasmic	O
reticulum	O
of	O
cells	O
.	O

Cytochrome	B
P450	I
constitutes	O
the	O
major	O
enzyme	O
family	O
capable	O
of	O
catalyzing	O
the	O
oxidative	O
biotransformation	O
of	O
most	O
drugs	O
and	O
other	O
lipophilic	O
xenobiotics	O
and	O
are	O
therefore	O
of	O
particular	O
relevance	O
for	O
clinical	O
pharmacology	O
,	O
primarily	O
found	O
in	O
liver	O
cells	O
but	O
they	O
are	O
also	O
located	O
in	O
cells	O
throughout	O
the	O
body	O
.	O

Up	O
-	O
to	O
-	O
date	O
,	O
there	O
are	O
approximately	O
60	O
Cytochrome	B
P450	I
genes	O
in	O
humans	O
(	O
https	O
:	O
/	O
/	O
ghr	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
primer	O
/	O
genefamily	O
/	O
cytochromep450	O
)	O
.	O

Hepatic	O
Cytochrome	B
P450	I
mutations	O
can	O
alter	O
systemic	O
drug	O
metabolism	O
and	O
distribution	O
,	O
however	O
,	O
the	O
possibility	O
that	O
mutated	O
or	O
polymorphic	O
variants	O
of	O
Cytochrome	B
P450	I
exist	O
in	O
the	O
brain	O
is	O
not	O
well	O
studied	O
.	O

The	O
Cytochrome	B
P450	I
,	O
family	O
2	O
,	O
subfamily	O
C	O
,	O
polypeptide	O
19	O
(	O
CYP2C19	O
gene	O
)	O
is	O
located	O
within	O
a	O
cluster	O
of	O
Cytochrome	B
P450	I
genes	O
(	O
CYP2C19	O
)	O
on	O
chromosome	O
10q23	O
.	O
33	O
with	O
reference	O
sequence	O
number	O
(	O
NM_000769	O
)	O
and	O
ensemble	O
accession	O
number	O
ENST00000371321	O
.	O
8	O
.	O

We	O
checked	O
nucleotide	O
human	O
sequence	O
homology	O
of	O
CYP2C19	O
(	O
NP_000760	O
.	O
1	O
)	O
with	O
National	O
Institute	O
of	O
Health	O
databases	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
)	O
,	O
and	O
we	O
found	O
that	O
84	O
%	O
of	O
CYPC29	O
(	O
NP_000760	O
.	O
1	O
)	O
,	O
81	O
%	O
of	O
CYP2C18	O
isoform	O
2	O
precursor	O
(	O
NP_000762	O
.	O
2	O
)	O
,	O
81	O
%	O
of	O
Cytochrome	B
P450	I
2C8	O
isoform	O
c	O
(	O
NP_000763	O
.	O
1	O
)	O
,	O
79	O
%	O
of	O
Cytochrome	B
P450	I
2C8	O
isoform	O
b	O
(	O
NP_001185783	O
.	O
1	O
)	O
,	O
78	O
%	O
Cytochrome	B
P450	I
2C8	O
isoform	O
a	O
precursor	O
(	O
NP_000761	O
.	O
3	O
)	O
,	O
58	O
%	O
Cytochrome	B
P450	I
2E1	O
precursor	O
(	O
NP_000764	O
.	O
1	O
)	O
,	O
56	O
%	O
Cytochrome	B
P450	I
2F1	O
isoform	O
X7	O
(	O
XP_016881875	O
.	O
1	O
)	O
,	O
and	O
48	O
%	O
CYPP450	O
2F1	O
isoform	O
X4	O
(	O
XP_011524855	O
.	O
1	O
)	O
.	O

Oxidative	O
processes	O
are	O
mediated	O
primarily	O
by	O
the	O
Cytochrome	B
P450	I
family	O
of	O
enzymes	O
,	O
whereas	O
conjugation	O
reactions	O
are	O
conducted	O
largely	O
by	O
the	O
enzyme	O
uridine	O
5	O
-	O
diphospho	O
-	O
glucuronyltransferase	O
.	O

Cytochrome	B
P450	I
endoplasmic	O
reticulum	O
-	O
associated	O
degradation	O
:	O
therapeutic	O
and	O
pathophysiological	O
implications	O
.	O

Cytochrome	B
P450	I
1A	O
(	O
CYP1A	O
)	O
,	O
one	O
of	O
the	O
major	O
Cytochrome	B
P450	I
subfamily	O
in	O
humans	O
,	O
not	O
only	O
metabolizes	O
xenobiotics	O
including	O
clinical	O
drugs	O
and	O
pollutants	O
in	O
the	O
environment	O
,	O
but	O
also	O
mediates	O
the	O
biotransformation	O
of	O
important	O
endogenous	O
substances	O
.	O

From	O
prokaryotes	O
to	O
eukaryotes	O
,	O
from	O
plants	O
to	O
animals	O
,	O
from	O
non	O
-	O
human	O
primates	O
to	O
humans	O
,	O
thousands	O
of	O
Cytochrome	B
P450	I
genes	O
have	O
been	O
identified	O
and	O
named	O
.	O

Among	O
the	O
human	O
Cytochrome	B
P450	I
isoforms	O
,	O
CYP1A	O
is	O
an	O
important	O
subfamily	O
involved	O
in	O
the	O
metabolism	O
of	O
drugs	O
,	O
environmental	O
pollutants	O
and	O
physiological	O
substances	O
,	O
.	O

Although	O
progesterone	O
is	O
mainly	O
converted	O
to	O
pregnanediol	O
,	O
direct	O
hydroxylation	O
of	O
progesterone	O
mediated	O
by	O
Cytochrome	B
P450	I
is	O
also	O
involved	O
^	O
,	O
^	O
,	O
.	O

Sulfotransferases	O
and	O
glucuronidases	O
conjugate	O
estrone	O
into	O
estrogen	O
conjugates	O
,	O
and	O
some	O
Cytochrome	B
P450	I
isoforms	O
also	O
hydroxylate	O
it	O
into	O
catechol	O
estrogens	O
or	O
estriol	O
.	O

Linoleic	O
acid	O
is	O
metabolized	O
by	O
a	O
variety	O
of	O
enzymes	O
,	O
including	O
Cytochrome	B
P450	I
,	O
lipoxygenase	O
,	O
and	O
cyclooxygenase	O
.	O

Comprehensive	O
Analyses	O
of	O
Cytochrome	B
P450	I
Monooxygenases	O
and	O
Secondary	O
Metabolite	O
Biosynthetic	O
Gene	O
Clusters	O
in	O
Cyanobacteria	O
.	O

Cytochrome	B
P450	I
monooxygenases	O
(	O
CYPs	O
/	O
P450s	O
)	O
contribute	O
to	O
the	O
production	O
and	O
diversity	O
of	O
various	O
secondary	O
metabolites	O
.	O

Of	O
the	O
genes	O
that	O
were	O
upregulated	O
and	O
have	O
more	O
than	O
10	O
protein	O
to	O
protein	O
interactions	O
are	O
:	O
Cytochrome	B
P450	I
1a1	O
,	O
IL6	O
,	O
UGT1A6	O
,	O
EGFR	O
,	O
and	O
CYP1B1	O
(	O
see	O
.	O

Cytochrome	B
P450	I
1A1	O
was	O
upregulated	O
by	O
more	O
than	O
300	O
-	O
fold	O
and	O
CYP1B1	O
by	O
10	O
-	O
fold	O
in	O
the	O
Bioprinted	O
cells	O
.	O

Amino	O
acid	O
levels	O
determine	O
metabolism	O
and	O
Cytochrome	B
P450	I
function	O
of	O
hepatocytes	O
and	O
hepatoma	O
cell	O
lines	O
.	O

As	O
these	O
Cytochrome	B
P450	I
enzymes	O
differ	O
significantly	O
between	O
species	O
,	O
drug	O
biotransformation	O
and	O
hepatotoxicity	O
can	O
only	O
be	O
evaluated	O
in	O
freshly	O
isolated	O
primary	O
human	O
hepatocytes	O
^	O
.	O

Nevertheless	O
,	O
as	O
these	O
models	O
still	O
do	O
not	O
reach	O
drug	O
biotransformation	O
capacities	O
of	O
fresh	O
Primary	O
Human	O
Hepatocytes	O
,	O
the	O
major	O
goal	O
of	O
toxicologists	O
remains	O
the	O
generation	O
of	O
expandable	O
models	O
with	O
stable	O
Cytochrome	B
P450	I
activity	O
levels	O
close	O
to	O
those	O
of	O
fresh	O
PHH	O
^	O
,	O
.	O

Hepatocyte	O
-	O
Like	O
Cells	O
differ	O
from	O
Primary	O
Human	O
Hepatocytes	O
at	O
the	O
transcriptional	O
,	O
proteomic	O
,	O
and	O
epigenetical	O
level	O
,	O
and	O
specifically	O
express	O
low	O
levels	O
of	O
hepatic	O
transcription	O
factors	O
and	O
Cytochrome	B
P450	I
enzymes	O
^	O
,	O
,	O
,	O
.	O

We	O
also	O
show	O
that	O
extracellular	O
amino	O
acids	O
represent	O
a	O
tool	O
to	O
drive	O
both	O
metabolic	O
maturation	O
and	O
the	O
expression	O
of	O
Cytochrome	B
P450	I
enzymes	O
,	O
and	O
this	O
in	O
both	O
Hepatocyte	O
-	O
Like	O
Cells	O
and	O
HepG2	O
hepatoma	O
cells	O
.	O

Surprisingly	O
,	O
Cytochrome	B
P450	I
genes	O
were	O
found	O
to	O
be	O
co	O
-	O
regulated	O
with	O
metabolic	O
rather	O
than	O
developmental	O
genes	O
,	O
we	O
found	O
a	O
strong	O
correlation	O
between	O
modules	O
containing	O
Cytochrome	B
P450	I
genes	O
and	O
genes	O
involved	O
in	O
gluconeogenesis	O
,	O
mitochondrial	O
metabolism	O
,	O
AA	O
metabolism	O
,	O
and	O
BETA	O
-	O
oxidation	O
.	O

As	O
a	O
lower	O
correlation	O
was	O
found	O
with	O
modules	O
linked	O
to	O
development	O
,	O
polarity	O
,	O
and	O
cytoskeleton	O
,	O
we	O
hypothesized	O
that	O
an	O
immature	O
metabolism	O
is	O
the	O
prime	O
reason	O
for	O
low	O
Cytochrome	B
P450	I
expression	O
.	O

As	O
overexpression	O
of	O
hepatic	O
Transcription	O
Factors	O
has	O
been	O
shown	O
to	O
enhance	O
Cytochrome	B
P450	I
activity	O
to	O
some	O
extent	O
^	O
,	O
,	O
we	O
next	O
assessed	O
whether	O
these	O
might	O
also	O
rewire	O
hepatic	O
metabolism	O
.	O

Hence	O
,	O
although	O
overexpression	O
of	O
hepatic	O
Transcription	O
Factors	O
could	O
induce	O
a	O
metabolic	O
switch	O
from	O
a	O
glucose	O
to	O
a	O
pyruvate	O
-	O
fueled	O
metabolism	O
,	O
they	O
could	O
not	O
induce	O
a	O
gluconeogenic	O
and	O
oxidative	O
phenotype	O
,	O
and	O
Cytochrome	B
P450	I
function	O
was	O
only	O
modestly	O
increased	O
.	O

Surprisingly	O
,	O
despite	O
the	O
clear	O
correlation	O
between	O
metabolism	O
,	O
AA	O
catabolism	O
,	O
and	O
Cytochrome	B
P450	I
expression	O
observed	O
in	O
the	O
WGCNA	O
,	O
AA3	O
only	O
marginally	O
induced	O
the	O
expression	O
of	O
CYP3A4	O
when	O
exceeding	O
the	O
nutritional	O
need	O
(	O
Supplementary	O
Fig	O
,	O
C	O
)	O
.	O

As	O
aside	O
from	O
CYP3A4	O
,	O
also	O
other	O
Cytochrome	B
P450	I
isoforms	O
were	O
induced	O
in	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
medium	O
(	O
Supplementary	O
Fig	O
)	O
,	O
Amino	O
Acids	O
represent	O
a	O
valuable	O
tool	O
to	O
induce	O
Cytochrome	B
P450	I
enzymes	O
.	O

The	O
top	O
deregulated	O
pathways	O
when	O
comparing	O
HLC	O
Liver	O
Differentiation	O
Medium	O
D20	O
with	O
Primary	O
Human	O
Hepatocytes	O
contained	O
several	O
genes	O
involved	O
in	O
AA	O
catabolism	O
,	O
glucose	O
metabolism	O
,	O
metabolic	O
pathways	O
,	O
and	O
metabolism	O
of	O
xenobiotics	O
by	O
Cytochrome	B
P450	I
enzymes	O
and	O
AMP	O
-	O
activated	O
protein	O
kinase	O
)	O
,	O
we	O
next	O
stratified	O
these	O
into	O
four	O
quadrants	O
.	O

We	O
found	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
to	O
induce	O
several	O
Cytochrome	B
P450	I
isoforms	O
in	O
the	O
HepG2	O
and	O
HUH7	O
.	O
5	O
hepatic	O
cell	O
lines	O
(	O
Supplementary	O
Fig	O
)	O
,	O
whereas	O
again	O
glycine	O
could	O
be	O
replaced	O
by	O
serine	O
,	O
alanine	O
,	O
or	O
leucine	O
(	O
Supplementary	O
Fig	O
.	O

As	O
both	O
isoforms	O
are	O
expressed	O
in	O
kidney	O
cells	O
^	O
,	O
this	O
may	O
suggest	O
that	O
Amino	O
Acids	O
might	O
also	O
regulate	O
Cytochrome	B
P450	I
isoforms	O
in	O
other	O
cell	O
types	O
.	O

Liver	O
mRNA	O
expression	O
of	O
Cyp1a2	O
,	O
Cyp3a11	O
(	O
human	O
CYP3A4	O
)	O
and	O
Cyp2e1	B
was	O
increased	O
in	O
mice	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
(	O
100	O
,	O
200	O
,	O
400	O
,	O
800	O
mg	O
/	O
kg	O
)	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
liver	O
mRNA	O
expression	O
of	O
Cyp1a2	O
,	O
Cyp2e1	B
and	O
Cyp3a11	O
was	O
increased	O
in	O
mice	O
treated	O
with	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
(	O
800	O
mg	O
/	O
kg	O
)	O
for	O
4	O
h	O
,	O
8	O
h	O
,	O
and	O
12	O
h	O
enhanced	O
hepatic	O
CYP1A2	O
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
hepatic	O
CYP1A2	O
expression	O
after	O
treated	O
mice	O
for	O
8	O
h	O
and	O
12	O
h	O
enhanced	O
hepatic	O
CYP2E1	O
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
only	O
increased	O
hepatic	O
CYP2E1	O
expression	O
after	O
treated	O
mice	O
for	O
12	O
h	O
enhanced	O
hepatic	O
CYP3A4	O
protein	O
expression	O
when	O
mice	O
were	O
treated	O
with	O
different	O
doses	O
of	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
for	O
12	O
h	O
for	O
different	O
times	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
Tetrahydroxystilbene	O
-	O
2	O
-	O
O	O
-	O
Beta	O
-	O
D	O
-	O
Glucoside	O
increased	O
hepatic	O
CYP3A4	O
expression	O
after	O
treated	O
mice	O
for	O
4	O
h	O
,	O
8	O
h	O
and	O
12	O
h	O
(	O
Fig	O
.	O

The	O
expression	O
of	O
additional	O
CYPs	O
(	O
Cyp1a1	O
,	O
Cyp1b1	O
,	O
Cyp2e1	B
)	O
was	O
observed	O
in	O
the	O
skin	O
of	O
C57BL	O
/	O
6J	O
mice	O
by	O
Flowers	O
et	O
al	O
.	O
.	O
In	O
the	O
mouse	O
skin	O
the	O
expression	O
of	O
several	O
Cyp	O
genes	O
was	O
demonstrated	O
on	O
the	O
RNA	O
level	O
.	O

Cyp1a1	B
,	O
Cyp1b1	O
and	O
Cyp3a11	O
,	O
but	O
not	O
Ahr	O
expression	O
in	O
the	O
skin	O
also	O
were	O
enhanced	O
by	O
7	O
,	O
12	O
-	O
Dimethylbenz	O
[	O
A	O
]	O
Anthracene	O
.	O

48	O
h	O
after	O
application	O
of	O
7	O
,	O
12	O
-	O
Dimethylbenz	O
[	O
A	O
]	O
Anthracene	O
,	O
skin	O
expression	O
of	O
Pxr	O
and	O
Cyp1a1	B
mRNAs	O
were	O
markedly	O
increased	O
,	O
Cyp1b1	O
and	O
Cyp3a11	O
only	O
moderately	O
and	O
Ahr	O
not	O
at	O
all	O
.	O

Despite	O
a	O
lower	O
constitutive	O
expression	O
of	O
Cyp4a10	O
in	O
the	O
female	O
hearts	O
,	O
acute	O
DOX	O
-	O
induced	O
cardiotoxicity	O
caused	O
a	O
marked	O
induction	O
of	O
Cyp4a10	O
in	O
the	O
hearts	O
of	O
both	O
male	O
and	O
female	O
mice	O
,	O
suggesting	O
that	O
this	O
enzyme	O
may	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
sexual	O
dimorphism	O
of	O
DOX	O
-	O
induced	O
cardiotoxicity	O
.	O

In	O
agreement	O
with	O
previous	O
studies	O
,	O
the	O
mRNA	O
levels	O
of	O
Cyp4a12	O
and	O
Cyp4a14	O
were	O
below	O
the	O
levels	O
of	O
detection	O
in	O
the	O
hearts	O
of	O
both	O
male	O
and	O
female	O
mice	O
in	O
the	O
current	O
study	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
although	O
previous	O
studies	O
identified	O
Amino	O
Acids	O
as	O
important	O
for	O
hepatocyte	O
survival	O
,	O
proliferation	O
,	O
and	O
protein	O
synthesis	O
^	O
,	O
,	O
we	O
here	O
demonstrate	O
that	O
increasing	O
Amino	O
Acids	O
to	O
levels	O
30	O
-	O
fold	O
above	O
that	O
of	O
typical	O
hepatocyte	O
media	O
,	O
actively	O
induces	O
a	O
metabolic	O
switch	O
,	O
as	O
well	O
as	O
Cytochrome	B
P450	I
enzyme	I
expression	O
and	O
function	O
(	O
Supplementary	O
Table	O
.	O

Meanwhile	O
QC	O
further	O
improved	O
the	O
therapeutic	O
efficacy	O
by	O
increasing	O
the	O
bioavailability	O
of	O
Mycophenolic	O
Acid	O
through	O
inhibiting	O
Cytochrome	O
P450	B
enzyme	I
.	O

Using	O
^	O
1H	O
-	O
^	O
13C	O
HSQC	O
nuclear	O
magnetic	O
resonance	O
NMR	O
titrations	O
of	O
bacterial	O
P450cam	B
(	O
CYP101	O
)	O
,	O
it	O
has	O
been	O
shown	O
that	O
,	O
in	O
the	O
presence	O
of	O
excess	O
camphor	O
,	O
a	O
second	O
camphor	O
molecule	O
binds	O
at	O
the	O
surface	O
of	O
the	O
protein	O
,	O
besides	O
the	O
one	O
bound	O
within	O
the	O
buried	O
active	O
site	O
.	O

In	O
total	O
agreement	O
with	O
the	O
results	O
of	O
NMR	O
titrations	O
that	O
were	O
performed	O
on	O
P450cam	B
,	O
a	O
two	O
-	O
step	O
recognition	O
process	O
was	O
also	O
described	O
in	O
^	O
1H	O
-	O
NMR	O
measurements	O
on	O
bacterial	O
P450	O
BM3	O
.	O

Influence	O
of	O
mentioned	O
extracts	O
and	O
their	O
key	O
constituents	O
on	O
warfarin	O
pharmacodynamic	O
and	O
kinetic	O
actions	O
and	O
Cytochrome	B
P450	B
Enzymes	I
activity	O
were	O
evaluated	O
.	O

Furthermore	O
,	O
potential	O
involvement	O
in	O
Cytochrome	B
P450	B
Enzymes	I
inhibition	O
was	O
also	O
investigated	O
in	O
vitro	O
on	O
isolated	O
primary	O
rat	O
hepatocytes	O
.	O

Significant	O
reduction	O
in	O
CYP2C8	O
,	O
2C9	O
,	O
and	O
3A4	O
was	O
seen	O
upon	O
concomitant	O
use	O
of	O
warfarin	O
with	O
ellagic	O
acid	O
,	O
guava	O
leaves	O
and	O
quercetin	O
,	O
unlike	O
pomegranate	O
that	O
insignificantly	O
affected	O
Cytochrome	B
P450	B
Enzymes	I
activities	O
.	O

In	O
addition	O
,	O
the	O
potential	O
inhibition	O
of	O
selected	O
Cytochrome	B
P450	B
Enzymes	I
enzymes	O
that	O
are	O
responsible	O
for	O
warfarin	O
metabolism	O
is	O
investigated	O
with	O
the	O
herbal	O
drugs	O
in	O
vitro	O
on	O
rat	O
isolated	O
primary	O
hepatocytes	O
.	O

After	O
16	O
h	O
of	O
incubation	O
,	O
each	O
well	O
of	O
cultured	O
rat	O
hepatocytes	O
were	O
treated	O
with	O
25	O
l	O
of	O
warfarin	O
,	O
guava	O
leaves	O
extract	O
,	O
quercetin	O
,	O
pomegranate	O
peel	O
extract	O
,	O
ellagic	O
acid	O
,	O
a	O
combination	O
of	O
warfarin	O
with	O
each	O
test	O
compound	O
in	O
addition	O
to	O
the	O
control	O
Cytochrome	B
P450	B
Enzymes	I
inhibitors	O
namely	O
;	O
ketoconazole	O
,	O
sulfamethoxazole	O
or	O
trimethoprim	O
.	O

A	O
comparison	O
with	O
the	O
Raman	O
spectra	O
underlying	O
the	O
relRI	O
trends	O
(	O
c	O
,	O
d	O
)	O
revealed	O
that	O
this	O
was	O
due	O
to	O
overall	O
more	O
cells	O
,	O
with	O
more	O
ferrous	O
cytochrome	B
c	I
,	O
being	O
present	O
in	O
previously	O
stressed	O
samples	O
compared	O
to	O
unstressed	O
samples	O
.	O

Moreover	O
,	O
Nitrosospira	O
also	O
showed	O
significantly	O
more	O
ferrous	O
cytochrome	B
c	I
content	O
in	O
its	O
oxygen	O
-	O
deprived	O
cultures	O
.	O

However	O
,	O
other	O
than	O
in	O
N	O
.	O
eutropha	O
,	O
cells	O
with	O
more	O
ferric	O
cytochrome	B
c	I
content	O
did	O
occur	O
in	O
oxygen	O
-	O
deprived	O
Nitrosospira	O
,	O
resulting	O
in	O
a	O
relRI	O
curve	O
widely	O
parallel	O
to	O
that	O
of	O
the	O
unstressed	O
samples	O
.	O

The	O
occurrence	O
of	O
cells	O
with	O
extremely	O
ferrous	O
overall	O
cytochrome	B
c	I
content	O
in	O
previously	O
stressed	O
samples	O
may	O
have	O
been	O
caused	O
by	O
electron	O
storage	O
within	O
the	O
ammonia	O
-	O
oxidization	O
pathway	O
that	O
increased	O
the	O
amount	O
of	O
ferrous	O
heme	O
c	O
among	O
the	O
total	O
cytochrome	B
c	I
content	O
of	O
a	O
given	O
cell	O
.	O

It	O
can	O
be	O
assumed	O
that	O
the	O
summarized	O
redox	O
state	O
of	O
a	O
given	O
cell	O
changes	O
considerably	O
faster	O
than	O
its	O
total	O
cytochrome	B
c	I
content	O
,	O
which	O
requires	O
protein	O
expression	O
to	O
occur	O
.	O

In	O
a	O
proof	O
-	O
of	O
-	O
concept	O
study	O
,	O
confocal	O
Raman	O
microscopy	O
with	O
excitation	O
resonant	O
to	O
the	O
heme	O
c	O
moiety	O
of	O
cytochrome	B
c	I
was	O
used	O
successfully	O
to	O
compare	O
the	O
cytochrome	B
c	I
content	O
and	O
activity	O
of	O
stressed	O
and	O
unstressed	O
Nitrosomonas	O
europaea	O
(	O
Nm	O
50	O
)	O
,	O
Nitrosomonas	O
eutropha	O
(	O
Nm	O
57	O
)	O
,	O
Nitrosospira	O
briensis	O
(	O
Nsp	O
10	O
)	O
,	O
and	O
Nitrosospira	O
species	O
(	O
Nsp	O
02	O
)	O
in	O
vivo	O
,	O
based	O
on	O
no	O
more	O
than	O
1000	O
individual	O
cells	O
per	O
sampling	O
.	O

In	O
addition	O
,	O
the	O
marker	O
allowed	O
the	O
distinction	O
between	O
cells	O
with	O
more	O
ferric	O
or	O
more	O
ferrous	O
cytochrome	B
c	I
content	O
,	O
giving	O
insight	O
in	O
the	O
ongoing	O
cytochrome	B
c	I
electron	O
transport	O
activity	O
at	O
the	O
time	O
of	O
measurement	O
.	O

Notably	O
,	O
cells	O
with	O
predominantly	O
ferrous	O
cytochrome	B
c	I
content	O
were	O
found	O
in	O
deprived	O
N	O
.	O
eutropha	O
and	O
Nitrosospira	O
samples	O
,	O
which	O
may	O
be	O
indicative	O
of	O
ongoing	O
electron	O
storage	O
at	O
the	O
time	O
of	O
measurement	O
.	O

A	O
further	O
study	O
comparing	O
the	O
results	O
obtained	O
with	O
resonant	O
Raman	O
microscopy	O
and	O
quantified	O
results	O
obtained	O
by	O
proteomics	O
or	O
transcriptomics	O
of	O
the	O
same	O
cultures	O
sampled	O
at	O
the	O
same	O
time	O
might	O
allow	O
a	O
quantification	O
of	O
the	O
cytochrome	B
c	I
content	O
elevation	O
reported	O
by	O
Raman	O
microscopy	O
.	O

As	O
mentioned	O
earlier	O
,	O
hypoxia	O
leads	O
to	O
change	O
in	O
mitochondria	O
,	O
including	O
decreased	O
oxidative	O
phosphorylation	O
level	O
,	O
cytochrome	B
c	I
oxidase	O
activity	O
and	O
increased	O
ROS	O
production	O
.	O

However	O
,	O
the	O
presence	O
of	O
cytochrome	B
c	I
nitrite	O
reductase	O
genes	O
(	O
nrfAH	O
,	O
)	O
in	O
the	O
genomes	O
of	O
strains	O
F1	O
^	O
T	O
and	O
F21	O
^	O
T	O
suggests	O
that	O
the	O
dissimilatory	O
reduction	O
of	O
nitrite	O
could	O
occur	O
at	O
lower	O
non	O
-	O
toxic	O
concentrations	O
of	O
nitrite	O
.	O

The	O
napEDABC	O
gene	O
cluster	O
of	O
B	O
.	O
diazoefficiens	O
encodes	O
NapE	O
,	O
a	O
membrane	O
protein	O
of	O
6	O
.	O
6	O
kDa	O
with	O
unknown	O
function	O
;	O
NapD	O
(	O
11	O
.	O
8	O
kDa	O
)	O
,	O
a	O
chaperone	O
involved	O
in	O
the	O
maturation	O
of	O
NapA	O
;	O
NapA	O
(	O
94	O
.	O
5	O
kDa	O
)	O
,	O
the	O
catalytic	O
subunit	O
that	O
contains	O
a	O
Mobis	O
-	O
MGD	O
active	O
site	O
and	O
[	O
4Fe4S	O
]	O
cluster	O
;	O
and	O
NapB	O
(	O
16	O
.	O
9	O
kDa	O
)	O
,	O
the	O
electron	O
transfer	O
subunit	O
,	O
which	O
is	O
a	O
diheme	O
cytochrome	O
c_552	O
.	O

In	O
Bj	O
-	O
USDA	O
6	O
NapB	O
,	O
both	O
the	O
cytochrome	B
c	I
-	O
binding	O
sites	O
and	O
motif	O
for	O
translocation	O
via	O
the	O
general	O
secretory	O
pathway	O
were	O
conserved	O
.	O

This	O
is	O
supported	O
by	O
the	O
need	O
for	O
an	O
infinitesimal	O
PO_2	O
gradient	O
for	O
O_2	O
to	O
diffuse	O
from	O
the	O
sarcoplasm	O
to	O
cytochrome	B
c	I
oxidase	O
and	O
the	O
estimate	O
that	O
a	O
mitochondrial	O
PO_2	O
of	O
~	O
1	O
mmHg	O
may	O
be	O
sufficient	O
to	O
support	O
maximal	O
mitochondrial	O
respiration	O
.	O
,	O
The	O
remaining	O
O_2	O
may	O
also	O
represent	O
muscle	O
metabolismperfusion	O
mismatch	O
,	O
and	O
an	O
inevitable	O
lower	O
O_2	O
extraction	O
from	O
the	O
blood	O
perfusing	O
the	O
skin	O
,	O
connective	O
tissue	O
,	O
fat	O
and	O
bone	O
marrow	O
of	O
the	O
leg	O
causing	O
venous	O
admixture	O
.	O

For	O
instance	O
,	O
after	O
2	O
weeks	O
of	O
highintensity	O
interval	O
training	O
that	O
elevated	O
the	O
cytochrome	B
c	I
oxidase	O
activity	O
by	O
20	O
%	O
but	O
caused	O
no	O
change	O
in	O
Qmax	O
,	O
VO2max	O
was	O
increased	O
by	O
8	O
%	O
and	O
was	O
entirely	O
attributed	O
to	O
the	O
improved	O
systemic	O
(	O
calculated	O
a	O
-	O
vO2	O
difference	O
)	O
and	O
leg	O
(	O
increased	O
deoxyhaemoglobin	O
and	O
decreased	O
tissue	O
oxygenation	O
index	O
in	O
Vastus	O
Lateralis	O
,	O
assessed	O
using	O
NIRS	O
)	O
O_2	O
extraction	O
.	O

Due	O
to	O
the	O
easily	O
accessible	O
C	O
-	O
terminal	O
catalytic	O
center	O
,	O
TrxRs	O
can	O
reduce	O
a	O
broad	O
range	O
of	O
substrates	O
including	O
hydrogen	O
peroxide	O
,	O
selenite	O
,	O
lipoic	O
acid	O
,	O
ascorbate	O
,	O
and	O
ubiquinone	O
,	O
and	O
TrxR	O
-	O
2	O
was	O
demonstrated	O
to	O
act	O
on	O
cytochrome	B
c	I
,	O
but	O
the	O
main	O
substrates	O
remain	O
Thioredoxins	O
.	O

Early	O
work	O
with	O
rat	O
liver	O
mitochondria	O
shows	O
that	O
Chloroquine	O
alters	O
mitochondrial	O
lipid	O
composition	O
,	O
decreases	O
the	O
activities	O
of	O
NADH	O
dehydrogenase	O
,	O
succinate	O
dehydrogenase	O
,	O
and	O
cytochrome	B
c	I
,	O
and	O
inhibits	O
both	O
mitochondrial	O
respiration	O
and	O
ATP	O
synthesis	O
.	O

However	O
,	O
while	O
genes	O
indeed	O
include	O
a	O
cytochrome	O
b_6	O
,	O
there	O
is	O
no	O
homology	O
to	O
a	O
cytochrome	O
f	O
,	O
but	O
there	O
is	O
to	O
a	O
cytochrome	O
c_1	O
.	O

It	O
also	O
evoked	O
the	O
production	O
of	O
caspase	O
9	O
and	O
cytochrome	B
c	I
.	O
The	O
cytotoxic	O
effects	O
of	O
resminostat	O
were	O
reinforced	O
by	O
inhibitors	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
,	O
which	O
has	O
been	O
characterized	O
as	O
a	O
resistance	O
factor	O
of	O
resminostat	O
.	O

On	O
the	O
other	O
hand	O
,	O
it	O
is	O
known	O
that	O
if	O
the	O
levels	O
of	O
Reactive	O
Oxygen	O
Species	O
exceed	O
the	O
antioxidant	O
capacity	O
of	O
the	O
cell	O
,	O
homeostasis	O
is	O
disrupted	O
,	O
and	O
cell	O
survival	O
is	O
compromised	O
by	O
oxidization	O
of	O
proteins	O
and	O
the	O
release	O
of	O
the	O
mitochondrial	O
protein	O
cytochrome	B
c	I
into	O
the	O
cytoplasm	O
,	O
an	O
event	O
that	O
occurs	O
during	O
the	O
activation	O
of	O
apoptotic	O
machinery	O
with	O
the	O
activation	O
of	O
the	O
caspase	O
cascade	O
.	O

The	O
resulting	O
plasmid	O
was	O
transformed	O
in	O
E	O
.	O
coli	O
JM109	O
(	O
DE3	O
)	O
strain	O
,	O
previously	O
transformed	O
with	O
the	O
vector	O
pEC86	O
that	O
encodes	O
the	O
cytochrome	B
c	I
maturation	O
system	O
(	O
Ccm	O
)	O
.	O

We	O
visualized	O
localization	O
of	O
cytochromes	O
by	O
Raman	O
imaging	O
in	O
the	O
breast	O
and	O
brain	O
tissues	O
and	O
analyzed	O
cytochrome	B
c	I
vibrations	O
at	O
750	O
,	O
1126	O
,	O
1337	O
and	O
1584	O
cm1	O
as	O
a	O
function	O
of	O
malignancy	O
grade	O
.	O

We	O
found	O
that	O
the	O
concentration	O
of	O
reduced	O
cytochrome	B
c	I
becomes	O
abnormally	O
high	O
in	O
human	O
brain	O
tumors	O
and	O
breast	O
cancers	O
and	O
correlates	O
with	O
the	O
grade	O
of	O
cancer	O
.	O

Early	O
studies	O
on	O
glioma	O
cell	O
rat	O
xenografts	O
identified	O
lower	O
cytochrome	B
c	I
oxidase	O
(	O
COX	O
,	O
Complex	O
IV	O
)	O
and	O
SDH	O
(	O
Complex	O
II	O
)	O
enzyme	O
expression	O
in	O
more	O
hypoxic	O
areas	O
of	O
the	O
tumor	O
.	O

Cytochromes	O
are	O
classified	O
based	O
on	O
their	O
lowest	O
electronic	O
energy	O
absorption	O
band	O
in	O
their	O
reduced	O
state	O
:	O
cytochrome	O
P450	O
(	O
450	O
nm	O
)	O
,	O
cytochrome	B
c	I
(	O
550	O
nm	O
)	O
,	O
cytochromes	O
b	O
(	O
565	O
nm	O
)	O
,	O
cytochromes	O
a	O
(	O
605	O
nm	O
)	O
.	O

The	O
family	O
of	O
cytochromes	O
are	O
localized	O
in	O
the	O
third	O
complex	O
in	O
the	O
electron	O
transport	O
chain	O
,	O
also	O
known	O
as	O
complex	O
III	O
or	O
Coenzyme	O
Q	O
-	O
Cyt	O
c	O
reductase	O
,	O
sometimes	O
called	O
the	O
cytochrome	O
bc_1	O
complex	O
(	O
cytochrome	O
b	O
,	O
cytochrome	O
c_1	O
)	O
,	O
as	O
well	O
as	O
in	O
cytochrome	B
c	I
loosely	O
associated	O
with	O
the	O
inner	O
membrane	O
of	O
the	O
mitochondrion	O
.	O

Cytochrome	O
c	O
,	O
which	O
is	O
reduced	O
to	O
cyt	O
c	O
Fe	O
^	O
2	O
+	O
(	O
ferrous	O
)	O
by	O
the	O
electron	O
from	O
the	O
complex	O
III	O
,	O
passes	O
an	O
electron	O
to	O
the	O
copper	O
binuclear	O
center	O
,	O
being	O
oxidized	O
back	O
to	O
cytochrome	B
c	I
(	O
cyt	O
c	O
Fe	O
^	O
3	O
+	O
(	O
ferric	O
)	O
)	O
.	O

Using	O
different	O
excitations	O
being	O
in	O
resonance	O
with	O
the	O
absorption	O
bands	O
of	O
the	O
cytochromes	O
one	O
can	O
spectrally	O
enhance	O
various	O
cytochrome	O
chromophores	O
in	O
the	O
complex	O
III	O
,	O
cytochrome	B
c	I
and	O
complex	O
IV	O
by	O
Resonance	O
Raman	O
enhancement	O
scattering	O
.	O

Using	O
different	O
excitations	O
,	O
we	O
are	O
able	O
to	O
monitor	O
contribution	O
of	O
cytochrome	O
family	O
in	O
the	O
electron	O
transfer	O
chain	O
in	O
the	O
mitochondrial	O
respiration	O
originating	O
from	O
cytochrome	O
b	O
,	O
c_1	O
in	O
complex	O
III	O
,	O
cytochrome	B
c	I
,	O
and	O
a	O
,	O
a_3	O
cytochromes	O
in	O
complex	O
IV	O
.	O

The	O
spectral	O
features	O
of	O
cytochrome	B
c	I
can	O
be	O
monitored	O
at	O
532	O
nm	O
due	O
to	O
absorbance	O
band	O
(	O
Q	O
band	O
)	O
centered	O
at	O
530	O
nm	O
.	O

It	O
is	O
well	O
known	O
that	O
cytochrome	B
c	I
is	O
undoubtedly	O
one	O
of	O
the	O
most	O
prominent	O
molecules	O
in	O
the	O
electron	O
transport	O
chain	O
required	O
to	O
fuel	O
life	O
via	O
ATP	O
,	O
but	O
its	O
role	O
in	O
molecular	O
mechanisms	O
associated	O
with	O
an	O
aggressive	O
phenotype	O
of	O
cancer	O
remain	O
largely	O
unclear	O
.	O

In	O
this	O
paper	O
we	O
explore	O
a	O
hypothesis	O
involving	O
the	O
role	O
of	O
reduction	O
-	O
oxidation	O
pathways	O
related	O
to	O
cytochrome	B
c	I
in	O
cancer	O
state	O
.	O

To	O
show	O
the	O
perfect	O
match	O
between	O
Raman	O
spectra	O
of	O
human	O
tissue	O
samples	O
and	O
Raman	O
spectrum	O
of	O
cytochrome	B
c	I
the	O
correlation	O
analysis	O
was	O
performed	O
(	O
Pearson	O
correlation	O
coefficient	O
was	O
equal	O
0	O
.	O
99951	O
at	O
the	O
confidence	O
level	O
0	O
.	O
95	O
with	O
the	O
p	O
-	O
value	O
of	O
0	O
.	O
00001	O
)	O
.	O

shows	O
the	O
average	O
Raman	O
spectra	O
of	O
the	O
ex	O
vivo	O
human	O
breast	O
cancer	O
tissue	O
surgically	O
resected	O
specimens	O
,	O
ductal	O
cancer	O
,	O
grade	O
of	O
malignancy	O
WHO	O
G3	O
at	O
different	O
excitations	O
532	O
nm	O
,	O
633	O
nm	O
,	O
785	O
nm	O
,	O
(	O
number	O
of	O
patients	O
n	O
=	O
5	O
)	O
,	O
and	O
Raman	O
spectrum	O
of	O
the	O
pure	O
cytochrome	B
c	I
at	O
532	O
nm	O
excitation	O
.	O

B	O
shows	O
the	O
spectrum	O
of	O
isolated	O
cytochrome	B
c	I
.	O
Using	O
532	O
nm	O
laser	O
excitation	O
one	O
can	O
monitor	O
spectral	O
features	O
of	O
complex	O
III	O
and	O
cytochrome	B
c	I
due	O
to	O
Q	O
bands	O
at	O
500	O
-	O
550	O
nm	O
related	O
to	O
intra	O
-	O
porphyrin	O
transitions	O
of	O
the	O
heme	O
group	O
in	O
cytochrome	B
c	I
.	O
Excitation	O
at	O
633	O
nm	O
provides	O
information	O
about	O
cytochromes	O
a	O
and	O
a_3	O
(	O
1744	O
cm	O
^	O
1	O
and	O
1396	O
cm	O
^	O
1	O
,	O
both	O
in	O
cyt	O
oxidized	O
and	O
reduced	O
cytochrome	O
oxidase	O
;	O
1584	O
cm	O
^	O
1	O
,	O
heme	O
a	O
+	O
a_3	O
oxidized	O
form	O
)	O
.	O

First	O
,	O
let	O
us	O
concentrate	O
on	O
the	O
contribution	O
of	O
cytochrome	B
c	I
using	O
532	O
nm	O
excitation	O
.	O

Comparison	O
of	O
the	O
Raman	O
spectra	O
of	O
the	O
brain	O
tissue	O
in	O
and	O
the	O
Raman	O
spectra	O
of	O
the	O
breast	O
tissue	O
in	O
A	O
with	O
purified	O
cytochrome	B
c	I
in	O
B	O
shows	O
that	O
the	O
Raman	O
enhancement	O
upon	O
532	O
nm	O
excitation	O
corresponds	O
perfectly	O
to	O
vibrations	O
of	O
cytochrome	B
c	I
.	O
To	O
show	O
the	O
perfect	O
match	O
between	O
Raman	O
spectra	O
of	O
human	O
tissue	O
samples	O
and	O
Raman	O
spectrum	O
of	O
cytochrome	B
c	I
the	O
correlation	O
analysis	O
was	O
performed	O
(	O
Pearson	O
correlation	O
coefficient	O
was	O
equal	O
0	O
.	O
99951	O
at	O
the	O
confidence	O
level	O
0	O
.	O
95	O
with	O
the	O
p	O
-	O
value	O
of	O
0	O
.	O
00001	O
)	O
.	O

It	O
indicates	O
that	O
cytochrome	B
c	I
can	O
be	O
used	O
for	O
pathology	O
assessment	O
for	O
ex	O
vivo	O
tissues	O
.	O

To	O
check	O
if	O
vibrations	O
of	O
cytochrome	B
c	I
can	O
be	O
used	O
also	O
for	O
pathology	O
assessment	O
in	O
living	O
cells	O
we	O
analysed	O
Raman	O
spectra	O
of	O
brain	O
and	O
breast	O
cancer	O
cells	O
lines	O
at	O
in	O
vitro	O
incubation	O
.	O

We	O
compared	O
Raman	O
spectra	O
of	O
single	O
cells	O
at	O
in	O
vitro	O
incubation	O
and	O
Raman	O
spectrum	O
of	O
cytochrome	B
c	I
.	O
To	O
show	O
the	O
perfect	O
match	O
between	O
Raman	O
spectra	O
of	O
human	O
cells	O
and	O
Raman	O
spectrum	O
of	O
cytochrome	B
c	I
the	O
correlation	O
analysis	O
was	O
performed	O
(	O
Pearson	O
correlation	O
coefficient	O
was	O
equal	O
0	O
.	O
99941	O
at	O
the	O
confidence	O
level	O
0	O
.	O
95	O
with	O
the	O
p	O
-	O
value	O
of	O
0	O
.	O
00002	O
)	O
.	O

Examples	O
of	O
cytochrome	B
-	I
c	I
-	O
resonant	O
Raman	O
spectra	O
as	O
recorded	O
from	O
native	O
cultures	O
of	O
Nitrosomonas	O
europaea	O
(	O
Nm	O
50	O
)	O
,	O
Nitrosomonas	O
eutropha	O
(	O
Nm	O
57	O
)	O
,	O
Nitrosospira	O
briensis	O
(	O
Nsp	O
10	O
)	O
,	O
and	O
Nitrosospira	O
species	O
(	O
Nsp	O
02	O
)	O
under	O
well	O
aerated	O
(	O
+	O
O_2	O
)	O
and	O
oxygen	O
-	O
deprived	O
(	O
O_2	O
)	O
growth	O
conditions	O
are	O
shown	O
in	O
.	O

^	O
While	O
MCF	O
-	O
7	O
cells	O
used	O
to	O
develop	O
the	O
ER	O
-	O
Luc	O
cells	O
express	O
metabolic	O
enzymes	O
from	O
the	O
cytochrome	B
P450	I
superfamily	I
(	O
and	O
thus	O
possess	O
the	O
ability	O
for	O
endogenous	O
biotransformation	O
of	O
chemicals	O
)	O
,	O
formation	O
of	O
MBP	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
S9	O
enzymes	O
.	O

and	O
the	O
highest	O
andrographolide	O
was	O
detected	O
in	O
leaf	O
as	O
compared	O
to	O
other	O
panchang	O
(	O
Pandey	O
and	O
Mandal	O
;	O
Sharma	O
et	O
al	O
.	O
.	O
Therefore	O
,	O
some	O
other	O
isomers	O
of	O
cytochrome	B
p450	I
(	O
cytochrome	B
p450	I
98	O
,	O
cytochrome	B
p450	I
706	O
,	O
etc	O
.	O
)	O

The	O
metabolic	O
activation	O
of	O
PCBs	O
is	O
initiated	O
by	O
cytochrome	B
p450	I
(	O
CYP	O
)	O
family	O
members	O
and	O
includes	O
the	O
oxidation	O
of	O
PCBs	O
to	O
OH	O
-	O
PCBs	O
.	O

Subsequent	O
genetic	O
studies	O
based	O
on	O
mitochondrial	O
DNA	O
(	O
cytochrome	B
b	I
and	O
data	O
from	O
restriction	O
profiles	O
across	O
the	O
entire	O
mitochondrial	O
genome	O
)	O
,	O
supported	O
some	O
,	O
but	O
not	O
all	O
,	O
of	O
these	O
designations	O
[	O
,	O
.	O

Progestin	O
receptor	O
membrane	O
component	O
1	O
is	O
a	O
single	O
transmembrane	O
heme	O
-	O
binding	O
protein	O
containing	O
a	O
cytochrome	B
b_5	I
motif	O
,	O
which	O
has	O
been	O
proposed	O
as	O
a	O
progesterone	O
binding	O
protein	O
in	O
vertebrates	O
(	O
,	O
.	O

For	O
example	O
,	O
Progestin	O
Receptor	O
Membrane	O
Component	O
1	O
is	O
a	O
heme	O
-	O
binding	O
protein	O
with	O
a	O
cytochrome	O
b_5	O
motif	O
,	O
which	O
binds	O
and	O
activates	O
P450	O
proteins	O
and	O
is	O
involved	O
in	O
steroidogenesis	O
and	O
drug	O
metabolism	O
.	O

Pgrmc1	O
has	O
a	O
role	O
in	O
the	O
regulation	O
of	O
cholesterol	O
and	O
steroid	O
synthesis	O
because	O
of	O
its	O
cytochrome	O
b_5	O
motif	O
and	O
its	O
ability	O
to	O
bind	O
and	O
activate	O
P450	O
proteins	O
(	O
,	O
.	O

The	O
recombinant	O
baculosomes	O
with	O
hyperexpressed	O
CYP3A4	O
and	O
coexpressed	O
NADPH	O
cytochrome	O
P450	O
reductase	O
and	O
cytochrome	O
b_5	O
,	O
was	O
used	O
as	O
source	O
of	O
enzyme	O
.	O

All	O
major	O
protein	O
complexes	O
involved	O
in	O
photosynthesis	O
were	O
impacted	O
:	O
the	O
light	O
-	O
harvesting	O
complexes	O
were	O
affected	O
with	O
the	O
down	O
regulation	O
of	O
32	O
chlorophyll	O
a	O
/	O
b	O
-	O
binding	O
proteins	O
as	O
well	O
as	O
4	O
proteins	O
involved	O
in	O
chlorophyll	O
synthesis	O
,	O
38	O
proteins	O
associated	O
with	O
photosystems	O
I	O
and	O
II	O
were	O
downregulated	O
,	O
2	O
proteins	O
involved	O
in	O
the	O
NDH	O
complex	O
as	O
well	O
as	O
7	O
subunits	O
of	O
the	O
chloroplastic	O
ATP	O
synthase	O
,	O
and	O
a	O
subunit	O
of	O
the	O
cytochrome	O
b6	O
-	O
f	O
complex	O
,	O
were	O
also	O
downregulated	O
.	O

Results	O
of	O
two	O
different	O
approaches	O
,	O
experimental	O
surface	O
gillnets	O
capture	O
and	O
environmental	O
DNA	O
metabarcoding	O
assays	O
based	O
on	O
12S	O
ribosomal	O
RNA	O
and	O
cytochrome	B
b	I
,	O
were	O
compared	O
during	O
3	O
years	O
(	O
2014	O
-	O
2016	O
)	O
.	O

This	O
fragment	O
is	O
proved	O
to	O
be	O
reliable	O
on	O
degraded	O
DNA	O
,	O
is	O
informative	O
to	O
discriminate	O
vertebrates	O
species	O
and	O
is	O
adapted	O
to	O
survey	O
fish	O
diversity	O
(	O
eg	O
)	O
;	O
(	O
ii	O
)	O
a	O
longer	O
cytochrome	B
b	I
fragment	O
(	O
235bp	O
)	O
to	O
potentially	O
improve	O
the	O
taxonomic	O
resolution	O
.	O

For	O
this	O
study	O
,	O
a	O
PCR	O
approach	O
targeting	O
short	O
fragments	O
of	O
two	O
mitochondrial	O
markers	O
(	O
12S	O
RNA	O
and	O
cytochrome	B
b	I
,	O
hereafter	O
12S	O
and	O
cytb	O
respectively	O
,	O
)	O
was	O
designed	O
.	O

Progesterone	O
receptor	O
membrane	O
component	O
1	O
is	O
a	O
multifunctional	O
protein	O
with	O
a	O
C	O
-	O
terminal	O
cytochrome	O
b_5	O
domain	O
^	O
.	O

Progesterone	O
Receptor	O
Membrane	O
Component1	O
regulates	O
cell	O
proliferation	O
and	O
apoptosis	O
in	O
granulosa	O
and	O
luteal	O
cells	O
via	O
interaction	O
between	O
its	O
cytoplasmic	O
cytochrome	O
b_5	O
binding	O
domain	O
(	O
amino	O
acids	O
70	O
-	O
130	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
RNA	O
-	O
binding	O
protein	O
-	O
1	O
(	O
PAIR	O
-	O
BP1	O
)	O
^	O
,	O
.	O

A	O
molecular	O
clock	O
model	O
estimated	O
the	O
divergence	O
time	O
between	O
sturgeon	O
and	O
paddlefish	O
at	O
204	O
.	O
1	O
Mya	O
,	O
approximately	O
10	O
%	O
later	O
than	O
previous	O
estimates	O
based	O
on	O
cytochrome	B
b	I
data	O
(	O
184	O
.	O
4	O
Mya	O
)	O
.	O

(	O
2000	O
)	O
to	O
be	O
sister	O
species	O
based	O
the	O
mitochondrial	O
genes	O
NADH	O
dehydrogenase	O
subunit	O
4L	O
(	O
ND4L	O
)	O
and	O
NADH	O
dehydrogenase	O
subunit	O
4	O
(	O
ND4	O
)	O
,	O
but	O
cytochrome	B
b	I
(	O
cytb	O
)	O
,	O
16S	O
ribosomal	O
DNA	O
(	O
rDNA	O
)	O
,	O
and	O
12S	O
rDNA	O
did	O
not	O
confirm	O
this	O
.	O

CYP2B6	O
variants	O
,	O
reference	O
allele	O
P450	O
oxidoreductase	O
(	O
POR	O
)	O
,	O
and	O
reference	O
allele	O
cytochrome	B
b	I
_5	O
vectors	O
were	O
previously	O
generated	O
,	O
and	O
recombinant	O
proteins	O
previously	O
expressed	O
in	O
insect	O
cells	O
,	O
as	O
described	O
.	O
,	O
Haplotype	O
selection	O
was	O
based	O
on	O
the	O
known	O
clinical	O
significance	O
and	O
frequency	O
of	O
the	O
polymorphism	O
,	O
and	O
a	O
desire	O
to	O
inform	O
the	O
mechanistic	O
basis	O
for	O
the	O
influence	O
of	O
these	O
polymorphisms	O
on	O
metabolism	O
.	O

According	O
to	O
our	O
analysis	O
,	O
first	O
,	O
Ech	O
,	O
and	O
cytochrome	O
b0	O
were	O
not	O
present	O
among	O
the	O
ruminal	O
microorganisms	O
.	O

A	O
genus	O
-	O
specific	O
conventional	O
cytochrome	B
b	I
Polymerase	O
Chain	O
Reaction	O
has	O
shown	O
high	O
sensitivity	O
in	O
field	O
studies	O
,	O
detecting	O
70	O
%	O
submicroscopic	O
malaria	O
.	O

Examples	O
of	O
these	O
multi	O
-	O
targets	O
are	O
chromosomal	O
small	O
subunit	O
ribosomal	O
RNA	O
18S	O
locus	O
,	O
cytochrome	B
b	I
gene	O
on	O
the	O
mitochondrial	O
genome	O
,	O
the	O
chromosomal	O
subtelomeric	O
targets	O
telomere	O
-	O
associated	O
repetitive	O
element	O
2	O
(	O
TARE	O
-	O
2	O
)	O
and	O
var	O
gene	O
acidic	O
terminal	O
sequence	O
.	O

Indeed	O
,	O
transcriptomic	O
and	O
proteomic	O
analysis	O
in	O
other	O
diatom	O
species	O
(	O
Thalassiosira	O
pseudonada	O
,	O
T	O
.	O
oceanica	O
,	O
and	O
Pseudo	O
-	O
nitzschia	O
granii	O
)	O
showed	O
downregulation	O
of	O
the	O
heme	O
b	O
-	O
containing	O
cytochrome	O
b_6f	O
and	O
conservation	O
of	O
the	O
PSII	O
proteins	O
expression	O
(	O
;	O
.	O

Two	O
mitochondrial	O
genes	O
and	O
one	O
nuclear	O
gene	O
were	O
used	O
for	O
phylogenetic	O
analyses	O
,	O
cytochrome	O
oxidase	O
I	O
(	O
coxI	O
)	O
,	O
cytochrome	B
b	I
(	O
cytb	O
)	O
and	O
recombination	O
activating	O
gene	O
2	O
(	O
RAG2	O
)	O
,	O
respectively	O
(	O
see	O
Table	O
in	O
Supplementary	O
Data	O
for	O
a	O
complete	O
list	O
of	O
sequences	O
and	O
other	O
details	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
17	O
,	O
20	O
-	O
lyase	O
activity	O
of	O
CYP17A1	O
is	O
dependent	O
on	O
augmentation	O
by	O
cytochrome	O
b_5	O
(	O
CYB5A	O
)	O
in	O
addition	O
to	O
electron	O
transfer	O
from	O
P450	O
Oxidoreductase	O
.	O

In	O
addition	O
,	O
plants	O
express	O
redox	O
co	O
-	O
factors	O
dedicated	O
to	O
secondary	O
metabolism	O
,	O
such	O
as	O
specialized	O
cytochrome	O
b5	O
proteins	O
,	O
and	O
many	O
CYPs	O
depend	O
on	O
such	O
co	O
-	O
factors	O
for	O
optimal	O
activity	O
.	O

Sort	O
=	O
Bait	O
,	O
cytochromes	O
P450	O
(	O
limonene	O
6	O
-	O
monooxygenase	O
(	O
CYP2C19	O
)	O
,	O
steroid	O
-	O
20	O
,	O
22	O
-	O
lyase	O
(	O
CYP11A1	O
)	O
,	O
steroid	O
-	O
11BETA	O
-	O
hydroxylase	O
(	O
CYP11V1	O
)	O
,	O
aldosterone	O
synthase	O
(	O
CYP11B2	O
)	O
,	O
taurochenodeoxycholate	O
-	O
6ALPHA	O
-	O
monooxygenase	O
(	O
CYP3A4	O
)	O
,	O
cyclic	O
hydrocarbon	O
hydroxylase	O
(	O
CYP3A5	O
)	O
,	O
4	O
-	O
nitrophenol	O
-	O
2	O
-	O
hydroxylase	O
(	O
CYP2E1	O
)	O
,	O
microsomal	O
cytochrome	B
b5	I
(	O
CYB5A	O
)	O
,	O
NADPH	O
-	O
cytochrome	O
-	O
P450	O
-	O
reductase	O
,	O
NADPH	O
-	O
adrenodoxin	O
reductase	O
,	O
adrenodoxin	O
,	O
and	O
ferrochelatase	O
,	O
SMAD4	O
,	O
RAB27B	O
)	O
were	O
prepared	O
at	O
the	O
Institute	O
of	O
Bioorganic	O
Chemistry	O
(	O
Republic	O
of	O
Belarus	O
)	O
by	O
molecular	O
cloning	O
and	O
heterologous	O
expression	O
in	O
a	O
bacterial	O
system	O
(	O
E	O
.	O
coli	O
)	O
,	O
followed	O
by	O
purification	O
using	O
metal	O
-	O
affinity	O
and	O
ion	O
exchange	O
chromatography	O
[	O
,	O
.	O

The	O
electron	O
leakage	O
in	O
the	O
electron	O
transport	O
chain	O
during	O
respiration	O
is	O
generally	O
considered	O
as	O
the	O
main	O
source	O
of	O
mitochondrial	O
Reactive	O
Oxygen	O
Species	O
but	O
other	O
mitochondrial	O
enzymatic	O
systems	O
,	O
such	O
as	O
monoamine	O
oxidase	O
and	O
cytochrome	B
b5	I
reductase	O
in	O
the	O
outer	O
membranes	O
,	O
cytochromes	O
P450	O
enzymes	O
in	O
the	O
inner	O
membranes	O
,	O
or	O
several	O
matrix	O
enzymes	O
such	O
as	O
aconitase	O
,	O
can	O
also	O
produce	O
Reactive	O
Oxygen	O
Species	O
(	O
Andreyev	O
,	O
Kushnareva	O
,	O
Murphy	O
,	O
&	O
Starkov	O
,	O
;	O
Andreyev	O
,	O
Kushnareva	O
,	O
&	O
Starkov	O
,	O
.	O

(	O
presence	O
of	O
CYP	O
and	O
cytochrome	B
b5	I
)	O
.	O

This	O
finding	O
was	O
consistent	O
with	O
that	O
of	O
a	O
mouse	O
study	O
that	O
showed	O
that	O
liver	O
microsomal	O
EROD	B
activity	O
was	O
unaffected	O
by	O
berberine	O
when	O
CYP1A2	O
mRNA	O
was	O
elevated	O
.	O

Interestingly	O
,	O
the	O
presence	O
of	O
highly	O
conserved	O
LxxxL	O
motif	O
between	O
L121	O
and	O
L125	O
was	O
observed	O
in	O
the	O
amino	O
acid	O
sequences	O
of	O
cytochrome	B
b_5	I
from	O
various	O
eukaryotes	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

Based	O
on	O
these	O
leucine	O
residues	O
present	O
in	O
the	O
transmembrane	O
ALPHA	O
-	O
helices	O
of	O
cytochrome	B
b_5	I
and	O
cytochrome	O
P450	O
,	O
a	O
leucine	O
zipper	O
-	O
like	O
structure	O
can	O
be	O
found	O
in	O
the	O
transmembrane	O
interactions	O
of	O
the	O
cytochrome	O
P450	O
-	O
cytochrome	B
b_5	I
complex	O
^	O
,	O
-	O
,	O
.	O

The	O
experimental	O
results	O
indicate	O
that	O
the	O
topology	O
of	O
cytochrome	B
b_5	I
in	O
the	O
DMPC	O
lipid	O
bilayers	O
suggest	O
that	O
amino	O
acid	O
residues	O
,	O
L121	O
and	O
L125	O
are	O
located	O
near	O
the	O
upper	O
chain	O
/	O
glycerol	O
region	O
,	O
which	O
has	O
an	O
unique	O
environment	O
for	O
membrane	O
-	O
associated	O
proteins	O
.	O

Herein	O
,	O
possible	O
driving	O
forces	O
for	O
the	O
transmembrane	O
complex	O
formation	O
in	O
cytochrome	O
P450	O
-	O
cytochrome	B
b_5	I
would	O
be	O
a	O
combination	O
of	O
:	O
(	O
i	O
)	O
van	O
der	O
Waals	O
-	O
London	O
interactions	O
^	O
,	O
(	O
ii	O
)	O
electrostatic	O
attraction	O
,	O
estimated	O
by	O
1	O
-	O
3	O
kcal	O
,	O
between	O
oppositely	O
charged	O
electric	O
dipolar	O
moments	O
in	O
the	O
association	O
of	O
C	O
-	O
and	O
N	O
-	O
terminal	O
ALPHA	O
-	O
helices	O
^	O
,	O
and	O
(	O
iii	O
)	O
hydrophobic	O
interactions	O
of	O
ALPHA	O
-	O
helices	O
near	O
the	O
surface	O
of	O
the	O
lipid	O
bilayer	O
based	O
on	O
the	O
leucine	O
zipper	O
-	O
like	O
motifs	O
^	O
,	O
-	O
,	O
.	O

These	O
types	O
of	O
specific	O
transmembrane	O
dimerization	O
motifs	O
can	O
be	O
found	O
in	O
the	O
amino	O
acid	O
sequences	O
of	O
both	O
cytochrome	B
b_5	I
and	O
cytochrome	O
P450	O
;	O
however	O
,	O
the	O
transmembrane	O
region	O
of	O
cytochrome	O
P450	O
reductase	O
does	O
not	O
possess	O
such	O
type	O
of	O
dimerization	O
motifs	O
^	O
.	O

This	O
study	O
represents	O
the	O
first	O
experimental	O
report	O
revealing	O
the	O
topology	O
and	O
structure	O
of	O
the	O
transmembrane	O
domains	O
of	O
membrane	O
-	O
bound	O
cytochrome	O
P450	O
-	O
cytochrome	B
b_5	I
complex	O
in	O
the	O
functional	O
full	O
-	O
length	O
form	O
.	O

In	O
particular	O
,	O
the	O
remarkable	O
sensitivity	O
enhancement	O
of	O
NMR	O
signals	O
achieved	O
by	O
DNP	O
at	O
cryogenic	O
temperatures	O
can	O
potentially	O
provide	O
structural	O
information	O
of	O
in	O
-	O
vivo	O
membrane	O
protein	O
complexes	O
at	O
-	O
work	O
,	O
as	O
we	O
have	O
recently	O
demonstrated	O
for	O
cytochrome	B
b_5	I
in	O
in	O
-	O
cell	O
conditions	O
^	O
,	O
.	O

Further	O
studies	O
of	O
chrysin	O
dimethylether	O
,	O
isorhamnetin	O
,	O
pinocembrin	O
,	O
and	O
tangeretin	O
inhibition	O
of	O
CYP3A4	O
are	O
needed	O
to	O
determine	O
inactivation	O
kinetics	O
and	O
steps	O
of	O
the	O
catalytic	O
cycle	O
of	O
cytochrome	B
P450	I
3A4	I
that	O
are	O
affected	O
by	O
the	O
inhibitor	O
or	O
potential	O
reactive	O
intermediate	O
products	O
/	O
metabolites	O
.	O

Similarly	O
,	O
the	O
blue	O
light	O
induced	O
the	O
expression	O
of	O
putative	O
LDA	O
enzymes	O
including	O
aryl	O
-	O
alcohol	O
dehydrogenase	O
(	O
XLOC_008717	O
)	O
,	O
pyranose	O
2	O
-	O
oxidase	O
(	O
XLOC_009983	O
)	O
,	O
and	O
monooxygenase	O
(	O
XLOC_003435	O
)	O
and	O
the	O
red	O
light	O
influenced	O
the	O
expression	O
of	O
cytochrome	B
P	I
-	I
450	I
(	O
XLOC_007791	O
,	O
XLOC_00671	O
,	O
XLOC_006683	O
,	O
XLOC_001969	O
,	O
and	O
XLOC_007717	O
)	O
.	O

Cytochrome	B
c	I
showed	O
a	O
significant	O
response	O
to	O
Bombyx	O
Mori	O
Nucleopolyhedrovirus	O
infection	O
in	O
our	O
previous	O
transcriptome	O
study	O
.	O

Cytochrome	B
c	I
content	O
was	O
found	O
to	O
be	O
elevated	O
in	O
oxygen	O
-	O
deprived	O
and	O
previously	O
oxygen	O
-	O
deprived	O
samples	O
.	O

CYP2B6	B
*	O
6	O
is	O
the	O
most	O
commonly	O
studied	O
variant	O
haplotype	O
because	O
of	O
its	O
high	O
population	O
frequency	O
and	O
has	O
been	O
associated	O
with	O
low	O
activity	O
in	O
vivo	O
.	O
,	O
However	O
,	O
it	O
is	O
also	O
important	O
to	O
note	O
that	O
part	O
of	O
this	O
loss	O
of	O
activity	O
may	O
be	O
due	O
to	O
differences	O
in	O
mRNA	O
or	O
protein	O
expression	O
or	O
splicing	O
,	O
and	O
not	O
strictly	O
related	O
to	O
catalytic	O
activity	O
.	O
,	O
CYP2B6	B
*	O
6	O
(	O
and	O
CYP2B6	B
*	O
9	O
)	O
have	O
also	O
been	O
reportedly	O
associated	O
with	O
more	O
rapid	O
in	O
vivo	O
nicotine	O
metabolism	O
.	O

We	O
previously	O
demonstrated	O
that	O
common	O
CYP2B6	B
haplotypes	O
,	O
including	O
missense	O
variants	O
and	O
noncoding	O
variants	O
that	O
affect	O
gene	O
splicing	O
,	O
are	O
associated	O
with	O
differences	O
in	O
in	O
vivo	O
nicotine	O
metabolism	O
.	O

However	O
,	O
the	O
small	O
contribution	O
of	O
CYP2B6	B
to	O
hepatic	O
nicotine	O
metabolism	O
is	O
unlikely	O
to	O
influence	O
smoking	O
behaviors	O
.	O

CYP2B6	B
mRNA	O
expression	O
has	O
been	O
reported	O
in	O
human	O
brain	O
,	O
although	O
direct	O
evidence	O
of	O
CYP2B6	B
activity	O
in	O
brain	O
tissue	O
was	O
not	O
previously	O
demonstrated	O
.	O

It	O
has	O
therefore	O
been	O
suggested	O
that	O
genetically	O
determined	O
variation	O
in	O
CYP2B6	B
activity	O
in	O
extrahepatic	O
tissues	O
might	O
influence	O
smoking	O
behavior	O
by	O
altering	O
local	O
nicotine	O
levels	O
in	O
the	O
brain	O
.	O

Given	O
the	O
high	O
K	O
_m	O
of	O
CYP2B6	B
for	O
nicotine	O
,	O
we	O
further	O
probed	O
human	O
brain	O
microsomes	O
with	O
two	O
common	O
CYP2B6	B
substrates	O
,	O
ketamine	O
and	O
methadone	O
,	O
and	O
found	O
no	O
evidence	O
of	O
metabolism	O
of	O
either	O
.	O

Unlike	O
CYP2A6	O
,	O
CYP2B6	B
mRNA	O
expression	O
has	O
been	O
reported	O
in	O
human	O
brain	O
tissue	O
,	O
but	O
aside	O
from	O
its	O
role	O
in	O
bupropion	O
metabolism	O
,	O
genetic	O
variation	O
in	O
CYP2B6	B
has	O
not	O
been	O
associated	O
with	O
smoking	O
phenotypes	O
.	O

However	O
,	O
given	O
the	O
welldocumented	O
substrate	O
specificity	O
of	O
functional	O
variation	O
in	O
CYP2B6	B
,	O
it	O
was	O
also	O
necessary	O
to	O
determine	O
which	O
variants	O
affect	O
nicotine	O
metabolism	O
,	O
a	O
question	O
not	O
previously	O
addressed	O
in	O
vitro	O
.	O

Nevertheless	O
,	O
if	O
undetected	O
CYP2B6	B
activity	O
does	O
occur	O
in	O
the	O
human	O
brain	O
,	O
with	O
the	O
potential	O
to	O
influence	O
smoking	O
behavior	O
in	O
a	O
similar	O
manner	O
to	O
FMO3	O
,	O
associations	O
between	O
CYP2B6	B
genotype	O
and	O
nicotine	O
dependence	O
should	O
be	O
detectable	O
in	O
human	O
genetic	O
studies	O
based	O
on	O
our	O
in	O
vitro	O
activity	O
results	O
together	O
with	O
previously	O
published	O
findings	O
regarding	O
variation	O
in	O
CYP2B6	B
expression	O
.	O

The	O
genes	O
that	O
are	O
overexpressed	O
in	O
Theca	O
cells	O
(	O
cluster	O
4	O
)	O
are	O
particularly	O
involved	O
in	O
cholesterol	O
import	O
(	O
SCARB1	O
,	O
STARD5	O
)	O
,	O
bile	O
acid	O
metabolism	O
(	O
CH25H	O
)	O
,	O
HDL	O
-	O
mediated	O
lipid	O
transport	O
(	O
APOA1	O
,	O
PLTP	O
,	O
SCARB1	O
)	O
,	O
lipid	O
degradation	O
(	O
LPL	O
,	O
PLIN5	O
)	O
,	O
and	O
steroidogenesis	O
(	O
CYP27A	O
,	O
CYP7B1	O
,	O
TM7SF2	O
)	O
.	O

Cell	O
viability	O
,	O
apoptosis	O
rate	O
and	O
expressions	O
of	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
were	O
determined	O
prior	O
to	O
the	O
experiment	O
for	O
assessing	O
endothelial	O
function	O
at	O
12	O
hours	O
following	O
bubble	O
contact	O
.	O

3738	O
;	O
1	O
:	O
1000	O
dilution	O
)	O
,	O
cytochrome	B
C	I
(	O
Cat	O
.	O

Bubble	O
contact	O
for	O
10	O
,	O
20	O
or	O
30	O
minutes	O
induced	O
a	O
significant	O
decrease	O
in	O
cell	O
viability	O
and	O
remarkable	O
increases	O
in	O
apoptosis	O
rate	O
,	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
.	O

The	O
liver	O
metabolism	O
of	O
regorafenib	O
,	O
even	O
if	O
less	O
well	O
-	O
characterized	O
,	O
is	O
comparable	O
with	O
that	O
of	O
sorafenib	O
and	O
occurs	O
through	O
an	O
oxidative	O
process	O
mediated	O
by	O
Cytochrome	B
P450	I
3a4	I
and	O
glucuronidation	O
mediated	O
by	O
Udp	O
Glucuronosyltransferase	O
1a9	O
.	O

The	O
results	O
demonstrate	O
that	O
cytochrome	B
b	I
5	I
plays	O
a	O
dual	O
role	O
in	O
the	O
CYP3A4	O
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
:	O
(	O
1	O
)	O
cytochrome	B
b	I
5	I
mediates	O
CYP3A4	O
catalytic	O
activities	O
by	O
donating	O
the	O
first	O
and	O
second	O
electron	O
to	O
this	O
enzyme	O
in	O
its	O
catalytic	O
cycle	O
,	O
indicating	O
that	O
NADH	O
:	O
cytochrome	B
b	I
5	I
reductase	O
can	O
substitute	O
NADPH	O
-	O
dependent	O
POR	O
in	O
this	O
enzymatic	O
reaction	O
and	O
(	O
2	O
)	O
cytochrome	B
b	I
5	I
can	O
act	O
as	O
an	O
allosteric	O
modifier	O
of	O
the	O
CYP3A4	O
oxygenase	O
.	O

These	O
findings	O
demonstrated	O
that	O
cytochrome	B
b	I
_5	I
is	O
included	O
in	O
the	O
reduction	O
of	O
CYP3A4	O
catalyzed	O
both	O
by	O
the	O
NADPH	O
/	O
POR	O
system	O
and	O
a	O
system	O
consisting	O
exclusively	O
of	O
NADH	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
,	O
and	O
thus	O
also	O
without	O
any	O
participation	O
of	O
NADPH	O
and	O
POR	O
.	O

Our	O
data	O
confirmed	O
previous	O
results	O
found	O
for	O
CYP3A4	O
and	O
for	O
CYP1A1	O
that	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
/	O
cytochrome	B
b	I
_5	I
/	O
NADH	O
can	O
replace	O
NADPH	O
/	O
POR	O
in	O
the	O
catalytic	O
cycle	O
of	O
the	O
CYP	O
reactions	O
in	O
the	O
monooxygenase	O
system	O
[	O
,	O
.	O

The	O
results	O
of	O
our	O
present	O
study	O
as	O
well	O
as	O
those	O
reported	O
previously	O
indicated	O
that	O
cytochrome	B
b	I
_5	I
can	O
play	O
a	O
dual	O
role	O
in	O
the	O
CYP3A4	O
-	O
mediated	O
oxidation	O
of	O
ellipticine	O
.	O

The	O
finding	O
that	O
cytochrome	B
b	I
_5	I
with	O
its	O
reductase	O
,	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
,	O
functions	O
as	O
an	O
exclusive	O
donor	O
for	O
both	O
electrons	O
in	O
the	O
first	O
and	O
second	O
reduction	O
steps	O
of	O
the	O
CYP3A4	O
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
opens	O
the	O
door	O
for	O
further	O
research	O
.	O

However	O
,	O
because	O
they	O
are	O
microsomes	O
(	O
particles	O
of	O
broken	O
endoplasmic	O
reticulum	O
)	O
,	O
other	O
enzymes	O
(	O
proteins	O
)	O
of	O
the	O
endoplasmic	O
reticulum	O
membrane	O
(	O
ie	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
)	O
are	O
also	O
expressed	O
at	O
basal	O
levels	O
in	O
these	O
Supersomes	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

Cyp1a2	B
Knockout	O
mice	O
liver	O
cDNA	O
microarray	O
analysis	O
showed	O
that	O
Cyp1a2	B
deficiency	O
affected	O
insulin	O
function	O
,	O
lipogenesis	O
,	O
fatty	O
acid	O
biosynthesis	O
and	O
cholesterol	O
biosynthesis	O
.	O

In	O
line	O
with	O
these	O
data	O
,	O
we	O
observed	O
a	O
significant	O
increase	O
in	O
the	O
expression	O
of	O
Cyp3a11	O
in	O
female	O
SPF	O
mice	O
compared	O
to	O
the	O
male	O
group	O
.	O

Sort	O
=	O
Bait	O
and	O
CYP11B2	B
.	O

Sort	O
=	O
Bait	O
CYP11B2	B
interaction	O
used	O
as	O
a	O
control	O
.	O

Sort	O
=	O
Bait	O
interacts	O
with	O
cytochrome	O
P450	O
CYP2E1	O
and	O
CYP11B2	B
,	O
while	O
the	O
affinity	O
of	O
TBXAS1CYP2E1	O
complex	O
formation	O
is	O
fivefold	O
higher	O
in	O
the	O
presence	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
non	O
-	O
peptide	O
endogenous	O
bioregulator	O
isatin	O
(	O
2	O
,	O
3	O
-	O
dioxindole	O
)	O
.	O

A	O
major	O
difference	O
between	O
CYP11A1	B
and	O
CYP90B1	O
is	O
the	O
stereo	O
specificity	O
.	O

The	O
latter	O
inserts	O
the	O
hydroxyl	O
group	O
in	O
the	O
S	O
position	O
,	O
whereas	O
CYP11A1	B
is	O
in	O
the	O
R	O
position	O
.	O

In	O
CYP90B1	O
,	O
the	O
active	O
site	O
is	O
characterized	O
by	O
the	O
conformations	O
side	O
-	O
chain	O
in	O
and	O
steroid	O
-	O
core	O
out	O
,	O
similar	O
to	O
CYP11A1	B
,	O
and	O
for	O
CYP90B1	O
the	O
3	O
-	O
hydroxy	O
group	O
hydrogen	O
is	O
bonded	O
with	O
H385	O
and	O
the	O
carbonyl	O
oxygen	O
of	O
V216	O
via	O
a	O
water	O
molecule	O
.	O

Within	O
the	O
adrenal	O
,	O
A4	O
can	O
serve	O
as	O
a	O
substrate	O
for	O
CYP11B1	B
,	O
yielding	O
the	O
11	O
-	O
oxygenated	O
androgen	O
precursor	O
,	O
11OHA4	O
,	O
with	O
conversion	O
of	O
testosterone	O
to	O
11BETA	O
-	O
hydroxytestosterone	O
(	O
11OHT	O
)	O
,	O
also	O
occurring	O
.	O

Treatment	O
of	O
resveratrol	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
,	O
ellipticine	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
,	O
or	O
tryptamine	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
0001	O
,	O
n	O
=	O
3	O
)	O
significantly	O
reduced	O
the	O
viral	O
load	O
in	O
CCS	O
-	O
EVs	O
exposed	O
U1	O
cells	O
,	O
suggesting	O
the	O
role	O
of	O
CYP	B
1A1	I
and	O
2A6	O
,	O
and	O
oxidative	O
stress	O
on	O
viral	O
load	O
increase	O
in	O
U1	O
cells	O
(	O
A	O
,	O
B	O
)	O
.	O

In	O
our	O
study	O
,	O
genetic	O
variation	O
of	O
mitochondrial	O
cytochrome	B
B	I
was	O
found	O
in	O
the	O
two	O
Chinese	O
woodchuck	O
populations	O
with	O
different	O
outcomes	O
of	O
experimental	O
WHV	O
infection	O
.	O

Though	O
all	O
of	O
the	O
animals	O
belong	O
to	O
the	O
same	O
subspecies	O
M	O
.	O
himalayana	O
,	O
robusta	O
,	O
cytochrome	B
B	I
Allele	O
A	O
was	O
predominant	O
in	O
animals	O
with	O
high	O
replicative	O
pattern	O
of	O
WHV	O
infection	O
,	O
while	O
Allele	O
H	O
(	O
nucleotide	O
substitution	O
at	O
nt	O
695	O
from	O
T	O
to	O
C	O
)	O
in	O
those	O
with	O
low	O
replicative	O
pattern	O
.	O

Furthermore	O
,	O
cytochrome	B
B	I
Alleles	O
A	O
and	O
H	O
will	O
be	O
of	O
benefit	O
for	O
the	O
selection	O
of	O
high	O
WHV	O
susceptible	O
Chinese	O
woodchucks	O
,	O
which	O
could	O
be	O
used	O
as	O
an	O
animal	O
model	O
to	O
evaluate	O
antiviral	O
drugs	O
or	O
therapeutic	O
vaccines	O
[	O
,	O
.	O

Moreover	O
,	O
inhibitors	O
of	O
CYP19	B
aromatase	O
are	O
frequently	O
used	O
for	O
endocrine	O
therapy	O
of	O
breast	O
cancer	O
patients	O
,	O
while	O
the	O
role	O
of	O
genetic	O
variability	O
of	O
the	O
target	O
gene	O
in	O
the	O
treatment	O
efficacy	O
or	O
adverse	O
effects	O
is	O
yet	O
unexploited	O
for	O
therapeutic	O
decisions	O
.	O

CYP2B6	O
(	O
human	O
)	O
and	O
CYP2E1	O
(	O
rat	O
)	O
could	O
not	O
be	O
compared	O
between	O
species	O
because	O
the	O
respective	O
analogue	O
of	O
the	O
other	O
species	O
was	O
not	O
available	O
to	O
us	O
.	O
.	O
Positive	O
controls	O
for	O
each	O
of	O
the	O
isolated	O
cytochromes	O
showed	O
an	O
extent	O
of	O
metabolism	O
between	O
31	O
.	O
2	O
%	O
(	O
CYP1A2	O
)	O
and	O
100	O
%	O
(	O
CYP2C9	O
)	O
for	O
human	O
cytochromes	O
and	O
between	O
23	O
.	O
1	O
%	O
(	O
CYP2D2	O
)	O
and	O
100	O
%	O
(	O
CYP2B1	B
)	O
for	O
rat	O
cytochromes	O
(	O
data	O
not	O
shown	O
)	O
.	O

CYP1A1	B
protein	I
level	O
was	O
significantly	O
induced	O
by	O
berberine	O
in	O
MCF	O
-	O
7	O
cells	O
after	O
the	O
transfection	O
of	O
a	O
miR	O
-	O
21	O
-	O
3p	O
hairpin	O
inhibitor	O
,	O
demonstrating	O
that	O
miR	O
-	O
21	O
-	O
3p	O
suppressed	O
CYP1A1	B
protein	I
induction	O
.	O

Reported	O
Cutaneous	O
Dealkylase	O
Activity	O
For	O
7	O
-	O
Ethoxyresorufin	O
,	O
PROD	B
or	O
BROD	O
activities	O
(	O
LOD	O
1	O
,	O
4	O
and	O
1	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
)	O
.	O

report	O
that	O
in	O
human	O
skin	O
and	O
in	O
the	O
reconstructed	O
human	O
skin	O
model	O
EpiDerm	O
^	O
they	O
did	O
not	O
detect	O
PROD	B
activity	O
(	O
LOD	O
<	O
0	O
.	O
2	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
)	O
.	O

Likewise	O
Guth	O
did	O
not	O
detect	O
PROD	B
activity	O
in	O
StrataTest	O
^	O
(	O
LOD	O
4	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
)	O
.	O

reported	O
that	O
native	O
human	O
skin	O
had	O
a	O
low	O
level	O
of	O
CYP3A4	O
protein	O
,	O
moderately	O
induced	O
after	O
24	O
h	O
by	O
2	O
mM	O
phenobarbital	O
,	O
which	O
,	O
however	O
,	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
in	O
CYP3A4	O
-	O
dependent	O
BROD	B
activity	O
by	O
phenobarbital	O
(	O
0	O
.	O
5	O
-	O
2	O
mM	O
for	O
24	O
,	O
48	O
and	O
72	O
h	O
)	O
nor	O
by	O
rifampicin	O
(	O
50	O
and	O
100	O
M	O
for	O
24	O
h	O
)	O
nor	O
by	O
dexamethasone	O
(	O
10	O
and	O
50	O
M	O
for	O
24	O
,	O
48	O
and	O
72	O
h	O
)	O
.	O

It	O
is	O
unclear	O
why	O
our	O
patient	O
did	O
not	O
exhibit	O
any	O
side	O
or	O
adverse	O
effects	O
;	O
however	O
,	O
it	O
could	O
be	O
that	O
the	O
Carbamazepine	O
he	O
received	O
played	O
a	O
role	O
,	O
although	O
studies	O
have	O
shown	O
that	O
there	O
is	O
little	O
or	O
no	O
in	O
vivo	O
effects	O
of	O
CYP	B
2D6	I
on	O
Paliperidone	O
.	O

Another	O
intriguing	O
association	O
we	O
found	O
,	O
though	O
not	O
FDR	O
-	O
validated	O
,	O
is	O
an	O
association	O
of	O
rs62150087	O
(	O
CYP26B1	B
)	O
with	O
shorter	O
Disease	O
-	O
Free	O
Survival	O
.	O

However	O
,	O
it	O
seems	O
that	O
the	O
comparison	O
of	O
standard	O
middle	O
point	O
potentials	O
is	O
more	O
correct	O
,	O
as	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
is	O
bound	O
within	O
a	O
protein	O
matrix	O
,	O
and	O
a	O
considerable	O
difference	O
in	O
the	O
local	O
concentrations	O
of	O
O_2	O
and	O
O_2	O
^	O
is	O
questionable	O
.	O

A	O
possible	O
alternative	O
solution	O
is	O
that	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
mediates	O
the	O
formation	O
of	O
semiquinones	O
at	O
Q_D	O
and	O
Q_C	O
sites	O
.	O

Experimental	O
evidence	O
of	O
the	O
reduction	O
in	O
O_2	O
by	O
a	O
loosely	O
bound	O
plastosemiquinone	O
anion	O
radical	O
(	O
PQ	O
^	O
)	O
at	O
the	O
Q_C	O
site	O
was	O
provided	O
by	O
Yadav	O
et	O
al	O
.	O
.	O
The	O
authors	O
showed	O
that	O
PQ	O
^	O
can	O
be	O
formed	O
by	O
a	O
one	O
electron	O
reduction	O
in	O
PQ	O
at	O
the	O
Q_B	O
site	O
and	O
one	O
electron	O
oxidation	O
of	O
PQH_2	O
by	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
at	O
the	O
Q_C	O
site	O
.	O

Because	O
a	O
PQ	O
molecule	O
has	O
been	O
crystallographically	O
detected	O
in	O
the	O
Q_C	O
site	O
,	O
PQ	O
might	O
be	O
tightly	O
bound	O
within	O
the	O
Q_C	O
pocket	O
and	O
act	O
as	O
an	O
electron	O
carrier	O
from	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
to	O
P680	O
.	O

In	O
this	O
case	O
,	O
the	O
PQ	O
pool	O
can	O
serve	O
as	O
an	O
electron	O
donor	O
for	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
.	O

It	O
might	O
be	O
proposed	O
that	O
the	O
formation	O
of	O
O_2	O
^	O
in	O
a	O
cyt	O
b559	O
-	O
dependent	O
pathway	O
couples	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
and	O
quinones	O
and	O
depends	O
on	O
the	O
redox	O
state	O
of	O
the	O
PQ	O
pool	O
(	O
A	O
)	O
.	O

In	O
addition	O
,	O
the	O
Bax	O
,	O
cleaved	O
-	O
caspase3	O
and	O
Cytochrome	B
C	I
protein	O
expression	O
levels	O
were	O
further	O
increased	O
using	O
HIF	O
-	O
1ALPHA	O
knockdown	O
while	O
Bcl2	O
expression	O
levels	O
were	O
significantly	O
augmented	O
showed	O
that	O
si	O
-	O
RNA	O
reduced	O
the	O
HIF	O
-	O
1ALPHA	O
aggregation	O
in	O
mitochondria	O
in	O
hypoxia	O
-	O
stimulated	O
chondrocytes	O
(	O
Fig	O
.	O

In	O
addition	O
,	O
they	O
isolated	O
mitochondrial	O
and	O
cytosol	O
fractions	O
and	O
observed	O
a	O
time	O
-	O
dependent	O
release	O
of	O
Cytochrome	B
C	I
to	O
cytosol	O
.	O

The	O
molecular	O
docking	O
study	O
suggested	O
that	O
12n	O
could	O
be	O
used	O
as	O
an	O
inhibitor	O
of	O
CYP17A1	O
(	O
6CIZ	O
)	O
.	O

Then	O
,	O
the	O
17ALPHA	O
-	O
hydroxylase	O
activity	O
of	O
CYP17A1	O
converts	O
pregnenolone	O
to	O
17OH	O
-	O
pregnenolone	O
.	O

The	O
X	O
-	O
ray	O
structures	O
and	O
data	O
of	O
protein	O
targets	O
were	O
obtained	O
from	O
the	O
protein	O
data	O
bank	O
(	O
www	O
.	O
rcsb	O
.	O
org	O
)	O
:	O
CYP17A1	O
(	O
17a	O
-	O
hydroxylase	O
/	O
C17	O
,	O
20	O
-	O
lyase	O
,	O
Protein	O
Data	O
Bank	O
ID	O
:	O
6CIZ	O
,	O
6CHI	O
,	O
6CIR	O
,	O
5UYS	O
,	O
4NKZ	O
,	O
4NKX	O
,	O
4NKV	O
,	O
4NKW	O
,	O
and	O
3RUK	O
)	O
and	O
CYP19A1	O
(	O
aromatase	O
,	O
Protein	O
Data	O
Bank	O
ID	O
:	O
3S7S	O
)	O
.	O

Similarly	O
,	O
by	O
generating	O
Cyp27a1	O
^	O
/	O
Cyp46a1	O
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
we	O
expected	O
an	O
additive	O
genotype	O
effect	O
due	O
to	O
simultaneous	O
blockage	O
of	O
the	O
two	O
major	O
pathways	O
of	O
retinal	O
cholesterol	O
output	O
-	O
cholesterol	O
removal	O
via	O
metabolism	O
(	O
CYP27A1	O
and	O
CYP46A1	B
)	O
and	O
Lipoprotein	O
Particles	O
containing	O
Apolipoprotein	O
E	O
which	O
accepts	O
cholesterol	O
effluxed	O
from	O
cells	O
.	O

Rather	O
,	O
retinal	O
proteomics	O
pointed	O
to	O
enhanced	O
vesicle	O
formation	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
retina	O
as	O
an	O
expression	O
of	O
7	O
proteins	O
from	O
the	O
endosomal	O
,	O
secretory	O
,	O
and	O
protrusion	O
formation	O
pathways	O
(	O
CHGA	O
,	O
HDAC6	O
,	O
PAFAH1B	O
,	O
SEPT6	O
,	O
SRP19	O
,	O
TAGLN2	O
,	O
and	O
TAGLN3	O
,	O
)	O
was	O
increased	O
in	O
the	O
former	O
.	O

Hence	O
,	O
retinal	O
vesicle	O
formation	O
was	O
investigated	O
by	O
TEM	O
and	O
found	O
to	O
be	O
most	O
prominent	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
followed	O
by	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
and	O
then	O
Wild	O
Type	O
retina	O
(	O
;	O
.	O

Notably	O
,	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
,	O
vesicles	O
were	O
detected	O
at	O
both	O
apical	O
and	O
basal	O
Retinal	O
Pigment	O
Epithelium	O
sides	O
,	O
possibly	O
a	O
reflection	O
of	O
the	O
bi	O
-	O
directional	O
traffic	O
to	O
the	O
intraretinal	O
and	O
choroidal	O
vascular	O
networks	O
.	O

Traffic	O
to	O
the	O
intraretinal	O
vasculature	O
was	O
further	O
supported	O
by	O
abundant	O
vesicles	O
in	O
the	O
intraretinal	O
space	O
of	O
the	O
outer	O
nuclear	O
layer	O
and	O
neurovascular	O
units	O
of	O
the	O
ganglion	O
cell	O
layer	O
,	O
which	O
were	O
upregulated	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
retina	O
and	O
participate	O
in	O
glucose	O
production	O
and	O
utilization	O
as	O
well	O
as	O
fatty	O
acid	O
BETA	O
-	O
oxidation	O
.	O

If	O
energy	O
homeostasis	O
is	O
indeed	O
affected	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
,	O
there	O
should	O
be	O
an	O
increased	O
production	O
of	O
ATP	O
due	O
to	O
glycolysis	O
and	O
increased	O
acetyl	O
CoA	O
availability	O
as	O
the	O
latter	O
is	O
necessary	O
for	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
which	O
provides	O
NADPH	O
for	O
ATP	O
production	O
during	O
mitochondrial	O
or	O
extra	O
mitochondrial	O
oxidative	O
phosphorylation	O
.	O

Also	O
,	O
extracellular	O
vesicles	O
contain	O
proteins	O
,	O
therefore	O
enhanced	O
vesicle	O
formation	O
will	O
lead	O
to	O
retinal	O
protein	O
loss	O
,	O
if	O
this	O
loss	O
is	O
not	O
compensated	O
for	O
,	O
a	O
possible	O
reason	O
for	O
an	O
increase	O
in	O
abundance	O
of	O
the	O
overwhelming	O
majority	O
of	O
proteins	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
versus	O
Wild	O
Type	O
retina	O
.	O

The	O
expression	O
of	O
LAMTOR3	O
,	O
PSAT	O
,	O
BPHL	O
,	O
and	O
SLC14A1	O
,	O
which	O
are	O
involved	O
in	O
protein	O
homeostasis	O
,	O
was	O
increased	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
and	O
could	O
be	O
the	O
consequence	O
of	O
the	O
enhanced	O
extracellular	O
vesicle	O
formation	O
.	O

Thus	O
not	O
only	O
the	O
formation	O
of	O
extracellular	O
vesicles	O
seemed	O
to	O
be	O
enhanced	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
but	O
also	O
the	O
processes	O
which	O
are	O
required	O
(	O
ie	O
,	O
ATP	O
production	O
)	O
and	O
affected	O
(	O
ie	O
,	O
protein	O
homeostasis	O
and	O
ubiquitination	O
)	O
by	O
vesicle	O
formation	O
.	O

By	O
contrast	O
,	O
the	O
Cyp27b1	B
-	O
KO	O
rats	O
for	O
analysis	O
were	O
continuously	O
fed	O
the	O
CE	O
-	O
2	O
diet	O
because	O
most	O
male	O
Cyp27b1	B
-	O
Knockout	O
rats	O
were	O
not	O
able	O
to	O
survive	O
more	O
than	O
10	O
weeks	O
when	O
fed	O
the	O
F	O
-	O
2	O
diet	O
(	O
data	O
not	O
shown	O
)	O
.	O

Homozygotes	O
of	O
all	O
Genetically	O
Modified	O
strains	O
(	O
Cyp27b1	B
-	O
KO	O
,	O
Vdr	O
(	O
R270L	O
)	O
,	O
and	O
Vdr	O
-	O
KO	O
)	O
were	O
maintained	O
by	O
mating	O
of	O
heterozygotes	O
.	O

Genotypes	O
of	O
each	O
strain	O
were	O
determined	O
by	O
electrophoresis	O
of	O
PCR	O
products	O
of	O
the	O
target	O
site	O
for	O
Cyp27b1	B
-	O
KO	O
or	O
direct	O
sequencing	O
for	O
Vdr	O
(	O
R270L	O
)	O
and	O
Vdr	O
-	O
KO	O
(	O
see	O
Supplementary	O
Figs	O
.	O

The	O
target	O
site	O
for	O
Cyp27b1	B
-	O
KO	O
was	O
selected	O
to	O
delete	O
the	O
cysteine	O
at	O
position	O
462	O
in	O
exon	O
8	O
,	O
which	O
is	O
the	O
5th	O
ligand	O
of	O
heme	O
iron	O
and	O
an	O
active	O
center	O
of	O
Cyp27b1	B
(	O
see	O
Supplementary	O
Fig	O
.	O

Potential	O
off	O
target	O
sites	O
of	O
Cyp27b1	B
and	O
Vdr	O
in	O
rat	O
genomes	O
were	O
searched	O
by	O
the	O
CRISPR	O
Direct	O
tool	O
(	O
http	O
:	O
/	O
/	O
crispr	O
.	O
dbcls	O
.	O
jp	O
/	O
)	O
to	O
validate	O
the	O
off	O
-	O
target	O
events	O
.	O

Cyp27b1	B
-	O
KO	O
rats	O
and	O
Vdr	O
(	O
R270L	O
)	O
rats	O
were	O
fed	O
25	O
(	O
OH	O
)	O
D_3	O
for	O
comparison	O
of	O
its	O
effects	O
on	O
rickets	O
symptoms	O
.	O

